Cytoreductive surgery and radioimmunotherapy to treat peritoneal carcinomatosis of colorectal cancer : investigations towards improvement of outcome and morbidity by Aarts, Frits
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/65647
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Cytoreductive Surgery and Radioimmunotherapy to treat 
Peritoneal Carcinomatosis of Colorectal Cancer
Investigations towards Improvement of Outcome and Morbidity
Cytoreductive Surgery and Radioimmunotherapy to treat 
Peritoneal Carcinomatosis of Colorectal Cancer:
Investigations towards Improvement of Outcome and Morbidity; 
Thesis, Radboud University Nijmegen, The Netherlands
The work described in this thesis was performed at the Departments of 
Surgery and Nuclear Medicine, Radboud University Nijmegen Medical  
Center, The Netherlands
Publication of this thesis was financially supported by
Sanofi Aventis
Taureon
Hestia
Cover Design:
Frits Aarts & Karin Huiberts
Layout & Photography
Frits Aarts
Printed by
Ponsen en Looijen bv
ISBN 978-90-9023660-5
Copyright © by Frits Aarts, 2008, Nijmegen.
All rights preserved. No parts of this book may be reproduced, stored in a retrieval system, 
or transmitted, in any form or by any means, electronic, mechanical, photocopying, or 
otherwise, without prior permission of the holder of the copyright.
Cytoreductive Surgery and Radioimmunotherapy to treat 
Peritoneal Carcinomatosis of Colorectal Cancer
Investigations towards Improvement of Outcome and Morbidity
Een wetenschappelijke proeve
op het gebied van de Medische Wetenschappen
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. mr. S.C.J.J Kortmann,
volgens besluit van het College van Decanen
in het openbaar te verdedigen op vrijdag 30 januari 2009
om 13.30 uur precies
door
Frits Aarts
geboren op 15 november 1975
te Breda
Promotores
Prof. dr. R.P Bleichrodt
Prof. dr. O.C. Boerman
Prof. dr. W.J.G. Oyen
Copromotor
Dr. T. Hendriks
Manuscriptcommissie
Prof. dr. L.F. Massuger
Prof. dr. A.J. van der Kogel
Prof. dr. C.J.H. van de Velde (LUMC)
Paranymfen
Rieko Verhagen
Edde Voorheijen
The greatest thing you’ll ever learn is to love and be loved in return.
Voor Diana en Mael

Table of Contents
 
Chapter 1 Introduction and Outline.
Chapter 2 Intracavitary Radioimmunotherapy.
Chapter 3 Timing of Adjuvant Radioimmunotherapy after Cytoreductive 
Surgery in Experimental Peritoneal Carcinomatosis of 
Colorectal Origin.
Chapter 4 Hyperthermia and Fibrinolytic Therapy do not Improve 
the Beneficial Effect of Radioimmunotherapy following 
Cytoreductive Surgery in Rats with Peritoneal Carcinomatosis 
of Colorectal Origin.
Chapter 5 A Comparison between Radioimmunotherapy and Hyperthermic 
Intraperitoneal Chemotherapy for the Treatment of Peritoneal 
Carcinomatosis of Colonic Origin in Rats.
Chapter 6 The Effects of Experimental Radioimmunotherapy and 
Hyperthermic Intraperitoneal Chemotherapy on Anastomotic 
and Abdominal Wall Healing.
Chapter 7 Antibody Galactosylation to Improve Radioimmunotherapy.
Chapter 8 Pre-targeted Radioimmunoscintigraphy of Colorectal Cancer; 
Preliminary Data from a Patient Study.
Chapter 9 Summary and Future Directions.
Appendices Samenvatting 
 Dankwoord
 About the author
 Publications 
 List of abbreviations

Chapter 1
Introduction and Outline

Introduction
Peritoneal Carcinomatosis
Colorectal cancer (CRC) is second in incidence to lung cancer in men and 
breast cancer in women as a cause of cancer-related deaths in Europe and 
the USA. More than 900,000 new cases of CRC are diagnosed worldwide 
each year, and nearly 500,000 patients die as a result of CRC.1 In 19% of 
patients with CRC, distant metastases are found at the time of diagnosis.2 
One specific entity of the regional spread of CRC is peritoneal carcinomatosis 
(PC), which may develop in patients after resection of the primary tumor.3 
PC is present as synchronous disease at the time of resection of the primary 
tumor in 7% of patients with CRC and as metachronous carcinomatosis in 
4.5%.4 In approximately 25% of patients with recurrent CRC, the peritoneal 
cavity is the only site of metastatic disease.3
PC may result from spread of cells from the primary tumor into the peritoneal 
cavity or from tumor spillage during surgery of the primary tumor. Tumor 
cells can be isolated from the peritoneal cavity in as many as 30% of the 
patients during surgery.5 These cells may cause peritoneal metastases. 
However, their role in causing PC and the significance for the prognosis of 
these patients are still ambigious3.
The locations of peritoneal metastases—which are found mainly in the right 
paracolic gutter and in the subhepatic and right subdiaphragmatic spaces 
(a metastatic pattern that follows the intraabdominal fluid stream in the 
abdominal cavity)—support the hypothesis that free-floating tumor cells may 
cause PC. It is hypothesized that, after surgery, tumor cells are trapped in 
fibrin clots that place them beyond the reach of the immunologic defenses 
in the abdominal cavity. These tumor clots may be the nidus of peritoneal 
metastases. Peritoneal metastases may cause serious complications such as 
intestinal obstruction and the formation of fistulas and ascites. Therefore, it 
is worthwhile to develop methods to prevent and treat PC.
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Treatment of Peritoneal Carcinomatosis
Treatment of PC has historically comprised palliative measures only, either 
surgically (bypass of the obstruction) or chemotherapeutically. Several 
treatment regimens have been developed to offer patients with PC of CRC a 
chance of survival.
Patients with PC have a median survival of six months, if untreated. Therefore, 
nonoperative intervention was proposed instead of palliative surgical 
intervention in case of intestinal obstruction.6 Palliative chemotherapy alone 
did not improve survival in these patients.4,7
Sugarbaker explored the feasibility of radical debulking procedures, or 
cytoreductive surgery (CS), to treat PC.8 CS comprises the removal of all 
peritoneal tumor deposits, including a greater omentectomy. In most cases 
a partial peritonectomy, cholecystectomy, splenectomy, and partial bowel 
resection are performed to remove all visible tumor in all regions of the 
abdomen.8 The extent of PC is scored using the peritoneal cancer index 
(PCI) of Sugarbaker. See Figure 1. The radicality of the resections are graded 
R0–R3. See Table 1.9 Median survival ranges from 18 months to 39 months 
after R0 resections but from 13 months to 24 months after R2 resections 
and  only 5 months to 12 months after R3 resections.3 Fortunately, most 
resections (80%–90% are R0–R1 resections, probably because of careful 
patient selection.10,11 The results of treatment of patients with PC depend on 
the extent of the metastatic disease (PCI) and the type of resection performed 
(R0–R3).
R-stage Radicality
0 No visible tumor
1 <2.5 mm
2 >2.5 mm to <5 mm
3 >5 mm
Table 1. Resection type
12
Figure 1. Peritoneal cancer index
Sugarbaker introduced adjuvant intraperitoneal chemotherapy to reduce 
recurrent intraperitoneal disease after CS.12 Compared with intravenous 
administration, intraabdominal administration of direct cytotoxic (cell-cycle 
independent) chemotherapy agents results in higher local concentrations 
of chemotherapy in the abdominal cavity. Moreover, free-floating tumor 
cells are rinsed from the abdomen and killed by the cytotoxic agents. In 
addition, if administered at a later time, intraperitoneal chemotherapy may 
cause fibrous adhesions to form, preventing the chemotherapy from being 
distributed equally within the peritoneal cavity. The penetration depth of the 
used agents is 1 ± 3 mm.13 
Efforts to improve the outcome of intraperitonally administered chemotherapy 
resulted in investigations on the use of hyperthermia. In 1993 it was found 
that the therapeutic efficacy of intraperitoneal carboplatin was improved 
when administered under hyperthermic conditions (41.5°C). In vitro studies 
showed also that the antitumor effect of mitomycin C and cisplatin on 
human colon cancer cells increased when these treatments were combined 
with hyperthermia (43°C).14 See Table 2. Hyperthermia has a direct cytotoxic 
13
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effect (impaired DNA repair and denaturation of proteins), and the effect 
is dependent on temperature and exposure time. The penetration depth 
of hyperthermia, however, is limited to 1 mm; thus, the effect of direct 
cytotoxicity will be limited.15 Clinically, hyperthermic intraperitoneal 
chemotherapy (HIPEC) was originally performed after CS with anastomotic 
construction. Later, the anastomoses were constructed after the perfusion 
in order to decrease tumor entrapment within them. 
During the late 90s, phase I/II studies indicated that the use of HIPEC could 
achieve long-term survival (60% 2-year survival).16 Later, it was shown that 
a 2-year survival of 74% could be reached for patients who underwent a 
complete resection.17
Chemotherapy Agent Heat Synergysm
Mitomycin C yes
Cisplatinum yes
Melphalan yes
Mitroxantrone yes
Oxaliplatin yes
Irinotecan yes
5-fluorouracil no
Table 2. Heat synergism of chemotherapy agents
During HIPEC, the peritoneal cavity is continuously perfused for 60–120 
minutes with a hyperthermic dialysis fluid (41°C-43°C) containing the 
cytotoxic drug. The perfusion is generally performed using the closed-abdomen 
technique. See Figure 2.18,19 The closed system has two disadvantages. First, 
some parts of the abdominal cavity may not be reached by the perfusate 
because of adhesions, which may affect the intraabdominal temperature 
distribution as well. Second, tumor cells may be entrapped within the 
constructed bowel anastomoses. Because of these disadvantages, an open 
technique was developed. During the perfusion, the abdomen is left open, 
with retraction of the skin using an expander, allowing for intraabdominal 
manipulation and resulting in a more equal distribution of the chemotherapy 
agent. Thereafter, continuity of the bowel can be restored.
14
Figure 2. HIPEC procedure. 
Although PC is relatively common, most data on survival and morbidity are 
derived from phase I/II studies. There has been only one phase III study, 
comparing HIPEC (using a 17 mg/m2 dose of mitomycin C) to the standard 
treatment of PC (5-fluorouracil/leucovorin).20 This study showed that the 
application of HIPEC after CS significantly improved survival. At a median 
follow-up of 21.6 months, patients treated with the standard treatment 
showed a median survival of 12.6 months, compared to 21.6 months in 
patients treated with CS and HIPEC in PC of colorectal origin. The gain in 
survival, however, was achieved at the cost of significant morbidity of up to 
65%. Recurrent disease was found in 65% of patients.21,22
15
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Radioimmunotherapy in Peritoneal Carcinomatosis
Based on the results of the combined treatment of CS and HIPEC, efforts to 
improve survival while decreasing morbidity warranted the development of 
new, more specific, i.e., targeted, treatment modalities for PC.
Koppe and colleagues therefore investigated the feasibility and therapeutic 
efficacy of the intraperitoneal administration of radiolabeled antibodies 
against colon cancer cells (radioimmunotherapy, or RIT) in an experimental 
setting.23 In a rat model of PC, induced using the syngeneic colon 
carcinoma cell line CC531, CS was performed seven days after tumor 
induction. Subsequently, four days after surgery, the animals received an 
intraperitoneal injection of the anti-CC531 antibody MG1 labeled with the 
ß-radiation–emitting radionuclide 177lutetium (177Lu) at a dose of 1.5 mCi.23 
In this study, the median survival of the control rats that underwent an 
exploratory laparotomy only (without surgical removal of tumor) was 41 
days. The median survival of the animals that had undergone CS only was 
51 days. Median survival of animals that were treated with exploratory 
laparotomy followed by intraperitoneal RIT was 61.5 days. CS followed by 
RIT resulted in the highest median survival of 88 days.
The results of this experiment showed that animals treated with the 
combination of both CS and RIT survived longer than animals treated with 
either treatment modality alone. This experimental study thus provided 
the proof of principle that RIT as an adjuvant to CS could be an effective 
treatment for PC.
16
Outline of the Thesis
Based on the results of the studies performed by Koppe and colleagues, 
investigations were undertaken to improve the therapeutic effect and 
to decrease the treatment-related toxicity of RIT. Moreover, the effect on 
survival, treatment-related toxicity, and morbidity of adjuvant RIT after CS 
was compared to HIPEC, being the gold standard of care for the treatment 
of PC.
Within this thesis, the following questions have been answered:
• Is there clinical evidence of the treatment efficacy of locally or 
regionally administered RIT to treat solid cancer (Chapter 2)?
• Can survival of animals with induced PC of CRC be enhanced after 
CS and intraperitoneally administered RIT by altering the interval 
between the surgical procedure and the intraperitoneal administration 
of RIT, and if so, what would be the optimal interval (Chapter 3)?
• In the era of multimodality treatment of cancer, can the therapeutic 
effect of adjuvant RIT be improved by the concomitant application 
of other treatment modalities, such as fibrinolytic therapy or whole-
body hyperthermia (Chapter 4)?
• Following the determination of the optimal setting of adjuvant RIT, 
what is the therapeutic efficacy of adjuvant RIT after CS, compared 
to that of adjuvant HIPEC (Chapter 5)?
• What is the effect of adjuvant RIT, compared to that of HIPEC, on 
wound healing of the small and large bowel and the abdominal wall 
after CS (Chapter 6)?
• Is it possible to enhance the treatment efficacy of intraperitoneally 
administered RIT using a sugar-modified antibody (Chapter 7)? 
• Is imaging of patients with proven colorectal cancer using two-step 
pre-targeted radioimmunoscintigraphy feasible (Chapter 8)?
17
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Abstract
Radioimmunotherapy (RIT) potentially is an attractive treatment for radiosensitive 
early stage solid tumors and as an adjuvant to cytoreductive surgery. Topical 
administration of RIT may improve the efficacy because higher local concentrations 
are achieved. We reviewed the results of locally applied radiolabeled monoclonal 
antibodies for the treatment of solid tumors. Intracavitary RIT in patients with 
ovarian cancer and glioma showed improved targeting after local administration as 
compared to the intravenous administration. In addition, various studies showed 
the feasibility of locally applied RIT in these patients. Adjuvant RIT in ovarian cancer 
and glioma showed to be at least as effective as standard therapy. The information 
about RIT for peritoneal carcinomatosis of colorectal origin is scarce while results 
from pre-clinical data are promising. 
Studies on the application of radiolabeled antibodies in early urothelial cell cancer 
showed that intracavitary RIT may hold a promise. In patients with malignant pleural 
mesothelioma or malignant pleural effusion, RIT may play a role in the palliative 
treatment.
The future of RIT may therefore not only be in the inclusion in contemporary 
multimodality treatment, but also in the expansion to palliative treatment.
Chapter 2
Intracavitary Radioimmunotherapy to treat solid tumors
This chapter is based on:
Intracavitary radioimmunotherapy to treat solid tumors. Aarts F, Bleichrodt RP, 
Oyen WJ, Boerman OC. Cancer Biother Radiopharm. 2008 Feb;23(1):92-107

Introduction
Biologicals play an increasingly important role in the treatment of cancer. 
Monoclonal antibodies (mAbs) against CD20 are standard therapy in non-
Hodgkin’s lymphoma (NHL), anti-vascular endothelial growth factor (VEGF) 
antibodies are used to treat colon and lung carcinoma and anti-HER2 
antibodies play a role in breast cancer treatment. mAbs can also be used 
to direct anticancer drugs to tumor cells. Drugs, toxins, or radionuclides 
can be conjugated to mAbs for selective delivery of these agents to tumor 
tissues, thus sparing normal tissues in contrast to conventional systemic 
anticancer therapies.1,2 In radioimmunotherapy (RIT), mAbs are labeled 
with radionuclides to selectively irradiate tumor cells. RIT has proven to be 
effective in hematologic malignancies but is less effective in solid cancers.3–5 
Large solid tumors have a limited blood supply, rendering these tumors less 
accessible for therapeutic agents being delivered via the blood. Impaired 
blood supply and concomitant ischemia make tumor cells less radiosensitive. 
6,7 In addition, solid tumors have a high interstitial fluid pressure that limits 
the uptake and penetration of antibodies.8 As a result, in large tumors, the 
uptake of mAbs from the blood is relatively low and heterogeneous, thus 
limiting the efficacy of RIT. In small tumor lesions, the uptake of mAbs is 
higher and the heterogeneity of antibody uptake within the tumor can be 
overcome by the penetration range of the radiation. Therefore, RIT seems to 
be an attractive adjuvant therapy in small-volume disease or microscopic 
residual tumor deposits. RIT may also be administered topically in order to 
reduce systemic activity and enhance tumor targeting. In addition, there are 
conditions that are particularly suitable for RIT owing to tumor localization 
(i.e., the development of cancer within a natural cavity) and its concomitant 
pharmacologic advantages. In both preclinical and clinical studies, the mAb 
levels in intraperitoneally growing tumors were found to be higher during 
the first 24 hours after intraperitoneal administration, as compared to 
systemic administration, thus favoring this route of administration.9,10 In 
this paper, we reviewed the results of locally applied radiolabeled mAbs for 
the treatment of solid tumors.
 Intracavitary Radioimmunotherapy
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Radioimmunotherapy
Antibodies
Since the development of the hybridoma technology, it is possible to 
generate antibodies specifically directed against tumor-associated 
antigens. 11 Murine antibodies were the first clinically applied antibodies. 
A major disadvantage was the production of human antimouse antibodies 
(HAMAs) that could induce humoral immune responses. In order to reduce 
immunogenicity, recombinant DNA techniques were applied to produce 
chimeric and humanized mAbs.12 In chimeric mAbs, the variable regions of 
heavy and light chains are of murine origin, and these are then fused with 
the constant regions of human origin (Fig. 1). In humanized mAbs, only 
the Complimentarity Determining Regions (CDR) of the murine origin are 
grafted in a human antibody framework.13,14 To improve in vivo targeting 
properties, new antibody constructs have been produced, using recombinant 
DNA techniques (e.g., scFv, minibodies, diabodies, and so forth).
24
Radionuclides
The most commonly used radionuclides in RIT are beta-emitters. Beta-
particles are electrons that are emitted from the nucleus of an unstable 
atom. In RIT, iodine-131 (131I) and yttrium (90Y) are the most commonly used 
beta-emitters. More recently, rhenium-186 (186Re), copper-67 (67Cu), and 
lutetium-177 (177Lu) have also been applied (see Table 1) The differences 
in physical half-life, the presence or absence of gamma rays, the energy, 
and consequently the range of the beta-particles in tissue are important 
with respect to the radiation dose that can be delivered to the tumor. For 
example, 90Y-labeled mAbs are theoretically not suitable for the treatment 
of minimal or residual disease with a diameter of only a few millimeters 
or less, since 70% of the radiation energy will be deposited outside small 
Figure 1.
Most important forms of monoclonal antibodies used in clinical radioimmunotherapy.
A, Whole (murine) IgG (MW 150 kDa). Va, variable region; Co, constant region; B, F(ab’)2 fragment (MW 100 kDa); C, 
Fab’ fragment (MW 50 kDa); D, Chimeric IgG (67% human). The constant regions of the murine antibody have been 
replaced by their human analogues; E, Humanized IgG (90-95% human); F, Fully human IgG; G, Bispecific antibody. 
The antibody, with both arms originating from two separate antibodies, is reactive with two distinct antigens. Copyright 
British Journal of Surgery Society Limited. Reprinted by permission from M.J. Koppe et al. Radioimmunotherapy and 
colorectal cancer.
 Intracavitary Radioimmunotherapy
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tumors (diameter <5 mm) owing to the high energy of the ß-particles (mean, 
0.9 MeV).15 For this application, the use of 177Lu-labeled antibodies with 
medium-energy electron emissions is better suited.16 Internalization of the 
radiolabeled antibodies depends on various factors, including the antibody 
itself and the targeted antigen. All antibodies eventually are internalized 
by the target cell and subsequently catabolized.17 When internalized, the 
radiolabeled mAb is degraded in the lysosomes. In case of radioiodinated 
mAbs, the radiolabeled metabolites are excreted from the cell. Labeling of 
mAbs with radiometals, such as 90Y, 177Lu, and 67Cu, is performed by first 
linking chemical moieties that can complex the metal ions to the antibody 
(chelators such as DTPA, DOTA, or TETA). When catabolized, the radioactive 
metabolites of mAbs labeled with radiometals are trapped in the lysosomes, 
increasing the retention of these radiolabels in the tumor.18,19
Table1. 
RadioNuclides
Radionuclide Half life ß-energy γ-energy Range ß
131I 8 days 192 keV 362 keV 3 mm
90Y 64 hr 935 keV - 12 mm
188Re 17 hr 795 keV 155 keV 27 mm
177Lu 7 days 149 keV 208 keV 3 mm
67Cu 62 hr 141 keV 185 keV 2 mm
Intraperitoneal RIT
The abdominal cavity is lined with mesothelial cells that not only play a role 
in the sliding of the peritoneal surfaces, but also play an active roll in the 
immunologic response, inflammation, and coagulation.20 Peritoneal clearance 
is regulated via the peritoneum that behaves as a semipermeable membrane 
and the lymphatic lacunae underlining diaphragmatic stomata. This clearing 
process starts within minutes after contamination of the peritoneal cavity. 
Antibodies administered into the peritoneal cavity cross the peritoneal 
lining mainly by diffusion. The rate of diffusion depends on the volume 
26
of the instilled agent and the concomitant increase in fluid pressure.21,22 
Moreover, antibodies will be cleared via the diaphragmatic stomata. For 
RIT of intraperitoneal lesions, the intraperitoneal (i.p.) administration is 
advantageous, as compared to the systemic administration, because higher 
concentrations of the antibody can be reached in the tumor.23 When mAbs 
are administered into the peritoneal cavity, their pharmacokinetics are 
similar to that of other large-serum proteins. Apart from specific binding 
to i.p. tumors, there is transportation to thecirculation and subsequent 
uptake in normal tissues. 24,25 However, in both preclinical and in clinical 
studies, the concentration of mAbs in the tumor lesions is higher during 
the first 24 hours after an i.p. administration while blood levels are lower, 
as compared to a systemic administration. In addition, not only the tumor 
uptake is increased, but also the tumor:nontumor ratio. This favors this 
route of administration for i.p. growing tumors.10,26
Ovarian Cancer
Ovarian cancer mostly originates from the surface epithelium of the ovaries, 
and in most patients, metastases are confined to the peritoneal cavity without 
further distant metastases.27 The overall survival rate is 35%. The majority 
of patients presents with advanced disease at the time of diagnosis. Radical 
debulking, in combination with platinum- or taxol-based chemotherapy, is the 
standard treatment, resulting in 50% local recurrencesand a median survival 
of 2 years.28,29 Ovarian cancer seems to be well suited for i.p. administered 
adjuvant RIT.30 The disease has been targeted by using antibodies directed 
against tumorassociated antigens as the mucin-1 (MUC1) antigen, CA-125, 
TAG-72, and gp38 (see Table 2). As mentioned above, several preclinical and 
clinical studies demonstrated that an i.p. administration of RIT resulted in a 
higher uptake of radiolabeled antibodies in tumor, as compared to systemic 
route administration.10,26,31,32
 Intracavitary Radioimmunotherapy
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MUC-1
MUC-1 is expressed on glandular epithelium in the majority of 
adenocarcinomas, includingbreast, ovary, and pancreas, where it is both 
overexpressed as well as aberrantly glycosylated.33 One of the first RIT trials 
in patients with ovarian cancer was carried out by Epenetos et al., treating 24 
patients with stage III ovarian cancer in an adjuvant setting to cytoreductive 
surgery and platinum-based chemotherapy. In this study, 131I-labeled anti-
MUC1 mAbs, HMFG1-2, AUA 1, and H17E2, were used.34 The best response 
was found in the 16 patients with minimal or small-volume (<2 cm diameter) 
disease. No response was seen in the 8 patients with largevolume disease 
(>2 cm diameter) who all died of recurrent disease within 9 months. In 
another trial, the efficacy of adjuvant 90Y-labeled HMFG1 following surgery 
and chemotherapy was compared to a historic control group that was 
treated with surgery and chemotherapy alone. Five (5)-year survival in the 
RIT group was 80%, as compared to 55% in the control group.35 Later, these 
investigators reported that after 12 years of follow-up, the median survival 
of a group with complete remission following surgery, chemotherapy, and 
adjuvant 90Y-HMFG1 had not yet been reached. These results were better 
than the results in a historic control group that had a median survival of 
42% survival after 5 years of follow- up.36 Based on the encouraging results 
of these phase I/II studies, a phase III open-label, randomized, multicenter 
phase III trial was undertaken. This study included patients to be treated 
with 90Y-HMFG1 RIT (maximum dose, 25 mCi; N = 224) and compared them 
to conventionally treated patients (N =223).37 Patients were eligible after 
a complete clinical response to platinum-based chemotherapy following 
surgical cytoreduction. Intraperitoneally administered RIT was applied after 
a confirmed macroscopically negative laparoscopy. This study failed to show 
a benefit in overall survival or a prolonged disease-free survival after RIT. 
Although peritoneal recurrence was significantly delayed in the RIT group, 
extraperitoneal metastases, mainly located in the para-aortic lymph nodes, 
were found more frequently than in the control group (49% versus 14%).38
28
TAG-72
TAG-72 is a mucin-like antigen that is heterogeneously expressed in virtually 
all ovarian cancers. The pharmacology, metabolism, and tissue distribution 
of 90Y-labeled anti-TAG-72 B72.3 was investigated in 9 patients with ovarian 
cancer.39 Following this report, Meredith et al.40 and Rosenblum et al.41 performed 
i.p. RIT studies in patients with chemotherapy-resistant or refractory ovarian 
cancer limited to the peritoneal cavity. Rosenblum et al. included 58 patients 
treated with 90Y-labeled B72.3, 1–25 mCi, resulting in 2 complete remissions 
and 30 patients with stable disease with a median of 6 months (range, 4–24). 
In a study using 177Lu-labeled CC49, a secondgeneration anti-TAG-72 antibody 
with a higher affinity for TAG-72 than the B72.3 antibody (dose, 10–50 mCi/
m2), Alvarez et al. included 27 patients. Fourteen (14) of these patients with 
small (<1 cm) or microscopic disease were stable for 6–35 months, whereas 
in patients with measurable disease (>1 mm), only 1 patient showed a partial 
response. The other patients showed progression within 3 months.42 Meredith 
et al. published a report including 12 patients treated with 177Lu-labeled CC49, 
10–30 mCi/m2.40 This resulted in complete remission in 3 patients and stable 
disease in 1. Complete responses were only found in patients with microscopic 
disease. Following the report by Roselli et al.,43 who showed that interferon 
(IFN) enhances the expression of TAG-72, Meredith et al. Subsequently tested 
the feasibility and efficacy of a combination of subcutaneous (s.c.) injections of 
IFN, i.p. paclitaxel (100 mg/m2), and RIT consisting of 40–45 mCi/m2 177Lu-
labeled CC49. This study included 44 patients with ovarian cancer, 27 of 
whom had only microscopic disease or disease not measurable on computed 
tomography (CT).44 Four (4) of 17 patients with macroscopic disease on CT 
showed a partial response (decrease of >50% diameter), whereas 4 of 27 patients 
with  microscopic disease showed progression- free time intervals of more than 
18 months. Subsequently, the same research group treated 20 patients with 
persistent or recurrent ovarian cancer after conventional cytoreductive surgery 
and chemotherapy, with a combination of RIT using 90Y-labeled CC49 and a 
single i.p. administered dose of paclitaxel (100 mg/m2) and IFN. In 3 of 11 
patients with nonmeasurable disease, disease-free survival was more than 18 
months. The researchers concluded that this combination of treatments was 
well tolerated and showed antitumor activity.
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gp38
MOv18 is an antibody directed against the folate receptor gp38, which is 
expressed at high levels in 90% of serous ovarian carcinomas. The expression 
level on other epithelial tissues is low.45 The murine MOv18 mAb is highly 
immunogenic, inducing human antimouse antibodies (HAMA) in most 
patients. MOv18 targeting of ovarian cancer was investigated by van Zanten-
Przybysz et al.26 by comparing the i.p. administration to the intravenous 
(i.v.) injection. Ex vivo measured tumor uptake after i.p. administration was 
3.4%– 12.3%, whereas this was 3.6%–5.4% after the i.v. administration.32 In 
addition, van Zanten-Przybysz et al. determined the pharmacokinetics and 
tumor accumulation of both i.v. and i.p. administered cMOv18 in the same 
patient in a dual-label 125/131I-study in 15 patients. They showed a tumor 
uptake of 4.9% and 2.4% injected dose per kilogram (ID/kg) after the i.v. 
and i.p administration after 2 days, respectively. After 6 days, there was no 
difference in tumor uptake between the routes of administration (3.8% and 
3.9%ID/ kg for i.v. and i.p). Moreover, the mean AUC for the blood-activity 
versus time curve was 3.5 times higher after the i.v injection at 2 days and 
2.1 times higher at 6 days, as compared to the i.p injection. The researchers, 
therefore, concluded that the i.p. route could be advantageous owing to the 
significantly lower bone marrow toxicity as a result of lower blood levels of 
the radiolabeled antibody when administered i.p.26 Crippa et al. tested the 
efficacy of i.p. administered RIT, using 131I-MOv18 (mean dose, 100 mCi) in 
16 patients with minimal or small-volume ovarian cancer.46 Clinical follow-
up and/or third-look evaluation performed 90 days after the administration 
of RIT showed a complete response in 5, stable disease in 6, and progressive 
disease in 5 patients. Of the 5 patients that showed a complete response, 1 
patient remained disease free after a follow-up of 34 months, whereas the 
remaining 4 patients relapsed after a mean period of 10.5 months.
30
CA-125
Mahe et al. performed a phase I study comprising of i.p. administered 120 mCi 
of the 131I-labeled anti-CA-125 antibody OC125 to 6 patients with residual 
macroscopic (<5 mm) or microscopic disease, resulting in stable disease in 
2 patients.47 In addition, there was HAMA formation in all 6 patients. The 
reported lack of efficacy might be owing to the nature of CA-125, being a 
antigen that is shed from the cell membrane.48,49 
In conclusion, the data available on the use of adjuvant i.p. RIT in patients 
with ovarian cancer show improved targeting after the i.p. administration, 
as compared to the i.v. administration. Despite the lack of survival benefit, 
the phase III study with 90Y-HMFG1 showed an improved local control of i.p. 
disease in patients treated with RIT.
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Colorectal Cancer
Colorectal cancer (CRC) may spread intraperitoneally, causing peritoneal 
carcinomatosis (PC). In 25% of the patients with recurrent CRC, this is the 
only site of metastasis.50 If untreated, patients suffering from PC have a 
median survival of only 6 months.51 Today’s gold standard for the treatment 
of PC is cytoreductive surgery, followed by heated i.p. chemotherapy or 
HIPEC.50 This highly specialized, extensive treatment is associated with a 
high morbidity (14%–55%) and high mortality (19%).50 Although the results 
of this treatment are promising, the median survival is 13–34 months52,53 
and the 5-year survival rate is 19%–27%.54,55 Owing to the high complication 
rates, there is a need for new treatment modalities. RIT for CRC has been 
under clinical investigation since 1992, mainly with anti-carcinoembryonic 
antigen (CEA) antibodies.56 The results of RIT in CRC were recently reviewed 
by our group.57 So far, only one trial gave the results of i.p. administered 
RIT in patients with advanced CRC. Patients with local as well as regional 
and systemic spread were included.58 Thirty-one (31) patients with large 
peritoneal metastases were treated. Patients received 5 cycles of i.p. 
administered 131I-labeled anti-CEA/TAG-72/MUC-1. This was done either 
as monotherapy (one antibody) or in combination with multiple antibodies. 
The average activity dose per cycle was 98 mCi. The researchers reported a 
median survival of 41 months, complete remission lasting 23 months in 10 
patients, stable disease that lasted for 12 months in 8 patients, and a partial 
remission in 10 patients. 
Preclinical studies in mice with colon cancer xenografts were performed by 
Keenan et al. As early as 1984, suggesting RIT might be successful for the 
treatment of colon cancer in humans.59 The preclinical as well as the clinical 
investigations of this group focussed on the i.v. route of administration, 
despite a more efficient tumor targeting in patients with PC after a i.p. 
administration than after an i.v. administration, as shown in a dual-label 
study of concomitant i.v.- and i.p.- administered 131I-labeled B72.3.10 
In nude mice with i.p. growing human colon carcinoma, the i.p. route of 
administration of radiolabeled MN14, an anti-CEA antibody, showed a 
higher tumor uptake during the first 48 hours (58.5% ± 6.8%ID/g for i.p. 
vs. 34.9% ± 4.7% ID/g for i.v.) after administration. Thereafter, the uptake 
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was similar.60 In addition, an increased therapeutic efficacy of 177Lu-(median 
survival, 136 days) and 131I-labeled MN14 (median, 100 days) was reported, 
when compared to equitoxic doses (8.33 MBq) of 90Y-(median, 82 days) and 
186Re-labeled MN14 (median, 72 days) in this model.61 The feasibility of i.p. 
RIT in an adjuvant setting to cytoreductive surgery, leaving only microscopic 
disease, was also investigated by Koppe et al. The researchers used 177Lu-
labeled MG1, a radiolabeled anti-CC531 (rat colon carcinoma) antibody 
administered after cytoreductive surgery (CS). In this model, adjuvant 
RIT resulted in a significantly improved survival of rats treated with the 
combination of CS and RIT, as compared to either CS or RIT alone.62 Despite 
these favorable preclinical studies, there are no clinical trials investigating 
the efficacy of RIT as an adjuvant treatment to cytoreductive surgery for 
peritoneal carcinomatosis of colorectal origin.
In conclusion, RIT is an effective treatment for i.p. metastases and an 
effective adjuvant to cytoreductive surgery in preclinical studies. The limited 
experience in phase I clinical trials warrants clinical studies.
34
RIT in brain tumors
An estimated 41,000 cases of primary central nervous system (CNS) tumors 
occur annually in the United States, 42% of which are glial tumors that are, 
in most cases, malignant.63 Glioblastoma multiforme, the most malignant 
form of CNS tumors, offers patients a very poor overall survival of only 
3.3% after 2 years, despite the combination of surgery, radiotherapy, and 
chemotherapy. 64 More than 90% of all recurrences are adjacent to the site of 
origin, indicating a failure of local tumor control. Conventional radiotherapy 
plays a primary role in brain cancer treatment. However, its lack of tumor 
specificity is a significant limitation of this form of therapy. Owing to its 
nonspecific nature, toxicity to normal brain limits the radiation dose that 
can be delivered to tumor cells and compromises the quality of life of the 
few longer term survivors. There are three factors responsible for treatment 
failure: (1) the delivery of therapeutic agents is limited by the blood-brain 
barrier (BBB), despite the fact that it is disrupted in regions of macroscopic 
tumor65; (2) dysfunctional tumor vasculature, as is the case in most solid 
tumors, leads to local hypoxia and a reduced responsiveness to chemo 
and radiotherapy in combination with an elevated intratumoral interstitial 
pressure66–68; (3) inter- and intratumoral cellular and genetic heterogeneity, 
leading to heterogeneous antigen expression. 69,70 
In general, adjuvant treatment consists of the use of local radiation by means 
of stereotactic radiotherapy or brachytherapy with implanted 125I rods. 
However, these approaches did not show additional effects on survival.71,72 
Recent applications of combinations of chemotherapy (temozolomide) with 
radiotherapy showed a survival benefit. The majority of patients, however, 
died within 1–2 years from progressive disease, underlining the need for new 
treatment strategies.73
The BBB regulates the exchange of substances between the vasculature and 
the CNS. This physiologic barrier is composed of tight junctions between 
the capillary endothelial cells and is supported by a microenvironment of 
astrocytes, pericytes, and microglial cells.74 This almost impenetrable barrier 
prohibits the delivery of potentially effective therapeutic agents, thereby 
limitating the treatment of CNS diseases. In the case of malignant disease, 
the deterioration of the BBB may occur, which may improve the delivery of 
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therapeutic agents to the CNS. Brain tumors can cause a complete breakdown 
of the BBB, eventually leading to peritumoral, vasogenic edema.74 Imaging 
of CNS malignancies, using radiolabeled antibodies, showed intratumoral 
accumulation following the i.v. administration, allowing for scintigraphic 
imaging. This indicates damage to the BBB. However, in general, there is 
insufficient targeting for therapeutic studies.75 To overcome the problem of 
limited penetration, the locoregional application of therapeutic agents in 
patients with malignant glioma has been investigated.76 To investigate the 
application of RIT, candidates for therapy, or tumor-associated antigens 
(TAAs), needed to be identified.
Tenascin-c
In the majority of clinical RIT studies in glioma patients, antitenascin mAbs 
were used. m81C6, a murine IgG2b with affinity for tenascin-c (TN), has 
been administrated through a s.c. implanted reservoir connected to an 
intracavitary-placed drain. TN is an extracellular matrix protein modulating 
cell-matrix interactions,77 which is overexpressed in malignant glioma tissue, 
but not expressed in the normal brain. The distribution and intensity of TN 
expression correlates well with tumor neovasculature and shows evident 
expression in aggressive histotypes as well as in those tumors with high 
proliferation indices.78–80 This distribution of TN makes it a suitable target in 
RIT in glioma (see Table 3). A series of phase I–III studies has been conducted 
at Duke University. In the first phase I study, 42 patients with recurrent 
glioma were included and the maximal tolerable dose (MTD) was assessed in 
a dose-escalation study after intracavitary (into the surgically created cavity; 
SCC) administration. This study showed that the MTD was 100 mCi for 
intracavitary-administered 131I-labeled 81C6, with neurotoxicity being the 
dose-limiting factor.81 The results of this study suggested that there was a 
potential survival benefit, as compared to patients treated with stereotactic 
radiotherapy and high-dose brachytherapy (a median survival of 60 weeks 
in the present study, as compared to 41 and 46 weeks, respectively). In the 
second study, 42 patients with newly diagnosed glioma were included in 
order to investigate dosimetry and doseresponse relationships.82,83 In these 
patients, the MTD was 120 mCi, with neurotoxicity being the dose-limiting 
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factor. The median survival of these patients was 79 weeks, as compared 
to 46 weeks of historic controls, when patients were treated with surgery, 
chemotherapy, and radiotherapy. Based on these encouraging results, a 
phase II trial was performed in 33 patients with newly diagnosed, previously 
untreated patients. The median survival after treatment with 120 mCi of 131I-
labeled 81C6 in this study was 79–85 weeks, depending on the pathologic 
type of glioma (patients with astrocytic oligodendroglioma showed a better 
response than those with glioblastoma multiforme).84 When 100 mCi 
of radiolabeled antibody was administered to 43 patients with recurrent 
glioma, survival was still 69 weeks.85 The results of these trials warranted 
a phase III trial, which is currently ongoing. Recently, a human/mouse 
chimeric mAb, originating from 81C6, has been developed, showing better 
tumor targeting in animal studies. The targeting capabilities of the antibody 
were subsequently tested in a phase I study that included 47 patients with 
recurrent disease.86 This chimeric antibody showed a prolonged retention 
time within the SCC, as compared to the antibody of murine origin. Owing 
to the enhanced circulatory half-life of the chimeric antibody, a MTD of 80 
mCi was found, as compared to 120 mCi found in previous studies with the 
murine antibody. In this phase I dose-escalation study, the median survival 
was 87 weeks for patients with newly diagnosed glioma and 65 weeks for 
those patients with recurrent disease. 
Riva et al. used another anti-tenascin antibody labeled with 131I, BC-2/4, 
initially injected directly into the tumor.87 Thereafter, the antibody was, in 
some patients repeatedly, administered into the SCC in 23 patients with 
recurrent glioblastoma. In their first report, no toxicity and an objective 
response in 11 patients, in whom were 3 complete remissions and a median 
survival of 16 months, were reported.88 The follow-up study compared 
the results of antibody administration in recurrent and newly diagnosed 
patients.89 The reported total median survival was 20 months. When bulky 
(median, 17 months) versus minimal disease (median, 26 months) were 
compared, the results supported the concept that RIT is most suitable in 
patients with small-volume disease. Later, combined data of 111 patients 
that were included in phase I and II studies showed a median survival 
of 20 months.90 The researchers concluded that the application of RIT is 
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most suitable in small-volume disease. In a following phase I study,91 the 
researchers switched to the application of an other radionuclide, 90Y, in 20 
patients and determined the MTD to be 25 mCi with neurotoxicity as the 
dose-limiting toxicity. No diffusion of the radiolabeled antibody to normal 
tissue was reported. However, this study failed to show clinical responses, 
presumably owing to the inclusion of patients with advanced disease.
Paganelli et al.92,93 investigated the use of the pretargeting technique 
consisting of the biotinylated antitenascin MAb BC4, avidin and 90Y-biotin, 
both i.v. administered as well as directly into the SCC, following surgical 
debulking. In this pretargeting approach, the large IgG-avidin conjugate was 
administered first, followed by a 90Y-labeled biotin injection. These studies 
showed no hematologic toxicity following the RIT when applied into the 
SCC, as compared to almost all the other studies that used mAbs, including 
the study where pretargeting was used and administered i.v. This latter 
study supports the local administration technique by showing a total body 
distribution of the biotinylated mAb and fast blood clearance within hours 
after the i.v. administration.
To summarize, the phase I–II studies from Duke University on the use of 
adjuvant RIT after debulking surgery in patients with malignant glioma 
indicate an improved survival, as compared to historic control groups. In 
addition, there was a reduction in treatment-related toxicity, compared to 
stereotactic radiotherapy or brachy therapy. This resulted in a phase III 
trial that is currently ongoing. The results from Riva et al., despite the more 
heterogeneous group of patients, support this conclusion. 
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Intravesical RIT
Bladder cancer is the second most common cancer of the genito-urinary 
system, mainly occurring in men. Two distinct types of urothelial cancer 
exist, the majority of which are superficial and noninvasive. However, 
the remaining 20% are solid, highly aggressive bladder cancers that are 
invasive and metastasize in an early phase of the disease.94 Cystectomy 
is the treatment of choice for a tumor stage of T2–T4 (muscle invasive), 
leaving local resection to CIS and T1 disease. In T1 urothelial carcinoma 
recurrence rates are as high as 80% after resection.95 When intravesical 
chemotherapy is added to surgery, recurrence rates are reduced by 50% at 
2 years. Part of the contemporary bladder-sparing treatment is the use of 
immunotherapy by means of an intravesical Bacille Calmette-Guérin (BCG) 
instillation, the results of which are comparable to those achieved with 
chemotherapy.96 Since the standard therapy in invasive bladder cancer is 
radical cystectomy, the role of RIT is limited to CIS and T1 disease. Despite 
several preclinical experiments, reports on the clinical use of radiolabeled 
antibodies in patients with bladder cancer are limited to investigations on 
radioimmunoscintigraphy studies rather than RIT (see Table 4). In these 
studies, antibodies directed against the target antigen MUC-1 are used. 
MUC-1 mucin is a high-molecular-weight cell-surface glycoprotein that 
is found on normal urothelium and that is both unregulated as well as 
abnormally glycosylated in bladder cancer.97 One of the first studies in 20 
patients was performed by Bamias et al., who intravesically administered 
the 111In-labeled anti-MUC-1 antibody HMFG2.98 Autoradiography of the 
resected specimen showed selective tumor targeting. Murray et al. used 
an intravesically administered 188Re-labeled C595 antibody in 3 patients 
with transitional cell carcinoma.99 In addition, this group investigated the 
intravesical administration of 67Cu-labeled C595 in 16 patients with bladder 
cancer and studied the systemic absorption of the radiolabeled antibody.100 
The results of this study showed no detectable activity above the background, 
meaning there was no systemic radiolabel present after the local application, 
while 80% of the tumors were successfully visualized.
Malamitsi et al. investigated the intravesical application of 99mTc-labeled 
MUC-1 antibody HMFG1 in 14 patients and concluded that, despite the 
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excellent imaging of tumors, future attempts to administer RIT using 
HMFG1 should not be undertaken owing to a low and heteroge-neous 
uptake in the 6 patients with positive imaging (0%–9% injected dose) caused 
by heterogeneous antigen expression.101
In conclusion, intravesically administered RIS in bladder cancer may hold a 
promise for RIT, using anti-MUC1 antibodies, in early urothelial cell cancer 
owing to selective targeting and low systemic concentrations of the targeting 
agent.
Table 4.
Intravesical
RIS
Indication TAA Antibody Nuclide Targeting
Author
Bamias et al.98 SUC MUC1 HMFG2 111In +
Murray et al.99 TCC MUC1 C595 188Re 4/5
Hughes et al.100 SUC-T2 MUC1 C595 67Cu 12/16
Malamitsi et 
al.101 
SUC MUC1 HMFG1
99mTc/
131I
+/-
Bamias et al.98 SUC MUC1 HMFG2 111In +
Intrathoracic RIT
The prognosis of patients with malignant pleural mesothelioma (MPM) is 
poor. In general, median survival is 6–16 months. The malignant form can be 
classified in two categories: diffuse or localized. Both are essentially insensitive 
to any treatment.102 Different agents for intracavitary chemotherapy to treat 
mesothelioma have been utilized. The response rate varied between 15% and 
37%, without effect on survival, even when used in combination with paclitaxel 
and docetaxel. The clinical data regarding studies that used intrathoracic 
chemotherapy adjuvant to surgical debulking were disappointing.103,104 
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Therefore, the intrathoracic application of chemotherapeutic agents is mainly 
used to treat malignant pleural effusion.105,106 Another obstacle for RIT of 
mesothelioma is the low tumor antigen (mesothelin, tenascin-c) expression.107 
Enhancing antigen expression with proinflammatory cytokines, however, do 
not improve survival after immunotherapy.108
Mesothelin is a 40-kD cell-surface glycosylated phosphatidylinositol (GPI)-
anchored glycoprotein, with functions in cell-to-cell adhesion expressed by 
normal mesothelial cells. It is highly overexpressed in cancers as malignant 
mesothelioma, pancreatic or ovarian carcinoma sarcomas, and in some 
gastrointestinal or pulmonary carcinomas.109 In preclinical studies, Hassan 
et al. and Fan et al. have used antimesothelin antibodies and antibody 
fragments linked to exotoxins to treat mesothelin-expressing tumors in nude 
mice. The development of experimental metastases was inhibited, and even 
a complete regression of the tumor was observed in some cases. 110,111
In conclusion, this antigen may be an attractive target for the intrathoracic 
application of RIT, but no clinical RIT studies have been performed. 
Currently, a clinical trial is being conducted, using a chimeric mAb 
(MORAb-009) directed against a cell-surface glycoprotein, GP-9, that is 
overexpressed in epithelial type cancers as mesothelioma, ovarian, and 
pancreatic cancer.(www.clinicaltrials.gov,trailnr.NCT00325494) GP-9 may, 
therefore, be a potentially suitable target for radiolabeled MORAb-009 in 
future RIT of MPM.
Malignant pleural effusion (MPE)
MPE is thought to arise from tumor emboli detaching from visceral 
tumor nodules and concomitant attachment to the parietal pleura. Also, 
direct tumor invasion (in lung cancers, chest wall neoplasms, and breast 
carcinoma), hematogenous spread to the parietal pleura, and lymphatic 
involvement may be a mechanism for development of MPE. The effusion is 
composed of extracellular matrix proteins, cytokines, and growth factors, 
thereby promoting cell proliferation and invasion.112 
In women, the most common causes of these effusions are breast and 
ovarian cancer, whereas in men, these are lung cancer and malignant 
pleural mesothelioma. Treatment of this specific entity can be done by either 
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therapeutical pleural aspiration (in case of a very short life expectancy), talc 
pleurodesis, or indwelling catheters. MPM with MPE is also an indication for 
intrapleural therapy, as is the case with MPE arising from ovarian cancer. 
Schmidt et al. described the successful intrapleural application of rituximab, 
an anti-CD20 mAb, in a patient with NHL who was free of symptoms 
for 8 months after this treatment.113 The researchers described a case 
report regarding treatment failure of repeated percutaneous drainage and 
bilateral continuous chest tube drainage. This result may be promising, in 
particular when considering the possibilities of the effects of the application 
of radiolabeled antibodies. This is the case with 90Y-labeled ibritumomab 
tiuxetan for the treatment of NHL, where the RIT produces significantly 
better responses than the mAb alone.114
Awaiting the results of the trial using MORAb- 009 in the case of MPM and 
the future development of TAAs directed against MPM, there may be a role 
for RIT in the treatment of MPM. In addition, RIT may play a role in the 
palliative treatment in patients with MPE, regardless of the origin of the 
primary tumor.
Discussion
The intracavitary application of radiolabeled antibodies combines the 
advantage of high tumor doses and low systemic toxicity. Therefore, higher 
doses of RIT can be applied than with systemic administration.
Currently, RIT with radiolabeled anti-CD20 antibodies is an accepted 
treatment for patients with NHL. For other indications, only a limited number 
of clinical phase I/II and one phase III RIT trials have been performed, 
using different antibodies and radionuclides in patients with different 
types of cancer. The results various studies on the therapeutic efficacy and 
toxicity of RIT in patients with ovarian cancer (90Y-HMFG-1, 177Lu-B72.3) 
and malignant glioma (131I-81C6) indicate that the adjuvant application of 
RIT within a confined area limits toxicity and improves tumor targeting. In 
addition, RIT should be applied as a treatment of patients with minimal 
residual or microscopic disease of solid cancers in order to gain from its 
maximal potential. 
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For the treatment of ovarian cancer, the application of RIT was studied in 
a randomized, phase III trial. Unfortunately, the results of the latter study 
showed no survival benefit. The lack of efficacy of adjuvant RIT in this trial 
could be owing to several factors. First, the selection of the high-energy 
beta-emitter 90Y, with a maximum tissue penetration of 12 mm, is not 
appropriate, since most of the energy will be deposited outside small tumor 
deposits in small-volume or microscopic disease. Second, the protein dose 
was augmented with 20 mg of unlabeled antibody to a total of 25 mg 90Y-
HMFG1, with the intent to provoke a human antimouse antibody response. 
This high antibody dose might have had a negative effect on the uptake of 
the radiolabel in the tumor lesions owing to the saturation of MUC-1
epitopes on the tumor cells.115 In the future, however, optimizing this 
treatment, using nuclides such as 177Lu that are more suitable for minimal 
residual disease than 90Y in order to enhance the antitumor effect, may 
result in survival benefit.
The same can be true for the treatment of peritoneal carcinomatosis of 
colorectal origin when trials will be undertaken to treat this entity. Progress 
has been made in the treatment of recurrent glioma by the application of RIT 
and this treatment may, therefore, become an additional adjuvant treatment 
modality in neuro-oncology.
Conclusion
In the case of superficial bladder cancer, promising results of preclinical 
and radioimmunoscintigraphy studies may precede phase I and II trials. 
When therapeutic options are no longer available, RIT may offer patients a 
chance of minimally invasive palliation in patients with MPM or MPE. The 
future of RIT may, therefore, not only be in the inclusion in contemporary 
multimodality treatment, but also in the expansion of its indication to 
palliative treatment as a supplement or even a substitution for present-day 
treatments.
44
References
 1.  Goyle S, Maraveyas A. Chemotherapy for colorectal cancer. Dig Surg 2005; 22:401-
414.
 2.  Yan T, Welch L, Black D et al. A systematic review on the efficacy of cytoreductive 
surgery combined with perioperative intraperitoneal chemotherapy for diffuse 
malignancy peritoneal mesothelioma. Ann Oncol 2007; 18:827-834.
 3.  Fisher RI, Kaminski MS, Wahl RL et al. Tositumomab and iodine-131 tositumomab 
produces durable complete remissions in a subset of heavily pretreated patients with 
low-grade and transformed non-Hodgkin‘s lymphomas. J Clin Oncol 2005; 23:7565-
7573.
 4.  Davis TA, Kaminski MS, Leonard JP et al. The radioisotope contributes significantly 
to the activity of radioimmunotherapy. Clin Cancer Res 2004; 10:7792-7798.
 5.  Gordon LI, Molina A, Witzig T et al. Durable responses after ibritumomab tiuxetan 
radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 
study. Blood 2004; 103:4429-4431.
 6.  Kaanders JH, Bussink J, van der Kogel AJ. ARCON: a novel biology-based approach 
in radiotherapy. Lancet Oncol 2002; 3:728-737.
 7.  Kaanders JH, Bussink J, van der Kogel AJ. Clinical studies of hypoxia modification in 
radiotherapy. Semin Radiat Oncol 2004; 14:233-240.
 8.  Heldin CH. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev 
Cancer 2004; 4:806-813.
 9.  Koppe MJ, Soede AC, Pels W et al. Experimental radioimmunotherapy of small 
peritoneal metastases of colorectal origin. Int J Cancer 2003; 106:965-972.
 10.  Colcher D, Esteban J, Carrasquillo JA et al. Complementation of intracavitary 
and intravenous administration of a monoclonal antibody (B72.3) in patients with 
carcinoma. Cancer Res 1987; 47:4218-4224.
 11.  Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of 
predefined specificity. Nature 1975; 256:495-497.
 12.  Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled 
monoclonal antibodies. Q J Nucl Med Mol Imaging 2006; 50:248-264.
 13.  Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004; 
5:292-302.
 14.  Lin MZ, Teitell MA, Schiller GJ. The evolution of antibodies into versatile tumor-
targeting agents. Clin Cancer Res 2005; 11:129-138.
 15.  Sharkey RM, Blumenthal RD, Behr TM et al. Selection of radioimmunoconjugates 
for the therapy of well-established or micrometastatic colon carcinoma. Int J Cancer 
1997; 72:477-485.
 16.  Uusijarvi H, Bernhardt P, Rosch F et al. Electron- and positron-emitting 
radiolanthanides for therapy: aspects of dosimetry and production. J Nucl Med 2006; 
47:807-814.
 
 Intracavitary Radioimmunotherapy
45
C
h
a
pte
R 2
 17.  Shih LB, Thorpe SR, Griffiths GL et al. The processing and fate of antibodies and 
their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine 
radiolabels. J Nucl Med 1994; 35:899-908.
 18.  Koppe MJ, Bleichrodt RP, Soede AC et al. Biodistribution and therapeutic efficacy 
of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 
to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal 
origin. J Nucl Med 2004; 45:1224-1232.
 19.  Novak-Hofer I, Schubiger PA. Copper-67 as a therapeutic nuclide for 
radioimmunotherapy. Eur J Nucl Med Mol Imaging 2002; 29:821-830.
 20.  Yao V, Platell C, Hall JC. Role of peritoneal mesothelial cells in peritonitis. Br J Surg 
2003; 90:1187-1194.
 21.  Dedrick RL, Flessner MF. Pharmacokinetic considerations on monoclonal antibodies. 
Prog Clin Biol Res 1989; 288:429-438.
 22.  Flessner MF, Dedrick RL. Monoclonal antibody delivery to intraperitoneal tumors in 
rats: effects of route of administration and intraperitoneal solution osmolality. Cancer 
Res 1994; 54:4376-4384.
 23.  van Ruth S, Verwaal VJ, Zoetmulder FA. Pharmacokinetics of intraperitoneal 
mitomycin C. Surg Oncol Clin N Am 2003; 12:771-780.
 24.  Koppe MJ, Bleichrodt RP, Soede AC et al. Biodistribution and therapeutic efficacy 
of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 
to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal 
origin. J Nucl Med 2004; 45:1224-1232.
 25.  Koppe MJ, Soede AC, Pels W et al. Experimental radioimmunotherapy of small 
peritoneal metastases of colorectal origin. Int J Cancer 2003; 106:965-972.
 26.  van Zanten-Przybysz I, Molthoff CF, Roos JC et al. Influence of the route of 
administration on targeting of ovarian cancer with the chimeric monoclonal antibody 
MOv18: i.v. vs. i.p. Int J Cancer 2001; 92:106-114.
 27.  Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface 
epithelium dogma: does the emperor have no clothes? Gynecol Oncol 1999; 72:437-
442.
 28.  Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet 
Gynecol 2006; 107:1399-1410.
 29.  Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. 
Semin Oncol 2006; 33:S3-11.
 30.  Rubin SC. Monoclonal antibodies in the management of ovarian cancer. A clinical 
perspective. Cancer 1993; 71:1602-1612.
 31.  Haisma HJ, Moseley KR, Battaile AI et al. Biodistribution, pharmacokinetics and 
imaging of 131I-labelled OC125 in ovarian cancer. Int J Cancer Suppl 1988; 2:109-
113.
 32.  Buijs WC, Tibben JG, Boerman OC et al. Dosimetric analysis of chimeric monoclonal 
antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and 
intravenous administration. Eur J Nucl Med 1998; 25:1552-1561.
46
 33.  Kalofonos HP, Karamouzis MV, Epenetos AA. Radioimmunoscintigraphy in patients 
with ovarian cancer. Acta Oncol 2001; 40:549-557.
 34.  Epenetos AA, Munro AJ, Stewart S et al. Antibody-guided irradiation of advanced 
ovarian cancer with intraperitoneally administered radiolabeled monoclonal 
antibodies. J Clin Oncol 1987; 5:1890-1899.
 35.  Nicholson S, Gooden CS, Hird V et al. Radioimmunotherapy after chemotherapy 
compared to chemotherapy alone in the treatment of advanced ovarian cancer: a 
matched analysis. Oncol Rep 1998; 5:223-226.
 36.  Epenetos AA, Hird V, Lambert H et al. Long term survival of patients with advanced 
ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol 
Cancer 2000; 10:44-46.
 37.  Verheijen RH, Massuger LF, Benigno BB et al. Phase III trial of intraperitoneal therapy 
with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with 
epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 
2006; 24:571-578.
 38.  Massuger LF, Verheijen RH, Seiden MV. Intraperitoneal disease control after i.p. 
concolidation treatment with yttrium-90- labeled HMFG1 monoclonal antibody in 
patients with epithelial ovarian cancer. Annual Meeting on 
  Women’s Cancer of the Society of Gynecologic Oncologist.  2005. 
Conference Proceeding
 39.  Rosenblum MG, Kavanagh JJ, Burke TW et al. Clinical pharmacology, metabolism, 
and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal 
administration. J Natl Cancer Inst 1991; 83:1629-1636.
 40.  Meredith RF, Partridge EE, Alvarez RD et al. Intraperitoneal radioimmunotherapy of 
ovarian cancer with lutetium-177-CC49. J Nucl Med 1996; 37:1491-1496.
 41.  Rosenblum MG, Verschraegen CF, Murray JL et al. Phase I study of 90Y-labeled 
B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose 
and EDTA coadministration on pharmacokinetics and toxicity. Clin Cancer Res 1999; 
5:953-961.
 42.  Alvarez RD, Partridge EE, Khazaeli MB et al. Intraperitoneal radioimmunotherapy of 
ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol 1997; 65:94-
101.
 43.  Roselli M, Guadagni F, Buonomo O et al. Systemic administration of recombinant 
interferon alfa in carcinoma patients upregulates the expression of the carcinoma-
associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen. 
J Clin Oncol 1996; 14:2031-2042.
 44.  Meredith RF, Alvarez RD, Partridge EE et al. Intraperitoneal radioimmunochemotherapy 
of ovarian cancer: a phase I study. Cancer Biother Radiopharm 2001; 16:305-315.
 45.  Miotti S, Facheris P, Tomassetti A et al. Growth of ovarian-carcinoma cell lines at 
physiological folate concentration: effect on folate-binding protein expression in vitro 
and in vivo. Int J Cancer 1995; 63:395-401.
 Intracavitary Radioimmunotherapy
47
C
h
a
pte
R 2
 46.  Crippa F, Bolis G, Seregni E et al. Single-dose intraperitoneal radioimmunotherapy 
with the murine monoclonal antibody I-131 MOv18: clinical results in patients with 
minimal residual disease of ovarian cancer. Eur J Cancer 1995; 31A:686-690.
 47.  Mahe MA, Fumoleau P, Fabbro M et al. A phase II study of intraperitoneal 
radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients 
with residual ovarian carcinoma. Clin Cancer Res 1999; 5:3249s-3253s.
 48.  O’Brien TJ, Tanimoto H, Konishi I et al. More than 15 years of CA 125: what is known 
about the antigen, its structure and its function. Int J Biol Markers 1998; 13:188-
195.
 49.  Haisma HJ, Battaile A, Stradtman EW et al. Antibody-antigen complex formation 
following injection of OC125 monoclonal antibody in patients with ovarian cancer. Int 
J Cancer 1987; 40:758-762.
 50.  Koppe MJ, Boerman OC, Oyen WJ et al. Peritoneal carcinomatosis of colorectal origin: 
incidence and current treatment strategies. Ann Surg 2006; 243:212-222.
 51.  Jayne DG, Fook S, Loi C et al. Peritoneal carcinomatosis from colorectal cancer. Br J 
Surg 2002; 89:1545-1550.
 52.  Glehen O, Cotte E, Schreiber V et al. Intraperitoneal chemohyperthermia and attempted 
cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. 
Br J Surg 2004; 91:747-754.
 53.  Culliford AT, Brooks AD, Sharma S et al. Surgical debulking and intraperitoneal 
chemotherapy for established peritoneal metastases from colon and appendix cancer. 
Ann Surg Oncol 2001; 8:787-795.
 54.  Glehen O, Kwiatkowski F, Sugarbaker PH et al. Cytoreductive surgery combined 
with perioperative intraperitoneal chemotherapy for the management of peritoneal 
carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004; 
22:3284-3292.
 55.  Elias D, Blot F, El OA et al. Curative treatment of peritoneal carcinomatosis arising 
from colorectal cancer by complete resection and intraperitoneal chemotherapy. 
Cancer 2001; 92:71-76.
 56.  Meredith RF, Khazaeli MB, Liu T et al. Dose fractionation of radiolabeled antibodies in 
patients with metastatic colon cancer. J Nucl Med 1992; 33:1648-1653.
 57.  Koppe MJ, Bleichrodt RP, Oyen WJ et al. Radioimmunotherapy and colorectal cancer. 
Br J Surg 2005; 92:264-276.
 58.  Riva P, Tison V, Arista A et al. Radioimmunotherapy of gastrointestinal cancer and 
glioblastomas. Int J Biol Markers 1993; 8:192-197.
 59.  Keenan AM, Colcher D, Larson SM et al. Radioimmunoscintigraphy of human colon 
cancer xenografts in mice with radioiodinated monoclonal antibody B72.3. J Nucl 
Med 1984; 25:1197-1203.
 60.  Koppe MJ, Soede AC, Pels W et al. Experimental radioimmunotherapy of small 
peritoneal metastases of colorectal origin. Int J Cancer 2003; 106:965-972.
48
 61.  Koppe MJ, Bleichrodt RP, Soede AC et al. Biodistribution and therapeutic efficacy of 
(125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal 
  antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases 
of colorectal origin. J Nucl Med 2004; 45:1224-1232.
 62.  Koppe MJ, Hendriks T, Boerman OC et al. Radioimmunotherapy is an effective 
adjuvant treatment modality after cytoreductive surgery of peritoneal carcinomatosis 
of colonic origin. J Nucl Med 2006; 47:1867-1874.
 63.  Reardon DA, Rich JN, Friedman HS et al. Recent advances in the treatment of 
malignant astrocytoma. J Clin Oncol 2006; 24:1253-1265.
 64.  Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: a population-
based study. Cancer Res 2004; 64:6892-6899.
 65.  Brooks DJ, Beaney RP, Lammertsma AA et al. Quantitative measurement of blood-
brain barrier permeability using rubidium-82 and positron emission tomography. J 
Cereb Blood Flow Metab 1984; 4:535-545.
 66.  Vajkoczy P, Menger MD. Vascular microenvironment in gliomas. Cancer Treat Res 
2004; 117:249-262.
 67.  Evans SM, Judy KD, Dunphy I et al. Hypoxia is important in the biology and aggression 
of human glial brain tumors. Clin Cancer Res 2004; 10:8177-8184.
 68.  Jain RK. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging 
of gene expression and function. J Control Release 2001; 74:7-25.
 69.  Burger PC, Vogel FS, Green SB et al. Glioblastoma multiforme and anaplastic 
astrocytoma. Pathologic criteria and prognostic implications. Cancer 1985; 56:1106-
1111.
 70.  Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer 
2000; 88:2887.
 71.  Souhami L, Seiferheld W, Brachman D et al. Randomized comparison of stereotactic 
radiosurgery followed by conventional radiotherapy with carmustine to conventional 
radiotherapy with carmustine for patients with glioblastoma multiforme: report of 
Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004; 
60:853-860.
 72.  Selker RG, Shapiro WR, Burger P et al. The Brain Tumor Cooperative Group NIH Trial 
87-01: a randomized comparison of surgery, external radiotherapy, and carmustine 
versus surgery, interstitial radiotherapy boost, external radiation therapy, and 
carmustine. Neurosurgery 2002; 51:343-355.
 73.  Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and 
adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996.
 74.  Arismendi-Morillo G, Castellano A. Tumoral micro-blood vessels and vascular 
microenvironment in human astrocytic tumors. A transmission electron microscopy 
study. J Neurooncol 2005; 73:211-217.
 75.  Schold SC, Jr., Zalutsky MR, Coleman RE et al. Distribution and dosimetry of I-123-
labeled monoclonal antibody 81C6 in patients with anaplastic glioma. Invest Radiol 
1993; 28:488-496.
 Intracavitary Radioimmunotherapy
49
C
h
a
pte
R 2
 76.  Guerin C, Olivi A, Weingart JD et al. Recent advances in brain tumor therapy: local 
intracerebral drug delivery by polymers. Invest New Drugs 2004; 22:27-37.
 77.  Hsia HC, Schwarzbauer JE. Meet the tenascins: multifunctional and mysterious. J 
Biol Chem 2005; 280:26641-26644.
 78.  Zagzag D, Friedlander DR, Dosik J et al. Tenascin-C expression by angiogenic vessels 
in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 
1996; 56:182-189.
 79.  McLendon RE, Wikstrand CJ, Matthews MR et al. Glioma-associated antigen 
expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor 
receptor. J Histochem Cytochem 2000; 48:1103-1110.
 80.  Kim CH, Bak KH, Kim YS et al. Expression of tenascin-C in astrocytic tumors: its 
relevance to proliferation and angiogenesis. Surg Neurol 2000; 54:235-240.
 81.  Bigner DD, Brown MT, Friedman AH et al. Iodine-131-labeled antitenascin monoclonal 
antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial 
results. J Clin Oncol 1998; 16:2202-2212.
 82.  Akabani G, Cokgor I, Coleman RE et al. Dosimetry and dose-response relationships 
in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled 
anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys 2000; 
46:947-958.
 83.  Cokgor I, Akabani G, Kuan CT et al. Phase I trial results of iodine-131-labeled 
antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed 
malignant gliomas. J Clin Oncol 2000; 18:3862-3872.
 84.  Reardon DA, Akabani G, Coleman RE et al. Phase II trial of murine (131)I-labeled 
antitenascin monoclonal antibody 81C6 administered into surgically created resection 
cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002; 
20:1389-1397.
 85.  Reardon DA, Akabani G, Coleman RE et al. Salvage radioimmunotherapy with murine 
iodine-131-labeled antitenascin monoclonal antibody 81C6 for 
 patients with recurrent primary and metastatic malignant brain tumors: phase II 
study results. J Clin Oncol 2006; 24:115-122.
 86.  Reardon DA, Quinn JA, Akabani G et al. Novel human IgG2b/murine chimeric 
antitenascin monoclonal antibody construct radiolabeled with 131I and administered 
into the surgically created resection cavity of patients with malignant glioma: phase I 
trial results. J Nucl Med 2006; 47:912-918.
 87.  Riva P, Arista A, Sturiale C et al. Treatment of intracranial human glioblastoma by 
direct intratumoral administration of 131I-labelled anti-tenascin monoclonal antibody 
BC-2. Int J Cancer 1992; 51:7-13.
 88.  Riva P, Arista A, Tison V et al. Intralesional radioimmunotherapy of malignant gliomas. 
An effective treatment in recurrent tumors. Cancer 1994; 73:1076-1082.
 89.  Riva P, Arista A, Franceschi G et al. Local treatment of malignant gliomas by direct 
infusion of specific monoclonal antibodies labeled with 131I: comparison of the results 
obtained in recurrent and newly diagnosed tumors. Cancer Res 1995; 55:5952s-
5956s.
50
 90.  Riva P, Franceschi G, Frattarelli M et al. 131I radioconjugated antibodies for the 
locoregional radioimmunotherapy of high-grade malignant glioma--phase I and II 
study. Acta Oncol 1999; 38:351-359.
 91.  Riva P, Franceschi G, Frattarelli M et al. Loco-regional radioimmunotherapy of high-
grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a 
phase I study. Clin Cancer Res 1999; 5:3275s-3280s.
 92.  Paganelli G, Bartolomei M, Ferrari M et al. Pre-targeted locoregional radioimmunotherapy 
with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. 
Cancer Biother Radiopharm 2001; 16:227-235.
 93.  Paganelli G, Grana C, Chinol M et al. Antibody-guided three-step therapy for high 
grade glioma with yttrium-90 biotin. Eur J Nucl Med 1999; 26:348-357.
 94.  Dinney CP. Therapy of invasive bladder cancer. Urology 2006; 67:56-59.
 95.  Nieder AM, Brausi M, Lamm D et al. Management of stage T1 tumors of the bladder: 
International Consensus Panel. Urology 2005; 66:108-125.
 96.  Shelley MD, Court JB, Kynaston H et al. Intravesical Bacillus Calmette-Guerin 
versus Mitomycin C for Ta and T1 Bladder Cancer. Cochrane Database Syst Rev 
2003.
 97.  Walsh MD, Hohn BG, Thong W et al. Mucin expression by transitional cell carcinomas 
of the bladder. Br J Urol 1994; 73:256-262.
 98.  Bamias A, Bowles MJ, Krausz T et al. Intravesical administration of indium-111-
labelled HMFG2 monoclonal antibody in superficial bladder carcinomas. Int J Cancer 
1993; 54:899-903.
 99.  Murray A, Simms MS, Scholfield DP et al. Production and characterization of 188Re-
C595 antibody for radioimmunotherapy of transitional cell bladder cancer. J Nucl 
Med 2001; 42:726-732.
 100.  Hughes OD, Bishop MC, Perkins AC et al. Targeting superficial bladder cancer by 
the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal 
antibody C595. J Clin Oncol 2000; 18:363-370.
 101.  Malamitsi J, Zorzos J, Varvarigou AD et al. Immunolocalization of transitional cell 
carcinoma of the bladder with intravesically administered technetium-99m labelled 
HMFG1 monoclonal antibody. Eur J Nucl Med 1995; 22:25-31.
 102.  Sterman DH, Kaiser LR, Albelda SM. Advances in the treatment of malignant pleural 
mesothelioma. Chest 1999; 116:504-520.
 103.  van Ruth S, Baas P, Haas RL et al. Cytoreductive surgery combined with intraoperative 
hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. 
Ann Surg Oncol 2003; 10:176-182.
 104.  van RS, van TO, Korse CM et al. Pharmacokinetics of doxorubicin and cisplatin 
used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive 
surgery for malignant pleural mesothelioma and pleural thymoma. Anticancer Drugs 
2003; 14:57-65.
 105.  Kasahara K, Shibata K, Shintani H et al. Randomized phase II trial of OK-432 in 
patients with malignant pleural effusion due to non-small cell lung cancer. Anticancer 
Res 2006; 26:1495-1499.
 Intracavitary Radioimmunotherapy
51
C
h
a
pte
R 2
 106.  Eitan R, Levine DA, bu-Rustum N et al. The clinical significance of malignant pleural 
effusions in patients with optimally debulked ovarian carcinoma. Cancer 2005; 
103:1397-1401.
 107.  Fitzpatrick DR, Peroni DJ, Bielefeldt-Ohmann H. The role of growth factors and 
cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J 
Respir Cell Mol Biol 1995; 12:455-460.
 108.  Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 
353:1591-1603.
 109.  Scherpereel A, Grigoriu B, Conti M et al. Soluble mesothelin-related peptides in 
the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006; 
173:1155-1160.
 110.  Hassan R, Viner JL, Wang QC et al. Anti-tumor activity of K1-LysPE38QQR, an 
immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian 
cancer and malignant mesothelioma. J Immunother 2000; 23:473-479.
 111.  Fan D, Yano S, Shinohara H et al. Targeted therapy against human lung cancer in 
nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. 
Mol Cancer Ther 2002; 1:595-600.
 112.  Lynch CC, Matrisian LM. Matrix metalloproteinases in tumor-host cell communication. 
Differentiation 2002; 70:561-573.
 113.  Schmidt HH, Renner H, Linkesch W. Intrapleural instillation of rituximab for the 
treatment of malignant pleural effusions in NHL. Haematologica 2004; 89:ECR39.
 114.  Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-
labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy 
for patients with relapsed or refractory low-grade, follicular, or transformed B-cell 
non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20:2453-2463.
 115.  Kranenborg MH, Boerman OC, de Weijert MC et al. The effect of antibody protein 
dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell 
carcinoma xenografts. Cancer 1997; 80:2390-2397.
52

Abstract
The purpose of this study was to investigate the effect of postoperative timing of 
radioimmunotherapy when administered as adjuvant treatment to cytoreductive 
surgery. PC was induced by intraperitoneal inoculation of CC-531 colon carcinoma 
cells in Wag/Rij rats. Subsequently, seven days after tumor induction, animals were 
subjected to exploratory laparotomy (C), CS only or CS + RIT at different time points 
after surgery. RIT consisted of 55 MBq 177lutetium- labelled anti-CC531 antibody 
MG1. The primary endpoint in this study was survival. CS with or without RIT was 
well-tolerated. Median survival of animals in the C and CS group was 29 days and 
39 days, respectively (P<0.04). Compared to CS alone, median survival of rats after 
adjuvant RIT was 77 days (P<0.0001), 52 days (P<0.0001) and 45 days (P<0.0001) 
when given directly, four days and 14 days after surgery, respectively. From this 
study we concluded that the efficacy of adjuvant RIT after CS for the treatment of 
PC of colonic origin decreases when the administration of the radiolabeled MAbs is 
postponed. Therefore, the results of this study indicate that adjuvant RIT should be 
given as early after surgery as possible.
Chapter 3
Timing of Adjuvant Radioimmunotherapy after Cytoreductive 
Surgery in Experimental Peritoneal Carcinomatosis of Colorec-
tal OriginColorectal Origin
This chapter is based on:
Timing of Adjuvant Radioimmunotherapy after Cytoreductive Surgery in 
Experimental Peritoneal Carcinomatosis of Colorectal Origin. Aarts F,  Koppe MJ, 
Hendriks T, van Eerd-Vismale J, Oyen W. J.G, Boerman O.C, Bleichrodt R.P. Ann 
Surg Oncol. 2007 Feb;14(2):533-40.
Introduction
If untreated, peritoneal carcinomatosis (PC) of colorectal carcinomas (CRC) 
is one of the end stages of colorectal cancer, occurring either synchronous 
or metachronous in 5-50% of patients.1 Efforts to improve survival in 
these patients include extensive surgical procedures in combination with 
(hyperthermic) intraperitoneal chemotherapy (HIPEC).2,3 An analysis 
of the results of 16 clinical trials on the use of cytoreductive surgery + 
HIPEC in patients with PC of colorectal origin, indicated that the extent 
of carcinomatosis and completeness of resection were the factors most 
prominently related to survival.4 Still, five-year survival rates of the patients 
with the most favorable clinicopathological characteristics varies from only 
20% to 53%, with most recurrences occurring intraperitoneally.5 Therefore, 
more effective adjuvant treatments are necessary to improve the results of 
CS.
In recent years, an increased interest in various experimental treatments 
developed to further improve this survival in both preclinical as well as in 
clinical studies.6-8. Preclinical studies focussed on the efficacy of targeted 
therapies for the treatment of PC, some utilizing monoclonal antibodies (MAbs) 
directed against tumor-associated antigens and labeled with a radionuclide 
in order to selectively irradiate tumor cells (radioimmunotherapy (RIT)).9,10 
Our previous RIT studies in Wag/Rij rats with intraperitoneal CC-531 tumors 
demonstrated the feasibility and efficacy of adjuvant intraperitoneal RIT 
after CS. RIT was given using 177Lu-labeled anti-CC531 antibodies that were 
administered 3 days after CS. Administration of RIT at this time interval 
caused prolonged survival but did not influence the number of cures. Based 
on these promising results we hypothesized that the efficacy of adjuvant 
RIT after CS could be further improved when the timing of postoperative 
administration of the radiolabeled Mabs would be optimized. To test this 
hypothesis, the efficacy of adjuvant RIT administered on various time points 
after CS was investigated.
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Materials and Methods 
Experimental Design
Seven days after intraperitoneal tumor induction with 2.0 x 106 CC-531 
tumor cells, 75 rats, fifteen per treatment group, were randomly assigned 
to undergo exploratory sham surgery ( Sham), CS only (CS), CS+RIT 
administered immediately postoperatively (CS+RIT 0), CS+RIT administered 
four days postoperatively (CS+RIT 4), or CS+RIT administered fourteen days 
postoperatively (CS+RIT 14). 
Cell line
The syngeneic rat colon carcinoma cell line CC531, originally induced in 
Wag/Rij rats by intravenous injection of 1,2- dimethylhydrazine11, was 
cultured and maintained as monolayer in RPMI-1640 medium (GIBCO, 
BRL Life Sciences Technologies, The Netherlands) supplemented with 10% 
fetal calf serum (GIBCO), 2 mM L-glutamine, penicillin (100 U/mL) and 
streptomycin (100 μg/mL) at 37° C in a humidified atmosphere with 5% CO2. 
Before inoculation, tumor cells were washed with 0.9% sodium chloride, 
disaggregated with 0.25% trypsin and resuspended in RPMI-1640 medium 
to a concentration of 1x106 cells/ ml. Two mL of this cell suspension was 
injected intraperitoneally, as previously described. 12
Animals
Male WAG/Rij rats (10-12 weeks old, body weight 240-260 g, Harlan, Horst, 
The Netherlands) were and housed under non-sterile standard conditions 
(temperature, 20–24°C; relative humidity, 50-60%; 12 h light/dark cycle) in 
filter-topped cages (2 rats per cage), with free access to food (Ssniff, Bio Services 
Uden, The Netherlands) and water. The rats were allowed to accustome to 
laboratory conditions for at least one week before experimental use. Physical 
condition was examined daily and total body weight was recorded twice a 
week by a biotechnician, who was blinded to the therapeutic regimen. All 
experiments were approved by the local Animal Welfare Committee of the 
Radboud University Nijmegen and were carried out in accordance with the 
Dutch Animal Welfare Act of 1997.
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Reagents
The murine MG1 MAb, an anti-CC531 IgG2a monoclonal antibody, was 
purchased from Antibodies for Research Applications BV (Gouda, The 
Netherlands). To allow labeling of the antibody with 177Lu, the MAb was 
conjugated with 2-(4-isothiocyanatobenzyl)-diethylenetriaminepentaacetic 
acid (ITC-DTPA, Macrocyclics, Dallas, Texas). Conjugation of the Mab was 
carried out in 0.1 mol/L NaHCO3 buffer, pH 9.5 using a 50-fold molar 
excess of DTPA, as described by Ruegg et al.13 with minor modifications 
(1 h conjugation at room temperature). The DTPA-MG1 conjugate (185 
μg) was labeled with 55MBq 177Lutetium (IDB Holland, Baarle Nassau The 
Netherlands) in a 0.25 M ammonium acetate buffer, pH 5.4 for 30 min 
at room temperature. The non–MAb-bound radiolabel was determined 
by instant thin-layer chromatography (ITLC) using ITLC silica gel strips 
(Gelman Sciences, Inc.), using 0.1 mol/L citrate buffer (pH 6.0) as the 
mobile phase (Rf=0 for MAb associated 177Lu, and Rf=0.8–1 for unbound 
177Lu). All radiolabeled MG1 preparations were purified by gelfiltration on a 
PD10 column (Amersham, Pharmacia Biotech, Maarsen, The Netherlands) 
and eluted with PBS supplemented with 0.5% BSA, 1 mM EDTA. After PD10 
elution, the radiochemical purity was checked by ITLC. The purified 177Lu-
MG1 was diluted in PBS with 0.5% BSA, 1 mM EDTA for injection. The 
specific activity of the administered 177Lu-MG1 preparation was 0.3 Mbq/μg. 
All conjugation and labeling procedures using 177Lu were performed under 
strict metal-free conditions. The immunoreactivity of the radio labeled MG1 
preparations was determined on freshly trypsinized CC531 cells essentially 
as described by Lindmo et al.14 with minor modifications. 15
RIT (185 μg MG1 per rat, radiolabeled with 55 MBq 177Lu in 3.0 ml) was 
intraperitonally injected immediately after surgery (RIT 0 group) or four (RIT 
4 group) or 14 days (RIT 14 group) after surgery to evaluate the optimal 
timing of RIT.
Surgery
Surgical procedures were performed under general anaesthesia using isoflurane 
3%, O2 and N2O 1:1. Thirty minutes prior to and once daily until the third 
day postoperatively, rats were given buprenorphine (5 µg, 0.1 mL/rat/day) for 
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analgesia. All rats underwent a complete midline laparotomy. Rats in the 
control group C underwent exploratory laparotomy only in order to score 
intraperitoneal tumor growth. In all experimental treatment groups CS was 
performed, consisting of a midline laparotomy and careful inspection of the 
abdominal contents for tumor growth. Tumor growth at each of the intra-
abdominal sites was scored 0 (no macroscopic tumor growth), 1 (limited 
tumor growth), 2 (moderate tumor growth), or 3 (abundant tumor growth). 
The sum of the tumor scores of all sites represented the peritoneal cancer 
index (PCI)16. Subsequently, CS was performed, removing macroscopic 
tumor deposits as radical as possible. Irresectable tumors were cauterized 
using an electrocautery device. CS was followed by RIT at different time 
intervals. After completion of the surgical cytoreduction the abdominal 
wall was closed in two layers using continuous Vicryl 3/0 sutures for the 
muscular component and iron wound clips for the skin. At the end of the 
procedure a 10 mL of warmed normal saline was given subcutaneously, for 
rehydration. 
Follow up
The primary endpoint was survival. As part of the assessment of physical 
well-being during the immediate postoperative period, general condition and 
body weight were measured daily in the first 7 days. After one week, rats 
were monitored daily and total body weight was monitored twice weekly until 
the humane endpoint had been reached, as determined by an experienced 
biotechnician who was blinded for the experimental procedures. At the time 
of the humane endpoint, rats showed signs of advanced PC, such as the 
presence of ascites, and were killed by O2/CO2-asphyxiation and dissected. 
At dissection, the tumor deposits were scored as described above. The 
experiment was terminated at 16 weeks after CS by killing and dissecting 
the remaining rats. In case macroscopic tumor was absent, all relevant 
organs, including the greater omentum, the mesentery and the diaphragm 
were removed for histopathological analysis. Slices were stained using 
hemotoxilin & eosin (H&E) and/or immunohistochemical staining using the 
murine MG1 antibody in combination with a horse-anti-mouse IgG antibody, 
HRP conjugated (Vector Laboratories Inc., Burlingame, CA, USA).
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Results
Surgery
No animals died during or immediately after surgery. Complications occurred 
in two rats during surgery. One rat needed resuscitation twice and in one 
rat the cecum was opened while removing a cecal tumor, without further 
adverse events. At laparotomy, all animals had extensive tumor growth. 
Multiple tumor deposits of 1-3 mm were found in the omentum. Other 
sites of tumor involvement were the liver hilum and the mesentery. Median 
PCI score at time of surgery (5, range 3-8) was similar in all experimental 
groups (p=0.2), indicating the treatment groups were well-balanced. (Table 
1) Omentectomy was routinely performed in all groups but the sham group. 
Residual disease remained in situ in 7 rats, equally distributed over the 4 
experimental groups (p=0.6). 
As a marker for treatment-related toxicity, body weight was measured and 
expressed as relative body weight compared to the body weight on the day of 
surgery. (Figure 1). Maximum body weight loss after Sham or CS only was 
similar (5.6 ± 1.4% vs. 6.5 ± 2.0% four days postoperatively, P=0.272). Rats 
that were given adjuvant RIT immediately postoperatively had a maximum 
body weight loss of 8.8 ± 2.1%, which was significantly higher than that after 
Sham surgery  (P=0.0001) or CS only (P=0.003). Maximum body weight loss 
of those rats that received adjuvant RIT four days postoperatively was 7.7 
± 2.5% five days postoperatively. At 21 days after surgery, body weight loss 
of the rats that received RIT fourteen days postoperatively, was significantly 
lower as compared to that of the rats that received adjuvant RIT immediately 
or four days postoperatively  (P=0.004). 
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Table 1.
Pathological 
characteristics
Median 
(range)
Group Sham CS RIT 0 RIT 4 RIT 14
Tumor score per 
site
Sucutaneous 0 (0-3) 0 (0-1) 0 (0-1) 0 (0-1) 0 (0-1)
Laparotomy scar 1 (0-3) 1 (0-3) 0 (0-2) 0 (0-2) 0 (0-2)
Greater omentum 2 (2) 2 (2) 2 (2-3) 2 (2-3) 2 (2-3)
Liver hilum 1 (0-1) 1 (0-1) 1 (0-1) 1 (0-1) 1 (0-1)
Perisplenic 0 (0) 0 (0-1) 0 (0) 0 (0) 0 (0-1)
Mesentery 1 (0-1) 1 (0-3) 1 (0-2) 1 (0-2) 1 (0-2)
Gonadal fatpads 0 (0-1) 0 (0-2) 1 (0-2) 1 (0-1) 1 (0-2)
Diaphragm 0 (0) 0 (0) 0 (0-1) 0 (0-1) 0 (0-1)
Parietal peritoneum 1 (0-1) 1 (0-1) 1 (0-1) 1 (0-2) 1 (0-1)
Total 5 (3-6) 5 (3-7) 5 (3-8) 5 (3-7) 6 (3-7)
Resection 
macroscopically
complete
Yes NA 14 14 13 12
 No NA 1 1 2 3
Table 1. CS = Cytoreductive Surgery, RIT 0 =  CS+RIT at day 0, RIT 4 = CS+RIT at day 4, RIT 
14 =  CS+RIT at day 14, NA Not Applicable
Rats generally gained weight from the fifth day post RIT onwards. In the RIT 
0 and RIT 14 groups, post RIT mean weight appeared lower than that of the 
other treatment groups, but these differences were not statistically significant.
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Figure 1. he absolute body weight of rats with peritoneal metastases during 15 weeks of 
follow- up after sham surgery (Sham), cytoreductive surgery (CS), or CS + RIT at day 0 
(RIT 0), CS + RIT at day 4 (RIT 4) or CS + RIT at day 14 (RIT 14) Data represent means ± 
standard error of the mean (SEM).
Survival
During the follow-up of 16 weeks, 64 rats died as a result of intraperitoneal 
tumor growth. In most cases, this was accompanied by the formation of 
ascites. The median amount of ascites was 33 ml (range 0-62) when rats 
were taken out of the experiment and did not differ significantly between 
the groups. (Figure 2) At dissection, all of the animals in the Sham group 
showed adhesions due to the massive amount of tumor growth at the site of 
the omentum and underlying small bowel. All the other treatment groups, 
except for two animals in the CS group, did not show signs of extensive 
or dense adhesions.Two rats, one in the CS group (57 days after surgery) 
and one in the RIT 0 group (26 days after surgery), were taken out of the 
experiment early because of intercurrent death without evidence of tumor 
related cause. These two rats had only small tumor deposits in the liver 
hilum, without obstruction of the biliary tree or vasculature, which could 
not explain deterioration. One animal in the RIT 0 group died most likely 
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due to a small bowel obstruction (ileus) without obvious cause. For the other 
rat no explanation was found as cause for the intercurrent death. 
Figure 2. Ascites weight in rats with peritoneal metastases at the time of death after 
sham surgery (Sham), cytoreductive surgery (CS), or CS + RIT at day 0 (RIT 0), CS + RIT 
at day 4 (RIT 4) or CS + RIT at day 14 (RIT 14). The horizontal lines in side the graph 
depict the median.
After 16 weeks, the experiment was terminated. At that time 9 rats (four 
in group RIT 0, three in group RIT 4 and two in group RIT 14) were still 
alive. Of those, one out of four rats in group RIT 0, two out of three rats 
in group RIT 4 and both rats in group RIT 14 showed macroscopic tumor 
deposits. Microscopic investigation showed tumor cells in one rat in RIT 0 
group while the other two rats in this group were free of tumor. The one rat 
in the RIT 4 group without macroscopic evidence was also free of tumor 
after microscopic investigation. At the time of death, median PCI of those 
rats with tumors was 9, range 0-16, with significant differences between the 
groups, (Sham vs. RIT 0 P=0.008, Sham vs. RIT 4 P=0.001 and Sham vs. RIT 
14 P<0.001). No significant differences were found between the Sham and 
CS group (P=0.25) and between the RIT groups. (Figure 3)
 Timing of Radioimmunotherapy
63
C
h
a
pte
R 3
Figure 3. PCI in rats with peritoneal metastases at the time of death after sham surgery 
(Sham), cytoreductive surgery (CS), or CS + RIT at day 0 (RIT 0), CS + RIT at day 4 
(RIT 4) or CS + RIT at day 14 (RIT 14). The horizontal lines in side the graph depict the 
median.
Rats treated with RIT in combination with CS and those treated with CS 
alone had an improved survival as compared to the animals in the control 
group. (Figure 4) Median survival of animals in the Sham and CS group was 
29 days (range 25-39) and 39 days (range 25-57) respectively, (P=0.04). 
Compared to CS alone, animals treated with adjuvant RIT had a median 
survival of 77 days (range 26-113, P<0.0001), 52 days (range 32-65, 
P<0.0001) and 45 days (range 33-111, P<0.0001) for the RIT 0, RIT 4 and 
RIT 14 groups, respectively. Moreover, the median survival proved to be 
significantly longer when RIT was administered directly postoperatively when 
compared to fourteen days after surgery (P<0.02), whereas RIT 0 compared 
to RIT 4 did not (P=0.17). 
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Figure 4. Survival curves for rats with peritoneal metastases after sham surgery (Sham), 
cytoreductive surgery (CS), or CS + RIT at day 0 (RIT 0), CS + RIT at day 4 (RIT 4) or CS 
+ RIT at day 14 (RIT 14).
Discussion
This study demonstrates that early application of RIT after CS has a 
pronounced effect on the efficacy of this combined treatment, as application 
of RIT directly after surgery was more effective than the application of RIT 14 
days after surgery. The positive effects on survival of 177Lu-labelled MG1 are 
in line with previous studies in this experimental model16. Our combined data 
therefore support the reproducibility of the model, methods and outcome.
The present model of WAG/Rij rats with the intraperitoneally growing 
syngeneic rat colon carcinoma CC-531 was used, because of the reproducible 
growth pattern of these tumors in Wag/Rij rats and its similarity to the 
human entity of PC12, regarding growth- and distribution pattern throughout 
the abdominal cavity. The MG1 MAb showed selective targeting of the CC531 
tumors in this model16. The antibody preferentially localizes in the CC-531 
tumors, with only minor cross-reactivity to other organs (thymus, lymph 
 Timing of Radioimmunotherapy
65
C
h
a
pte
R 3
node, salivary gland tissue and skin) 17. 177Lu was selected as the radionuclide 
for RIT because its high tumor uptake and retention and adequate physical 
properties for treatment of minimal residual disease (medium-energy 
ß-emission with a maximum penetration range in tissue of 2.5 mm, half-life 
of 6.7 days). The 177Lu-MG1 radionuclide-antibody combination has been 
shown to be effective in the model of PC as described above.16
The marked differences in survival between those rats that received 
adjuvant RIT immediately postoperatively and the rats that received 
RIT four or fourteen days later might be related to several factors. First, 
abdominal surgery inevitably results in peritoneal trauma, which may elicit 
an inflammatory response and the production of fibrinogen-rich peritoneal 
exudate.18 Activation of the coagulation cascade subsequently results in 
the formation of a fibrin network. It has been hypothesized that tumor 
cells can be encapsulated in the fibrin network and as such become less 
accessible to local therapy, such as chemotherapy or antibodies (tumor 
cell entrapment theory) 19 and may even increase tumor growth.20 In the 
present study, the formation of fibrin might have hampered tumor targeting 
of the radiolabeled MG1 antibodies and consequently might have impaired 
the therapeutic efficacy of RIT at four and fourteen days postoperatively. 
Second, the production of fibrin is a common pathway for the development of 
adhesions, which can be formed after abdominal surgery and develop within 
a week after surgery.21,22 Intra-abdominal adhesions may have hampered 
the distribution of the radiolabeled MAbs over the peritoneal surfaces in 
the rats that received adjuvant RIT four or fourteen days postoperatively. 
This hypothesis can be corroborated by the results reported by Dwivedi and 
colleagues.23 The authors reported adhesion formation 21 days following a 
comparable surgical technique with a 6 cm midline laparotomy, subsequent 
cecal abrasion and inspection of the entire small bowel. This resulted in thin 
and easily separable adhesions only 21 days after the surgical procedure. 
We can, however, not make an estimation of the the influences of thin and 
easy separable adhesions on the intraperitoneal distribution of RIT during 
the early and late time period after surgery since these thin adhesions were 
not an endpoint of this study and concomitantly were not recorded during 
this phase of the experiment. Third, since CC-531 is a rapidly growing 
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tumor in WAG/Rij rats, microscopic residual disease might have grown 
to macroscopic disease, especially in the rats that received adjuvant RIT 
fourteen days postoperatively.12 The uptake and consequently therapeutic 
efficacy of radiolabeled antibodies is inversely correlated with tumor size.24 
The growth of minimal residual disease into larger tumors in excess of 3 
mm might therefore have had a negative effect on therapeutic efficacy of the 
radiolabeled MAbs. 
Only a few preclinical studies addressing the relevance of  timing of 
postoperative adjuvant therapy have been undertaken 25-28. These studies 
showed that administration of adjuvant chemotherapy immediately after 
surgery impaired outcome when factors as (intestinal) wound healing and 
–recurrence are considered. Data of clinical studies with postoperative 
intraperitoneal chemotherapy support these preclinical data with regard to 
high mortality and morbidity rates29. To our knowledge, the present study 
is the first pre-clinical study investigating the issue of postoperative timing 
of RIT. 
To date, one randomized phase III clinical trial has been published investigating 
the efficacy of adjuvant RIT for the treatment of minimal PC residual 
disease. Verheijen et al. compared the efficacy of a single intraperitoneal 
administration of the 90Y-labeled murine anti-MUC1 MAb HMFG1 plus 
standard treatment to standard treatment alone in patients with stage Ic 
to IV ovarian cancer.30 Patients were randomized after they had attained 
a laparoscopically confirmed complete remission after CS and platinum-
based chemotherapy. The radiolabeled antibodies were administered 
intraperitoneally via a CAPD catheter after scintigraphic confirmation of 
equal intra-abdominal distribution. RIT using 90Y-HMFG1 did not prolong 
disease-free nor overall survival. The lack of efficacy of adjuvant RIT in this 
trial could be due to several factors. Firstly, the selection of the high-energy 
beta-emitter 90Y with a maximum tissue penetration of 12 mm does not 
seem appropriate in this particular setting, since most of the energy will be 
deposited outside the small tumor deposits. Furthermore, the protein dose 
was augmented with 20 mg of unlabeled antibody to a total of 25 mg 90Y-
HMFG1, with the intent to provoke a human-anti-mouse-antibody response. 
However, the high antibody dose might have had a negative effect on the 
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uptake of the radiolabel in the tumor lesions. The mechanism of antigen 
saturation due to excessive amounts of antibody may have interfered with 
intratumoral antibody uptake as described previously. 31,32 Thirdly, in view 
of the results of the present study, the time interval between CS and the 
administration of at least two months might have had a negative impact on 
the efficacy of RIT.
In addition, Behr et al. studied the application of  a high and low affinity 131I-
labeled anti-CEA antibody MN-14 in a hepatic metastasis model colorectal 
carcinoma and compared this treatment to contemporary 5-fluorouracil/
leucovorin and irinotecan at equitoxic doses, showing that RIT cured 20% of 
the animals with minimal disease. This preclinical study was followed by a 
phase II trial investigating the safety and efficacy of adjuvant RIT using the 
131I-labeled humanized anti-CEA MAb Labetuzumab (MN-14) in 23 patients 
who had undergone R0 liver resection for metastatic colorectal cancer, i.e. 
were surgically cured. Median disease-free and overall survival was 18 
months (95% CI 11-31) and 68 months (95% CI 41-infinity), with a five-
year survival rate of 51%. The authors concluded, that since these results 
seemed to be better than those obtained in historical controls, a phase III 
randomized controlled trial is justified. Adjuvant RIT was also performed 
in 33 patients with glioma at Dukes University. The median survival after 
treatment with 120 mCi of radiolabeled anti-tenascin antibody in this study 
was 79-85 weeks as compared to 46 weeks of historical controls. The results 
of these trials warranted a phase III trial, which is currently ongoing. 
The present study indicated that early administration of RIT is a highly effective 
treatment. Clinical studies utilizing intraperitoneal radioimmunotherapy 
should therefore be focused on immediate postoperative or intraoperative 
administration of RIT. 
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Abstract
The purpose of this study was to improve survival by combining CS and RIT with 
the application of whole body hyperthermia (WBH) and fibrinolytic therapy in the rat 
model of induced PC. 
As in our previous experiment, PC was induced by intraperitoneal inoculation of 
CC-531 colon carcinoma cells in Wag/Rij rats. Animals were subjected to CS only, 
CS+WBH, CS+RIT at normothermia and CS+WBH+RIT in experiment 1. WBH was 
induced by housing the rats at a temperature of 400C for 3 hours. In experiment 
2, rats were subjected to CS, CS followed by the intraperitoneal administration of 
recombinant tissue plasminogen activator (rtPA) twice daily for 3 days, CS followed 
by RIT (CS+RIT) and CS followed by RIT+rtPA. RIT consisted of 74 MBq 177Lu- labelled 
anti-CC531 antibody MG1. The endpoint was survival. 
Median survival of animals in the CS and CS+WBH group was 34 days and 37 days 
respectively (P=0.28). Median survival of rats that were treated with adjuvant NRIT or 
HRIT was 63 days and 86 days ((P<0.0003, P<0.0006 compared to CSH), respectively. 
No difference was found between CS+RIT and CS+WBH+RIT. In experiment 2, median 
survival after CS and CS+rtPA was 50 days and 42 days respectively (P=0.1). Median 
survival of CS+RIT was 106 days and 103 days for CS+RIT+rtPA (P<0.0001 compared 
to CS+rtPA). No difference was found between CS+RIT and CS+RIT+rtPA (P= 0.83). 
From these studies we concluded that the application of HT or rtPA in combination 
with adjuvant RIT after CS for the treatment of PC of colonic was feasible but did not 
potentiate the efficacy of RIT.
Chapter 4
Hyperthermia and fibrinolytic therapy do not improve 
the beneficial effect of radioimmunotherapy following 
cytoreductive surgery in rats with peritoneal carcinomatosis of 
colorectal origin.
This chapter is based on:
Hyperthermia and fibrinolytic therapy do not improve the beneficial effect of 
radioimmunotherapy following cytoreductive surgery in rats with peritoneal 
carcinomatosis of colorectal origin. Aarts F, Hendriks T, Boerman O.C, Oyen WJG 
and Bleichrodt RP. Cancer Biotherapy and Radiopharmaceuticals 2008 23(3);301-09

Introduction
Cytoreductive surgery followed by hyperthermic intraperitoneal 
chemotherapy or HIPEC is considered one of the most promising treatments 
of peritoneal carcinomatosis (PC) of colorectal carcinoma (CRC).1 In HIPEC, 
hyperthermia is used to enhance the chemosensitivity of the tumor.2 Median 
survival after these radical surgical debulking procedures (cytoreduction) 
is 13-34 months with a 5-year survival of 19–27 %, which constitutes a 
significant improvement to palliative treatment consisting of chemotherapy 
and palliative surgery.3-7 However, the improved survival is reached at the 
cost of a considerable morbidity of 23% and a mortality of 4%.4,8 Thus, the 
search for alternative treatment strategies is warranted.
Radioimmunotherapy (RIT) using radiolabeled monoclonal antibodies 
directed against tumor-associated antigens may be an attractive anti-cancer 
therapy in patients with small volume disease.9 In previous studies we have 
demonstrated the efficacy of RIT as an adjuvant to surgery in an animal 
model of PC. Survival in Wag/Rij rats with intraperitoneal CC-531 (colon 
carcinoma) tumors was significantly improved if cytoreductive surgery (CS) 
was followed by adjuvant RIT using the 177Lutetium-labeled anti-CC531 
monoclonal antibody (MAb) MG1.10 The effect was most explicit when RIT 
treatment was administered immediately following surgery, as compared to 
4 or 14 days after surgery.11 In rats with intraperitoneal CC531 tumors, 
RIT was found to be at least as effective as HIPEC, in terms of survival after 
cytoreductive surgery, while RIT induced less side effects than the adjuvant 
treatment with HIPEC.12 These experiments suggest that RIT is a promising 
therapeutic approach to ameliorate treatment of PC. The question now 
arises whether the efficacy of adjuvant RIT can be further improved. It has 
been shown in preclinical studies with subcutaneously growing xenografts 
that the efficacy of RIT can be enhanced by locally applied hyperthermia.13 
Hyperthermia increases tumor blood flow and interstitial pO2, reducing 
tumor hypoxia and disturbed cellular repair mechanisms.14-16 
During surgical procedures, tissue damage causes deposition of fibrin, 
which may result in the formation of fibrinous adhesions. This phenomenon 
occurs as the result of a shift in the equilibrium between coagulation and 
 Multimodality Radioimmunotherapy
75
C
h
a
pte
R 4
fibrinolysis, in favor of the coagulation system.17-19 Tumor cells may be 
trapped in these fibrin clots and become inaccessible to therapeutic agents, 
such as radiolabeled antibodies, which may promote tumor growth. 20-22 
Post-operative fibrinolytic therapy might prevent these events from occuring. 
Here, we report on two separate animal studies where we investigated if 
either whole body hyperthermia or fibrinolytic therapy (with tissue-type 
plasminogen activator, rtPA) could improve the efficacy of adjuvant RIT, as 
applied after cytoreductive surgery for peritoneal carcinomatosis of colonic 
origin.
Material and Methods
Experimental Design
Two experiments were performed to study the effects of hyperthermia and 
recombinant tPA (rtPA), respectively. In both experiments, intraperitoneal 
tumor growth was induced by the inoculation of tumor cells. After seven days, 
cytoreductive surgery was performed. In the hyperthermia experiment, 60 
rats, 15 in each treatment group, were randomly assigned to undergo either 
CS alone, CS followed by whole body hyperthermia (CS+H), CS followed by 
RIT (CS+RIT) or CS followed by whole body hyperthermia and RIT (CS+HRIT). 
In the fibrinolysis experiment, 58 rats were randomly assigned to undergo 
cytoreductive surgery alone (CS, n=15), CS followed by rtPA treatment 
(CS+rtPA, n=15), CS followed by RIT (CS+RIT, n=13) or a combination of both 
adjuvant treatments (CS+RIT+rtPA, n=15). In both experiments, survival 
was determined and at autopsy the extent of tumor growth was scored.
Cell line
The syngeneic rat colon carcinoma cell line CC531, originally induced in 
Wag/Rij rats by intravenous injection of 1,2- dimethylhydrazine 23, was 
cultured and maintained as monolayer in RPMI-1640 medium (GIBCO, 
BRL Life Sciences Technologies, The Netherlands) supplemented with 
10% fetal calf serum (GIBCO), 2 mM L-glutamine, penicillin (100 U/mL) 
and streptomycin (100 μg/mL) at 37 °C in a humidified atmosphere with 
5% CO2. Before inoculation, tumor cells were washed with 0.9% sodium 
76
chloride, disaggregated with 0.25% trypsin and resuspended in phosphate 
buffered NaCl solution, 0.9% (PBS) to a concentration of 1x106 cells/ml. 
Two mL of this cell suspension was injected intraperitoneally, as previously 
described.10 
Animals
Male Wag/Rij rats, ten to twelve weeks old (body weight 240-285 g, Harlan 
Horst, The Netherlands) were accustomed to laboratory conditions for at 
least 1 week before experimental use and housed under non-sterile standard 
conditions (temperature, 20–24°C; relative humidity, 50-60%; 12 h light/ 
dark cycle) in filter-topped cages (2 rats per cage), with free access to food 
(Ssniff, Bio Services Uden, The Netherlands) and water. Physical condition 
was examined daily and body-weight was recorded daily during the first 14 
days after surgery by a biotechnician, who was blinded to the therapeutic 
regimen. Thereafter, body-weight was recorded weekly. All experiments were 
approved by the local Animal Welfare Committee of the Radboud University 
Nijmegen and were carried out in accordance with the Dutch Animal Welfare 
Act of 1997.
Cytoreductive Surgery
Surgical procedures were performed under general anaesthesia using 
isoflurane 3%, O2 and N2O 1:1. All rats underwent a midline laparotomy, 
followed by careful inspection of the abdominal contents for the presence of 
tumor. Tumor growth at each of the intra-abdominal quadrants was then 
scored as 0 (no macroscopic tumor growth), 1 (limited), 2 (moderate) or 3 
(abundant). The peritoneal cancer index (PCI) was then the sum of the score 
for the for quadrants as described previously.10
In all treatment groups, cytoreductive surgery was performed, including a 
routine omentectomy, and all macroscopic tumor deposits were removed 
surgically. Irresectable tumors were cauterized. After completion of the 
surgical cytoreduction the abdominal wall was closed in two layers using 
continuous Vicryl 3/0 sutures for the muscular component and iron wound 
clips for the wound. After completion of the procedure 10 mL of warmed 
normal NaCl solution 0.9% was given subcutaneously, for rehydration. 
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Thirty minutes prior to surgery and once daily until the third postoperative 
day, rats were given buprenorphine (5 µg, 0.1 mL/rat/day) subcutaneously 
for analgesia. 
Radioimmunotherapy
The murine MG1 monoclonal antibody (MAb), an anti-CC531 IgG2a 
monoclonal antibody (Antibodies for Research Applications BV, Gouda, The 
Netherlands) that recognizes an 80 kDa cell surface antigen on CC531 cells, 
was used in these studies. The MG1 MAb localizes preferentially in tumors 
when injected in rats bearing CC-531 tumors 24. Labelling of the antibody 
with 177Lu (halflife 7 days, ß-energy 149 keV, γ- energy 208 keV, penetration 
depth 3 mm) was carried out as previously described.10 In brief, the MAb was 
conjugated with 2- (4-isothiocyanatobenzyl) diethylenetriamine pentaacetic 
acid (ITC-DTPA) (Macrocyclics, Dallas, TX), subsequently labelled with 
177Lutetium (IDB Holland, Baarle Nassau, The Netherlands) and purified by 
gel filtration on a PD10 column (Amersham, Pharmacia Biotech, Maarsen, 
The Netherlands). The purified 177Lu-MG1 preparation was diluted in PBS 
with 0.5% BSA for injection. The specific activity of the administered 177Lu-
MG1 preparation was 0.4 MBq/μg. The 177Lu labelling procedure was 
performed under strict metal-free conditions.
177Lu-labeled MG1 was used as the therapeutic agents in these experiments 
based on the favourable tumor-to-blood ratios obtained with  111In-labeled 
MG1 in this model as compared to 125I-labeled MG1 (9.2 ± 5.3 vs. 2.4 ± 1.4 
with P< 0.040) reported by Koppe et al.10 In addition, it was shown that 
intraperitoneal RIT using177Lu-labeled antibodies to treat small peritoneal 
metastases resulted in the highest percentage survival as compared to 
treatment with 131I-, 186Re- or 90Y-labeled antibodies.25
RIT (185 μg MG1/rat, radiolabeled with 74 MBq 177Lu in 3.0 ml) was 
intraperitoneally injected immediately following surgery, as this was 
determined to be the most optimal time point for adjuvant  administration 
in relation to CS.11 In addition, this was presumed to be the most optimal 
time point in relation to the application of hyperthermia.26
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Hyperthermia 
Immediately upon recovery from general anaesthesia, animals in the CS+H 
group and the CS+HRIT group were placed in an incubator preset at a 
temperature of 390C. After 30 minutes, the temperature was raised to 40 
0C. Inside the incubator, conditions were similar to those within the animal 
facility housing: a relative humidity between 20% and 40%. General whole 
body hyperthermia was maintained for three hours. The rectal temperature 
was monitored every 30 minutes. 
Fibrinolytic Therapy
Immediately after the surgical procedure and after closure of the abdominal 
wall, the fibrinolytic therapy was administrated. Fibrinolytic therapy 
comprised of the intraperitoneal administration of 1.25 mg human rtPA 
(Actilyse, Boehringer Ingelheim, Germany) twice daily during the first 
three days after surgery. This dose was chosen because it was shown to be 
effective in reducing intraperitoneal abscess formation in a model of induced 
peritonitis in rats.27
Follow up
The primary endpoint in both experiments was survival. Animals were observed 
daily by an experienced biotechnician, blinded to the  therapeutic regimen, 
who determined the humane endpoint. When this was reached (signs of 
massive hemorrhagic ascites, physical inactivity or signs of intra-abdominal 
tumor growth with invalidating consequences), rats were killed by O2/CO2 
asphyxiation and immediately dissected. At dissection, the intraperitoneal 
tumor growth was scored as described above. At 16 weeks postoperatively, 
the study was terminated and the remaining rats were killed and dissected. In 
case of absence of macroscopic tumor, all relevant organs, including the greater 
momentum, the mesentery and the diaphragm were removed for histology in 
order to examine tumor presence microscopically. Tissues were fixed in 1% 
formaldehyde, dehydrated and embedded in paraffin. Sections were stained 
using haematoxylin & eosin (H&E) and immunohistochemical stained using 
the murine MG1 antibody in combination with a peroxidase conjugated horse-
anti-mouse IgG antibody (Vector Laboratories Inc., Burlingame, CA, USA). 
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Results
Hyperthermia 
Surgery and adjuvant treatment
Preoperative clinical condition and body weight did not differ between 
groups. At laparotomy, tumor nodules were often present in the omentum, 
liver hilum, the mesentery and gonadal fat pads (1-3 mm diameter). Median 
PCI score at time of surgery was 8 (range 0-12, Table 1) and did not differ 
between groups (P=0.59). After CS, 2 of the 15 animals in the CS group had 
residual disease after surgery. During surgery, a bowel perforation occurred 
in one rat. No animals died during or immediately after surgery. Mean rectal 
temperatures during hyperthermia were equal in both hyperthermia groups: 
39.4 ± 0.8 0C in the CS+H group and 39.5  ± 1.2 0C in the CS+HRIT group, 
respectively. Two animals were euthanized directly after hyperthermia, one 
in the CS+H group and one in the CS+HRIT group. Two animals showed 
massive unexplained weight loss (one each in the CS and CS+HRIT groups) 
and were euthanized four days after surgery. All animals lost weight after 
surgery (Figure 1A). Maximum weight loss was 7.6 ± 1.3 (mean and SD) % 
and 8.5 ± 0.8 % for the CS and CS+H groups and 10.3 ± 0.4 % and 10.7 ± 
0.7 % for the CS+RIT and CS+HRIT groups, respectively. At day 4 and day 5 
after surgery, weight loss was significantly higher in the CS+RIT group than 
in the CS group (P<0.05). In addition, from day 5 until day 9, animals that 
were treated with CS+HRIT lost significantly more body weight as compared 
to animals treated with CS alone (P<0.05). 
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Table 1a. Hyperthermia
Disease 
characteristics
Median 
(range)
 CS CS+H CS+RIT CS+HRIT
Body weight 264 
(246-281)
265 
(251-278)
265
(249-282)
268
(252-285)
Tumor score per 
site
Greater omentum 2 (1-3) 2 (0-3) 2 (1-3) 2 (2-3)
Liver hilum 2 (1-3) 2 (0-2) 2 (0-3) 2 (1-2)
Perisplenic 1 (0-2) 1 (0-2) 1 (0-2) 1 (0-1)
Mesentery 1 (0-2) 1 (0-2) 1 (0-2) 2 (1-3)
Gonadal fatpads 1 (0-2) 1 (0-2) 1 (0-2) 1 (0-2)
Diaphragm 0 (0-1) 0 (0-1) 0 0 
Parietal 
peritoneum 1 (0-2) 1 (0-2) 1 (0-2) 1 (1-2)
Total 8 (4-11) 8 (0-12) 9 (3-10) 9 (7-11)
Complete 
Resection
Yes 13 15 15 15
No 2 0 0 0
 Multimodality Radioimmunotherapy
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Figure 1. Course of body weight during the first two weeks after cytoreductive surgery. 
Body weight (mean + SD) is given relative to weight at operation. Effect of hyperthermia.
Follow-up
Forty-nine (out of 56) animals reached the humane endpoint within 16 
weeks after surgery. At time of death, mean PCI in the CS, CS+H, CS+RIT 
and CS+HRIT groups was 20 (range 16-21), 20 (range 14-21), 17 (range 12-
20) and 15 (range 2-21), respectively (Figure 2). The PCI was significantly 
lower in the CS+HRIT group than in both the CS (P<0.01) and CS+H (P<0.05) 
groups. All these animals showed hemorrhagic ascites. At dissection, the 
volume of ascites was equal in all four groups (mean 19.9 g, P=0.35). Median 
survival after CS was 34 days (range 25-112, End Of Study) and after 
CS+H 37 days (range 15-83, Figure 3). The groups that were treated with 
adjuvant RIT survived significantly longer; after CS+RIT median survival 
was 63 days (range 39-112, P<0.0003 vs. CS+H) and after CS+HRIT 86 
days (range 35-112, P<0.0006 vs. CS+H). However, the apparent difference 
between the latter groups remained non-significant (P=0.72). Seven rats 
(1 in the CS group, 4 in the CS+RIT group and 2 in the CS+HRIT group) 
survived until 16 weeks after surgery and were killed subsequently. 
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Three of these animals had macroscopic tumor (2 in the CS+RIT group and 
1 in the CS+HRIT group). Microscopic investigation of the remaining four 
animals did not reveal any tumor.
Figure 2. Peritoneal cancer index at time of death. Individual values are given together with 
the median (horizontal bar). In the hyperthermia experiment (A), the PCI was significantly 
lower in the CS+HRIT group than in both the CS (P<0.01) and CS+H (P<0.05) groups.
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Figure 3. Survival in days. In the hyperthermia experiment, the groups that were treated 
with adjuvant RIT survived significantly longer.
Fibrinolytic therapy 
Surgery and adjuvant treatment
Preoperative clinical condition and body weight did not differ between 
groups. At laparotomy, tumor nodules were present in the omentum, liver 
hilum, the mesentery and gonadal fat pads (1-3 mm diameter). The median 
PCI score at time of surgery was 5 (range 3-10) and was similar in all groups 
(P=0.28, Table 1b). No animals died during or immediately after surgery. 
One animal in the CS+RIT group was killed two days after surgery due to a 
burst abdomen. All animals lost weight after surgery (Figure 4). Maximum 
weight loss was 6.6 ± 2.6 % and 7.9 ± 3.8 % in the CS and CS+rtPA groups 
and 10.1 ± 2.6 % and 9.5 ± 5.8 in the CS+RIT and CS+RIT+rtPA groups, 
respectively. There was a significant difference in weight loss between the 
CS and CS+rtPA groups from day 2 until day 4 (P<0.05). In addition, from 
day 3 onwards up until day 13, animals treated with RIT or RIT+rtPA lost 
significantly more weight than animals treated with CS alone (P<0.01 and 
P<0.05 respectively).
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Table 1b. Fybrinolytic Therapy
Disease 
characteristics
Median 
(range)
 CS CS+rtPA CS+RIT CS+RIT+rtPA
Body weight 274 
(257-290)
274 
(260-288)
275 
(253-292)
274 
(263-287)
Tumor score 
per site
Greater 
omentum 1 (1) 1 (1-3) 1 (1) 1 (1)
Liver hilum 1 (0-2) 1 (1) 1 (0-1) 1 (1-2)
Perisplenic 1 (0-1) 1 (1-0) 0 (0-1) 1 (0-1)
Mesentery 1 (0-1) 1 (0-3) 1 (0-1) 1 (0-1)
Gonadal 
fatpads 1 (0-1) 0 (0-1) 1 (0-1) 0 (0-1)
Diaphragm 0 (0) 0 (0) 0 (0) 0 (0)
Parietal 
peritoneum 1 (0-1) 0 (0-1) 1 (0-1) 0 (0-3)
Total 5 (4-6) 5 (4-10) 5 (3-8) 5 (4-6)
Complete 
Resection
Yes 15 15 13 15
No 0 0 0 0
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Figure 4. Course of body weight during the first two weeks after cytoreductive surgery. 
Body weight (mean + SD) is given relative to weight at operation. Effect of rtPA.
Follow up
Forty-seven (out of 57) animals reached the humane endpoint before the 
termination of the experiment 16 weeks after surgery. The mean PCI at 
the time of death in the CS, CS+rtPA, CS+RIT and CS+RIT+rtPA groups 
was 17 (range 14-21), 20 (range 13-21), 15 (range 0-19) and 17 (range 7-
21), respectively (Figure 5). The PCI was significantly lower in the CS+RIT 
group than in both the CS alone (P<0.01) and CS+RIT+rtPA (P<0.05 and 
P<0.01, respectively) groups. No difference in the volume of ascites was 
found between the groups at the time of sacrifiction. Median survival after 
CS alone and CS+rtPA was 50 days (range 30-112) and 42 days (range 23-
67) (P=0.09), respectively. The groups that were treated with adjuvant RIT 
survived significantly longer (Figure 6). The median survival of animals that 
were treated with CS+RIT was 106 days (range 54-112), while those treated 
with CS+RIT+rtPA survived for 103 days (range 46-112): P<0.0001 when 
compared to CS+rtPA for both these treatment groups. There was, however, 
no difference in survival between both RIT-treated groups (P=0.52).
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Of the 10 animals that were still alive at the end of the experiment  (1 in 
the CS group, 5 in the CS+RIT group and 4 in the CS+RIT+rtPA group), 3 
animals (2 in the CS+RIT group and 1 in the CS+RIT+rtPA group) showed 
macroscopic and one (in the CS+RIT group) showed microscopic tumor at 
dissection. 
Figure 5. Peritoneal cancer index at time of death. Individual values 
are given together with the median (horizontal bar). The PCI was 
significantly lower in the CS+RIT group than in both the CS (P<0.01) 
and CS+RIT+rTPA (P<0.05 and P<0.01, respectively) groups. 
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Figure 6. Survival in days. In the fibrinolytic therapy experiment, the groups that were 
treated with adjuvant RIT survived significantly longer.
Discussion
The present data demonstrate that application of RIT immediately after 
surgery (more than) doubles survival time. However, the results of both 
experiments demonstrate that the efficacy of RIT as an adjuvant treatment 
after cytoreductive surgery for peritoneal carcinomatosis is not significantly 
improved by hyperthermic treatment or the use of fibrinolytic drugs in an 
established model of PC in the rat. 
In Wag/Rij rats, the intraperitoneally growing syngeneic rat colon carcinoma 
cell line CC531 has been shown to present a highly reproducible model of 
PC that is similar to the human entity of PC.28 We have shown before that 
RIT with 177Lu-labelled MG1, administered after cytoreductive surgery, is a 
promising adjuvant treatment. 10,11 
In the clinical situation, hyperthermia may enhance the effect of radiotherapy 
during 1 hour and combined with a single high dose of radiotherapy. 29 
The application of prolonged (3-6 hours) mild whole body hyperthermia 
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(40 0C) in combination with low-dose RIT (131I-labeled anti-CEA antibody 
F-33-104) delayed the growth of subcutaneously growing human colon 
cancer xenografts.30 The 6 hour course of hyperthermia led to a mortality 
of 23%. Probably, a shorter time of hyperthermia is effective as well. It has 
been shown that the effect of hyperthermia, i.e. increased blood flow and 
oxygenation, even when applied for 60 min only, lasted for 24 h.31 Kinuya et 
al.32 demonstrated an increased (2.4 fold) accumulation of the radiolabeled 
antibody in subcutaneously growing human colon cancer xenografts in 
nude mice resulting in improved therapeutic efficacy when hyperthermia 
was applied directly after Ab injection. If hyperthermia was applied either 
two days prior or two days after the injection of the radiolabeled MAb, the 
opposite effect was observed. In the present study, we therefore applied whole 
body hyperthermia of 40 0C immediately after the intraperitoneal injection 
of the radiolabeled antibody. This procedure resulted in a hyperthermia-
related mortality of 7%. In contrast to the above-mentioned studies, the 
present study failed to show a significantly enhanced therapeutic efficacy of 
RIT after hyperthermia, although the median survival increased by 36 %. The 
lack of a significant effect of the adjuvant application of mild hyperthermia in 
our model may be due to various reasons. The micro-environmental factors 
influenced by hyperthermia are 1. perfusion, 2. vascular permeability, 3. 
pO2, 4. pH and 5. interstitial fluid pressure in the tumor.
31 
An increase in tumor perfusion reduces hypoxia, which may enhance 
radiosensitivity. This has been reported by Mittal and colleagues 33, who 
used an 131I-labeled anti-CEA antibody in combination with temperatures 
between 41 0C and 43 0C for the duration of 45 min to treat human colon 
cancer xenografts. The authors concluded that hyperthermia increased the 
effectiveness of RIT but without an increase uptake of the antibody in the 
tumor. Most likely, intraperitoneally growing small tumor nodules (<1 mm) 
originating from CC531 cells only have a small hypoxic fraction. This may 
explain the lack of increased efficacy in our model. 
Increased vascular permeability is reported to occur at temperatures 
exceeding 41.50C. Under the present experimental conditions these high 
temperatures would lead to an unacceptably high morbidity and thus is not 
applicable in this model.
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Abdominal surgery inevitably results in peritoneal trauma followed by the 
deposition of fibrin.34 Tumor cells can be encapsulated within this fibrin 
network and as such would become less accessible to intraperitoneal RIT35. 
Administration of rtPA will lyse fibrin and may counteract this effect. In the 
present study the administration of rtPA did not result in increased survival. 
This may be due to ineffective fibrinolysis. However, using a similar dose, 
Buyne et al. reported that two intraperitoneal injections with 1.25 mg rtPA 
reduced abscess formation with 30% in an intra-abdominal sepsis model.27 
Jacquet and colleagues found that intra-operative administration of rtPA 
(5mg/kg) resulted in a decreased number of tumor implants when colon 
carcinoma cells were administered intraperitoneally after creating peritoneal 
wounds.36 The applied dose of 1.25 mg twice daily for three days, however, 
did not result in an improved survival in the present study. Apparently, 
in the presently used model, fibrin deposition is not a factor limiting the 
effectiveness of RIT. The use of an alpha-emitter in this model may have been 
more appropriate than the use of 177Lu. One might argue that the penetration 
range of the alpha particles (<70 μm) is more suited for treating tumor cell 
clusters and very small tumor nodules, than the penetration range of the 
beta particles emitted by 177Lu (<3.3 mm).37
In summary, we showed that the administration of RIT adjuvant to CS in a 
model of induced PC of colonic origin improves survival. 
In addition, we demonstrated that the application of mild WBH or rtPA as 
adjunct to RIT and CS is feasible but did not show a significant additive 
effect to the combined treatment of RIT and CS in our model of PC of CRC. 
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Abstract
Survival in patients with peritoneal carcinomatosis (PC) of colorectal cancer 
is improved by radical surgical debulking procedures in combination with 
intraperitoneal chemotherapy, either in combination with normo- or hyperthermia 
(HIPEC). These procedures result in considerable morbidity and mortality rate of 
up to 23% and 4%, respectively. We compared the efficacy and toxicity of combined 
cytoreductive surgery (CS) and radioimmunotherapy (RIT) for treatment of peritoneal 
carcinomatosis of colonic origin to the standard of care in clinical practice, HIPEC. 
Regarding treatment related toxicity, the results were in favour of RIT. Survival of rats 
treated with CS+RIT was significantly longer than after CS alone, whereas survival 
after CS+HIPEC or CS alone were not significantly different. 
From this study we concluded that survival after CS is significantly improved by RIT. 
In contrast, adjuvant HIPEC did not and proved to be more toxic than RIT.
Chapter 5
A comparison between radioimmunotherapy and hyperthermic 
intraperitoneal chemotherapy for the treatment of peritoneal 
carcinomatosis of colonic origin in rats.  
This chapter is based on:
A Comparison Between Radioimmunotherapy and Hyperthermic Intraperitoneal 
Chemotherapy for the Treatment of Peritoneal Carcinomatosis of Colonic Origin 
in Rats. Aarts F, Hendriks T, Boerman O.C., van Eerd-Vismale J, Oyen W.J.G., 
Bleichrodt R.P. Ann Surg Oncol. 2007 Nov;14(11):3274-82.

Introduction
Peritoneal carcinomatosis (PC) of colorectal cancer (CRC) frequently is an 
end stage of colorectal cancer, occurring in 5-50% of the patients, either 
synchronous or metachronous1. If untreated, patients suffering from PC 
have a median survival of only six months2. Survival is significantly improved 
by radical surgical debulking procedures (cytoreduction) in combination 
with intraperitoneal chemotherapy, either in combination with normo- or 
hyperthermia (HIPEC)3-7. The median survival after cytoreductive surgery 
and HIPEC is 13-34 months4,8 and the 5-year survival rate is 19%-27% at 
the cost of considerable morbidity and mortality rates of up to 23% and 4%, 
respectively.6,9 
In the latest reported clinical trial on adjuvant RIT in the setting of colon 
cancer, Liersch et al. reported results of a Phase II trial with 131I-labeled 
anti-CEA antibody Labetuzumab administered to patients after complete 
resection of colorectal liver metastases. This study, where RIT was applied 
in an adjuvant setting to complete resection, resulted in a promising 5-
year survival rate of 51.5%.10 Radioimmunotherapy using radiolabelled 
monoclonal antibodies directed against tumour-associated antigens may be 
therefore be an attractive anti-cancer therapy in patients with small volume 
disease. 
We therefore have studied the application of RIT as adjuvant therapy 
following cytoreductive surgery (CS) in the setting of PC. In previous studies 
regarding PC of CRC in a rat model we showed that RIT could be an effective 
adjuvant treatment after CS. The efficacy of adjuvant RIT in combination 
with CS was investigated and compared to no treatment, CS only and RIT 
only. The results of this study showed a significantly improved survival of 
animals treated with CS followed by RIT (median 88 days) compared to those 
treated with CS only (median 51 days) and RIT only (median 61.1 days).11 
Based on the encouraging results, showing the observed increase in survival 
that was achieved with low dose RIT and concomitant low toxicity, we now 
aimed to compare the efficacy of this treatment to that of today’s standard 
of care, HIPEC12,13, in a preclinical setting. 
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Materials and Methodes 
Animal model of peritoneal carcinomatosis
WAG/Rij rats (10-12 weeks old, body weight 240-290 g, Harlan Horst, The 
Netherlands) were housed under non-sterile standard conditions (temperature, 
20–24°C; relative humidity, 50-60%; 12 h light/dark cycle) in filter-topped 
cages (2 rats per cage), with free access to food (Ssniff, Bio Services Uden, 
The Netherlands) and water. Rats were accustomed to laboratory conditions 
for at least one week before experimental use. Peritoneal carcinomatosis 
was induced by intraperitoneal inoculation of 2.0 x 106 CC-531 colon cancer 
cells, as described previously.14 All experiments were approved by the local 
Animal Welfare Committee of the Radboud University Nijmegen and were 
carried out in accordance with the Dutch Animal Welfare Act of 1997.
Operative procedure
Prior to the laparotomy, all rats were given 10 mL of saline in order to prevent 
hypovolemia. Surgical procedures were performed under general anaesthesia 
using isoflurane 3%, O2 and N2O 1:1. Thirty minutes prior to and once daily 
until the third day postoperatively, rats were given buprenorphine (5 µg, 
0.1 mL/rat/day) for analgesia. During the operation, rats were placed on 
a warmed mattress to limit body heat loss. All rats underwent a midline 
laparotomy. After opening the abdomen the extent of intraperitoneal tumour 
growth was scored semi quantitatively, 0 (no macroscopic tumour), 1 (little; 
located at 1-2 sites with a diameter of 1-2 mm), 2 (moderate; located at 1-2 
sites and a diameter 2-5 mm), or 3 (abundant; located at multiple sites and/
or diameter >5 mm) in all four quadrants of the abdomen. The sum of the 
tumour scores of all sites represented the peritoneal cancer index (PCI)11.
Subsequently, CS, including a routine omentectomy, was performed 
in all rats. Irresectable tumour deposits were cauterized using 
an electrocoagulation device. After completion of the surgical 
cytoreduction the abdominal wall was closed in two layers using 
continuous Vicryl 3/0 sutures for the muscular component and iron 
wound clips for the skin in animal treated with CS only or CS+RIT.
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Monoclonal antibody, radiolabeling and RIT
The murine MG1 monocolonal antibody (MAb), an anti-CC531 IgG2a 
monoclonal antibody that recognizes a 80 kDa cell surface antigen and 
localizes preferentially in tumours when injected in rats bearing CC-531 
tumours15, was purchased from Antibodies for Research Applications BV 
(Gouda, The Netherlands). Labeling of the antibody with 177Lu was carried 
out as previously described.11 In brief, the MAb was conjugated with 2-
(4-isothiocyanatobenzyl)-diethylenetriaminepentaacetic acid (ITC-DTPA) 
(Macrocyclics, Dallas, TX) and subsequently labelled with 177Lutetium (IDB 
Holland, Baarle Nassau The Netherlands) and purified by gel filtration on a 
PD10 column (Amersham, Pharmacia Biotech, Maarsen, The Netherlands). 
The purified 177Lu-MG1 preparation was diluted in PBS with 0.5% BSA for 
injection, the specific activity of the administered 177Lu-MG1 preparation 
was 0.4 MBq/μg. The labeling procedure using 177Lu was performed under 
strict metal-free conditions.
RIT (185 μg MG1/ rat, radiolabeled with 74 MBq 177Lu in 3.0 ml) was 
intraperitoneally injected immediately after surgery, as this was determined 
to be the most optimal time point for adjuvant administration.16 
Mitomycin-C
Mitomycin-C (MMC) was obtained from Nycomed Christiaens BV (Breda, 
The Netherlands) as a powder in glass vial (40mg/vial). Immediately before 
use, MMC was dissolved in 0.9% sodium chloride to the appropriate 
concentrations.
HIPEC procedure
Following CS, while the abdomen was still exposed, two multiperforated 
catheters (Argyle, Sherwood Medical, Ireland) were inserted laterally through 
the abdominal wall and subsequently fixed in the abdominal cavity. The 
inflow drain was placed in the right paracolic gutter, the outflow drain in the 
left subdiaphragmatic space. The intraperitoneal temperature was monitored 
with an intraabdominal thermometer, (PTFE Insulated thermocouple, VWR 
International, Amsterdam, The Netherlands), at the site with generally the 
highest tumour load (omentum). In addition, a thermometer was placed 
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inside the rectum. After placement of the catheters, the abdominal wall was 
closed using a continuous suture (Ethilon 3.0, Johnson & Johnson, Ethicon). 
(Figure 1) During the HIPEC procedure, rats were removed from the warmed 
mattress to prevent general hyperthermia. The perfusion system was filled 
with 250 ml saline, containing 4 mg MMC (Mitomycin-C Kyowa, Christiaens). 
The perfusate was heated in a tube coil using a thermostatically regulated 
water bath set to a temperature of 48°C and infused into the peritoneal cavity 
by a roller pump (Ismatec IPS-8, Ismatec SA, Glattbrugg, Switzerland.) for 
the duration of 60 minutes at 10 ml/min. Abdominal inflow temperature 
was set at 44°C. In order to achieve a uniform heat distribution, gentle 
massage of the abdomen was applied throughout the duration of the HIPEC 
procedure. After completion of the perfusion, the abdominal cavity was 
flushed with warmed (37°C) saline for a period of ten minutes. The abdomen 
was opened again to remove the catheters. Subsequently, the abdomen was 
closed as described above.
Figure 1. HIPEC Perfusion System; MMC Mitomycin C Kyowa 16 mg/l perfusate. Adapted 
from: A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) 
in tumor-bearing rats in the treatment of peritoneal carcinomatosis. Pelz JO, Doerfer 
J, Hohenberger W, Meyer T. BMC Cancer. 2005 30;5(1):56 Copyright BMC Cancer. 
Reproduced with permission.
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Intraperitoneal distribution of MMC and dose determination
Prior to the therapy experiment with HIPEC, we investigated the intraperitoneal 
distribution of the perfusion fluid using a Methylene Blue stained perfusate. 
The perfusate was administered in the same fashion as in the therapeutic 
experiment. After completion, the abdominal cavity was inspected for the 
presence of blue dye in all quadrants on both parietal as well as visceral 
peritoneum of the intra-abdominal organs and the diaphragm. Subsequently, 
a study to determine the dose of MMC that resulted in acceptable toxicity 
was performed in 9 animals (3 animals per group). Animals underwent a 
laparotomy including an omentectomy and complete bowel inspection 
followed by heated perfusion of the abdominal cavity with MMC at 4 mg/L 
or 16 mg/L. Control rats underwent laparotomy and an omentectomy only. 
Body weight and physical condition were monitored during 6 days following 
the procedure in order to assess treatment related toxicity. 
Treatment efficacy
Seven days after intraperitoneal tumour induction with 2.0 x 106 CC-531 
tumour cells, 45 rats, fifteen per treatment group, were randomly assigned 
to undergo either CS only, CS+RIT or CS+HIPEC. The operative procedures 
and application of the adjuvant therapies were performed as described 
above. Toxicity of the treatment was determined clinically and by weighing 
the rats. Body weight was expressed as relative body weight compared to the 
body weight on the day of surgery. Survival was scored and at autopsy the 
extent of tumour growth was determined. 
Follow up
The primary endpoint was 16-week survival. As part of monitoring physical 
condition during the immediate postoperative period, general condition was 
monitored and body weight was measured daily during the first two weeks. 
When the humane endpoint (HEP) was reached (signs of massive hemorrhagic 
ascites, physical inactivity or signs of intra-abdominal tumour growth with 
invalidating consequences), rats were killed by O2/CO2-administration 
and immediately dissected. The HEP was determined by an experienced 
biotechnician who was blinded to the therapeutic regimen. At the time of 
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the HEP rats were generally lethargic, showing signs of advanced PC as 
the presence of ascites. At dissection, the intraperitoneal tumour growth 
was scored as described above. At 16 weeks postoperatively, the study 
was terminated and the remaining rats were euthanized and dissected. 
In case of absence of macroscopic tumour, all relevant organs, including 
the greater momentum, the mesentery and the diaphragm were removed 
for histopathological staining in order to determine tumour presence 
microscopically. Sections were stained using haematoxylin & eosin (H&E) 
and/or immunohistochemical staining using the murine MG1 antibody in 
combination with a horse-anti-mouse IgG antibody, HRP conjugated (Vector 
Laboratories Inc., Burlingame, CA, USA).
Results
Intraperitoneal distribution of HIPEC and dose determination
The intraperitoneal distribution of the perfusate administered according to 
the above described procedure, showed a distribution pattern amongst all 
quadrants, including the diaphragm bilaterally and at the mesenterial root. 
Figure 2.
The applied dose of 16 mg MMC/L resulted in a maximum mean weight 
loss of 13.7% ± 2.9% at 4 days postoperatively. In addition, the first three 
days following the heated perfusion, animals were lethargic and suffered 
from diarrhoea from day two until day four postoperatively. In contrast, the 
maximum weight loss in the 4 mg/L was 8.3% ± 2.9% at day 3 and 7.5 % ± 
2.3% at day 3 in the control group. Figure 3. None of the animals died during 
the immediate postoperative period. Based on these observations, HIPEC, 
when administered at a dose of 16 mg/L for the duration of 60 minutes at 
the given temperature, was considered to be the maximal tolerable dose to 
be used for the HIPEC procedure.
Operative procedure
Preoperative body weight did not differ between groups, P=0.52. (Table 1) 
At laparotomy, tumour nodules were present in the omentum, liver hilum, 
the mesentery and gonadal fatpads (1-3 mm diameter). Median PCI score at 
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time of surgery was 5 (range 4-8) and was similar in all experimental groups. 
After surgical cytoreduction, residual disease remained in situ in 7 rats 
after cauterization and was equally distributed among the groups (P=0.84). 
The surgical procedures without adjuvant therapy took 20-30 minutes per 
animal.
Figure 2. Intraperitoneal distribution of Methylene 
Blue stained perfusate.
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Table 1.
Disease characteristics
Median 
(range)
CS CS+HIPEC CS+RIT 
Pre-operative Body Weight (g)
266
(251-287)
264
(245-285)
262 
(244-276)
Tumor score per site 
Greater omentum 2 (2-3) 2 (1-2) 2 (1-2)
Liver hilum 1 (0-1) 1 (0-1) 1 (0-1)
Perisplenic 0 (0-1) 0 (0) 0 (0)
Mesentery 1 (0-2) 1 (0-2) 1 (0-2)
Gonadal fatpads 0 (0-2) 0 (0-2) 1 (0-2)
Diaphragm 0 (0-1) 0 (1) 0 (0-1)
Parietal peritoneum 1 (0-1) 1 (0-1) 1 (0-1)
Total 5 (4-8) 5 (4-6) 5 (4-8)
Resection
macroscopically complete
Yes 12 13 13
 No 3 2 2
Figure 3. The relative body weight of Wag/Rij rats after exploratory laparotomy (Control) and 
heated intraperitoneal chemotherapy (HIPEC) given immediately postoperatively in different 
doses. Data represent means ± standard error of the mean (SEM).
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There was no intraoperative mortality. However, one rat in the CS+HIPEC and 
one rat in the CS+RIT group were euthanized after 2 and 9 days respectively. 
The animal in the CS+HIPEC group showed massive weight loss as a result 
of bowel necrosis and subsequent perforation, the cause of death of the 
animal in the CS+RIT group remained unclear.
The median intra-abdominal temperature during the HIPEC procedure, 
measured at the site where the greater omentum was removed, was 41.0 °C 
(range 40.4-41.6°C). In contrast, the median rectal temperature was 34.6°C 
(range 34.1-34.8 °C). (Figure 4). 
CS and CS+RIT were well tolerated whereas animals in the CS+HIPEC 
groups showed signs of physical discomfort; animals of the latter group 
were generally lethargic and showed pilo erection two days following the 
procedure. In addition, these animals all suffered from diarrhoea up to 4 
days after the HIPEC procedure. The relative body weight after of the various 
treatment groups is depicted in Figure 5. Maximum body weight loss after CS 
or CS+RIT was similar (7.3 ± 2.6% vs. 9.3 ± 1.8% four days postoperatively, 
P>0.05). Rats that received adjuvant HIPEC had a maximum body weight 
loss of 12.3 ± 1.7%, which was significantly higher than that after CS alone 
(P<0.001) or CS+RIT (P<0.001). Rats generally gained weight from the fifth 
postoperative day onwards. In the HIPEC group, however, postoperative 
mean body weight remained significantly lower than that of the animals in 
the CS group, until five weeks postoperatively.
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Figure 4. The recorded intra-abdominal and rectal temperature during the HIPEC 
procedure. Data represent means ± standard error of the mean (SEM).
Figure 5. The relative body weight of Wag/Rij rats with small peritoneal CC-531 tumours 
in the first 14 days after cytoreductive surgery (CS) only, CS + radioimmunotherapy given 
immediately postoperatively (RIT) or  heated intraperitoneal chemotherapy (HIPEC) given 
immediately postoperatively. Data represent means ± standard error of the mean (SEM).
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Treatment efficacy
During the experiment, 29 animals were euthanized due massive amounts of 
ascites that resulted from intraperitoneal tumour growth. The mean amount 
of ascites at the humane endpoint was 31 ml ± 22.6, 26.5 ml ± 23.8 and 
26.4 ml ± 22.6 ml in the CS, RIT and HIPEC groups, respectively (P=0.82). 
At the time of death, mean PCI in the CS, CS+HIPEC and CS+RIT groups 
was 18 (range 9-22), 12 (range 5-15) and 18 (range 16-19), respectively, with 
significant differences between the CS+HIPEC and both other treatment 
groups (P<0.001 for both comparisons). 
The survival curves of the various treatment groups are depicted in Figure 
6. Median survival of the rats that were treated with CS only was 57 days 
(range 36-112). Adjuvant HIPEC resulted in a median 
survival of 76 days (range 33-112), P=0.17, when compared to CS only. 
Median survival of the rats that were treated with CS followed by the 
adjuvant administration of RIT was improved to a median survival of 97 
days (range 49-112), P<0.001 compared to CS only. When compared to CS 
followed by adjuvant HIPEC, the adjuvant administration of RIT to surgery 
did not result in an improved survival, P=0.33). 
At the endpoint of the study, 16 weeks after CS, 14 animals (two animals in 
the CS group, five animals in the CS+HIPEC group and seven animals in the 
CS+RIT group) were still alive, without any physical signs of intraperitoneal 
tumour growth. Of these 14 animals that were still alive 16 weeks after 
surgery, one animal in the CS+HIPEC group and three animals in the 
CS+RIT group showed macroscopic evidence of tumour at dissection. In the 
remaining 10 animals (2 in the CS alone group, 4 in the HIPEC group and 4 
in the RIT group) not even microscopic tumour presence was found. 
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Figure 6. Kaplan-Meier survival curves for Wag/Rij rats with small peritoneal CC-531 
tumours after cytoreductive surgery (CS), CS + RIT (RIT) or CS + HIPEC (HIPEC).
Discussion
In the present study, adjuvant radioimmunotherapy after cytoreductive 
surgery for peritoneal carcinomatosis of colorectal origin in rats significantly 
improved survival, whereas HIPEC did not. In addition, the application of 
HIPEC was associated with considerably more toxicity as compared to RIT.
The treatment of peritoneal carcinomatosis was studied with CC-531 
syngeneic tumours that grew intraperitoneally in Wag/Rij rats. This model 
is highly reproducible and the growth and distribution pattern throughout 
the abdominal cavity are similar to the human entity of PC.14 Cytoreduction 
performed at 7 days after tumour reduction resulted in minimal residual 
disease (<1 mm). In this setting, both HIPEC and RIT result in maximum 
therapeutic efficacy.12,13,17
The MG1 MAb preferentially localizes in the CC-531 tumours 11, with only 
minor localization in thymus, lymph node, salivary gland tissue and skin15. 
177Lu was selected as the radionuclide for RIT of minimal residual disease 
because of its high tumour uptake and adequate physical properties including 
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a medium-energy ß-emission with a maximum penetration range in tissue 
of 2.5 mm. In our previous studies we have used the combination of 177Lu-
MG1 radionuclide-antibody. These studies demonstrated the combination 
to be highly effective for the improvement of survival in the model of PC as 
described above.11,18 Moreover, in previous experiments we have shown that 
radioimmunotherapy with a radiolabeled irrelevant antibody is less effective 
by far as compared to therapy with a radiolabeled specific antibody.19 HIPEC 
has been studied in only a few preclinical studies. 20-23 These studies showed 
that its use was associated with a decreased tumour load as compared to 
control groups20. However, in these studies, HIPEC was associated with a 
considerable toxicity, indicated by lethargy, marked body weight loss and 
bacterial translocation24. These results on toxicity are in corroboration with 
the results of our study and mimic the clinical effects of HIPEC. Clinical 
studies with postoperative intraperitoneal chemotherapy are associated 
with a high mortality and morbidity12. 
Of sixteen published reports on the use of HIPEC in the clinical setting, 
thirteen reports described the administration of MMC12. In vitro, MMC has 
also shown to inhibit growth of CC531 cells in a concentration a thousand 
fold lower than the concentration used in the present experiment.25 The 
applied dose of 16 mg/l MMC in our study is within the range of doses 
applied in clinical practice (5 mg/l - 20 mg/l 26) and is higher than described 
in other preclinical studies (2.25 mg/l 20 and 4 mg/l 23). In addition, in the 
present study HIPEC was applied as an adjuvant treatment to cytoreduction 
whereas Pelz et al. applied HIPEC as monotherapy with subsequent killing 
of the animals after only 10 days. 
The intraperitoneal distribution of MMC during the perfusion was studied 
before the start of the actual experiment and showed equal distribution 
amongst all quadrants. The effect of the perfusion technique on distribution 
differences and their associated differences in survival have never been 
studied clinically. Glehen and colleagues performed a large clinical study 
in 506 patients that were treated with both the open and closed abdomen 
perfusion technique. The authors reported no differences in survival between 
both perfusion techniques.6 This observation was confirmed by the study of 
Sugarbaker and colleagues27. 
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RIT with 74 MBq of the 177Lu-MG1 radionuclide-antibody in 3 mL has 
previously been shown to be an effective treatment for experimentally 
induced PC of colonic origin when administered intraperitoneally.11,16 The 
biodistribution of intraperitoneally injected 111In-labeled MG1 was studied by 
Koppe et. al. and showed a preferential uptake of the radiolabeled antibody 
in the tumour.11
The extraperitoneal temperature of 48°C necessary in order to obtain 
inflow temperatures of 44°C, would not have had a negative influence on 
the cytotoxicity of MMC, since Ahrar et al.28 showed that only temperatures 
exceeding 60 0C decreased its cytotoxic effect. On the other hand, one has 
to bear in mind the fact that the additive effect of hyperthermia in HIPEC in 
the clinical setting has not yet been proven in a randomized trial. Elias et al. 
and Glehen et al. both reported the use of early postoperative chemotherapy 
(EPIC), without hyperthermia, ranging from day one to day five after surgery, 
and HIPEC. Elias et al. found no significant difference in survival. 
Similarly, in the multicentre study in 506 patients of whom 53.3% and 24.3 
% underwent HIPEC and EPIC alone, no significant difference was found 
in survival between the two treatment groups. 6 The duration of the heated 
perfusion, 60 min. in this experiment, is in concordance with the recent 
consensus statement regarding Cytoreductive Surgery and Hyperthermic 
Intraperitoneal Chemotherapy in the Management of Peritoneal Surface 
Malignancies of Colonic Origin, stating that the perfusion should last 60-
120 minutes.13 These data on the dose of MMC, the used perfusion time and 
–temperature, together with our results that showed anti-tumour effect in 
the model of induced PC from CC531 cells (significantly lower PCI at HEP 
in favour of CS+HIPEC), we can conclude that the HIPEC model used in our 
study was able to induce regression of PC of colonic origin.
In the latest reported clinical trial on adjuvant RIT in the setting of colon 
cancer, Liersch et al. reported results of a Phase II trial with 131I-labeled 
anti-CEA antibody Labetuzumab administered to patients after complete 
resection of colorectal liver metastases. This study, where RIT was applied 
in an adjuvant setting to complete resection, resulted in a promising 5-year 
survival rate of 51.5%.10 The results of this study is in accordance with 
the conclusion of a recent review on the use of RIT to treat colon cancer.17 
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In this review, the authors state that the time may have come for clinical 
trials in which RIT is added to standard regimens, in order to establish the 
place of this treatment modality as an adjuvant treatment after CS. 
To our knowledge, the present study is the first study comparing the use 
of RIT and HIPEC in an adjuvant setting to CS for the treatment of PC 
in colorectal cancer. Our preclinical studies indicate that the application 
of RIT immediately following CS can improve survival in rats with PC of 
CRC. Moreover, from the present study we conclude that the use of adjuvant 
RIT is an effective treatment with low toxicity. When comparing to today’s 
standard of care, HIPEC, RIT was at least as effective. RIT consisted of an 
activity dose of 74 MBq of 177Lu-labeled MG1per rat, resulting in only minor 
toxicity, whereas the theoretical MTD of 177Lu-labeled antibodies in 250 g 
rats could be approximately 150 MBq.11 
There are, however, some challenges to the clinical applications of adjuvant 
RIT. E.g. after cytoredective surgery, patients are transferred to the intensive 
care unit. Optimal patient care has to be balanced with radiation safety 
issues for the medical staff. Previously, we reported on the optimal time 
interval between RIT and CS.16 In that study we showed that RIT should be 
administered as soon as possible after CS, with a window of opportunity for 
RIT administration up to 4 days after surgery. It can therefore be envisioned 
that for radiation safety reasons the therapy should be given not before 
discharge of the patient from ICU and removal of the abdominal drains.
Our study therefore justifies the consideration of intraperitoneal 
radioimmunotherapy after cytoreductive surgery in case of peritoneal 
carcinomatosis of colorectal cancer. In clinical studies this approach should 
be compared to HIPEC.
 Radioimmunotherapy vs. HIPEC
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Abstract
The purpose of this study was to investigate the effect of adjuvant radioimmunotherapy 
on anastomitic healing following cytoreductive surgery. In addition we compared the 
effects of adjuvant RIT to the effects of HIPEC with regard to anastomitic strength.
In order to do this, PC was induced by intraperitoneal inoculation of CC-531 colon 
carcinoma cells in Wag/Rij rats. Subsequently, seven days after tumour induction, 
animals were subjected to exploratory laparotomy (C). This was then followed by the 
construction of both a small bowel anastomosis as well as a colonic anastomisis. 
Immediately after the construction of these anastomoses, 74 MBq  177lutetium-
labelled anti-CC531 antibody MG1 was intraperitoneally administered, HIPEC was 
performed by the closed abdomen perfusion technique described in the previous 
chapter, or PBS was intraperitoneally injected. Anastomotic strength measurement 
was peformed by means of bursting pressure and breaking strength 3 and  5 days 
after anastomotic construction. 
From this study we concluded that adjuvant RIT after CS for the treatment of PC of 
colonic origin showed no detrimental effects on anastomotic healing and –strength.
Chapter 6
The Effects of Adjuvant Experimental Radioimmunotherapy 
and Hyperthermic Intraperitoneal Chemotherapy on Intestinal 
and Abdominal Healing after Cytoreductive Surgery for 
Peritoneal Carcinomatosis in the Rat.
This chapter is based on:
F. Aarts, R.P Bleichrodt, B. de Man, R. Lomme, O.C. Boerman and T. Hendriks. 
The effects of adjuvant experimental radioimmunotherapy and hyperthermic 
intraperitoneal chemotherapy on intestinal and abdominal healing after 
cytoreductive surgery for peritoneal carcinomatosis in the rat. Annals of Surgical 
Oncology, Accepted for publication

Introduction
Extensive surgical debulking procedures (cytoreductive surgery, CS) in 
combination with hyperthermic intraperitoneal chemotherapy (HIPEC) are 
considered as today’s first choice for the treatment of peritoneal carcinomatosis 
(PC).1 The extensive nature of the surgical procedure, where all macroscopic 
tumour is removed, often requires the construction of multiple bowel 
anastomoses.2,3 The concomitant application of cytotoxic temperatures and 
high local concentrations of chemotherapeutic agents result in a median 
survival of 13-34 months. This way, a 5-year survival rate of 19%-27% can 
be obtained.4-7  However, patients suffer from high morbidity and mortality 
rates of up to 50% and 8%, respectively. A substantial proportion of the 
morbidity consists of complications related to anastomotic repair such as 
anastomotic dehiscence and intra-abdominal abscess formation. In addition, 
enteral fistulae may develop.2,3 
Previously, we have demonstrated in rats with PC that CS followed by 
adjuvant radioimmunotherapy (RIT) effectively prolongs survival 8,9, and 
could be even more effective than HIPEC in this respect.10 Moreover, adjuvant 
intraperitoneal RIT resulted in significantly less treatment-related toxicity, 
as reflected in loss of body weight and the occurrence of diarrhoea and 
clinical discomfort.
Very recently, it has been reported that HIPEC reduces anastomotic strength 
in the colon of healthy rats 11. Our hypothesis is that RIT may be less 
detrimental in this respect. Here, we report on an experiment in rats with 
peritoneal carcinomatosis of colonic origin which were treated by CS and 
subsequent anastomotic construction in both ileum and colon. The effects 
of adjuvant HIPEC and RIT on the development of early wound strength in 
the intestine and the abdominal wall were determined.
Materials and Methods 
Study Design
Seven days after intraperitoneal tumour induction with CC531 tumour cells, 
72 rats (24 per treatment group) underwent CS, followed by the construction 
Radioimmunotherapy & Wound Healing
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of anastomoses in both ileum and colon. Thereafter, animals were randomly 
assigned to immediately receive either phosphate buffered saline (CS group) 
or adjuvant HIPEC (CS+HIPEC group) or RIT (CS+RIT group). Within each 
treatment group, half of the animals were sacrificed three and five days after 
operation for the measurement of mechanical and biochemical parameters for 
repair. A further nine animals, three for each experimental group, were used 
for histological examination of the anastomoses five days after surgery. 
Model of peritoneal carcinomatosis
Male WAG/Rij rats (10-12 weeks old, body weight 240-260 g, Harlan Horst, 
The Netherlands) were housed under non-sterile standard conditions 
(temperature, 20–24°C; relative humidity, 50-60%; 12 h light/dark cycle) 
in filter-topped cages (2 rats per cage), with free access to food (Ssniff, Bio 
Services Uden, The Netherlands) and water. Rats were allowed to accustom 
to laboratory conditions for at least one week before experimental use. 
Physical condition was examined daily and total body weight was recorded 
daily by a biotechnician, who remained blinded to the therapeutic regimen. 
All experiments were approved by the local Animal Welfare Committee of 
the Radboud University Nijmegen and were carried out in accordance with 
the Dutch Animal Welfare Act of 1997. The syngeneic rat colon carcinoma 
cell line CC531, originally induced in Wag/Rij rats by intravenous injection 
of 1,2- dimethylhydrazine12, was injected intraperitoneally, as previously 
described.8
Surgical procedures
Surgery was performed under general anaesthesia using isofluorane 
3%, O2 and N2O 1:1. All rats underwent a complete midline laparotomy, 
followed by careful inspection of the abdominal contents for tumour growth. 
Tumour growth at the various intra-abdominal locations was scored as 0 
(no tumour), 1 (little), 2 (moderate), or 3 (abundant). Within each animal, 
the sum of the tumour scores represented the peritoneal cancer index 
(PCI)8. Cytoreductive surgery, including an omentectomy, was performed 
by radically removing all macroscopic tumour deposits. Irresectable 
tumours were cauterized. Subsequently, 5 mm of the distal ileum was 
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resected, approximately 15 cm proximal to the cecum, and continuity was 
restored by constructing an end-to-end anastomosis with 8 single-layer, 
inverting, interrupted sutures (Ethilon 8-0, Ethicon, Germany). A similar 
procedure was then performed in the descending colon, approximately 
3 cm proximal to the peritoneal reflection. Following the construction of 
this anastomosis, saline (3 ml) was administered intraperitoneally or a 
RIT or HIPEC procedure were performed. After anastomotic construction, 
the abdominal wall was closed in two layers using continuous Vicryl 3/0 
sutures for the muscular component and iron wound clips for the skin. 
When followed by HIPEC, the laparotomy was closed in one layer after 
installing the catheters. Prior to and at the end of the procedure 10 mL of 
saline was given subcutaneously, for pre- and rehydration. Thirty minutes 
prior to surgery and twice daily until the third postoperative day, 
rats were given buprenorphine (5 µg, 0.1 mL/rat/day) for analgesia.
HIPEC
The HIPEC procedure was performed as previously described.10 Briefly, two 
multiperforated catheters were placed through the lateral abdominal wall 
bilaterally and the abdomen was closed, thus creating a closed perfusion 
system. The perfusion system was filled with 250 ml 0.9% NaCl, containing 
4 mg MMC (Mitomycin-C Kyowa, Christiaens). This perfusate was heated 
(inflow temperature was set at 44°C) and infused into the peritoneal cavity 
for the duration of 60 min. Gentle massage of the abdomen was used 
throughout the HIPEC procedure to achieve a uniform heat distribution 
within the peritoneal cavity. Following the heated perfusion, the abdominal 
cavity was flushed with warm (37 0C) 0.9% NaCl for a period of ten minutes. 
Thereafter, the continuous suture was opened and the perforated catheters 
were removed. Subsequently, the abdomen was closed in two layers. 
Radioimmunotherapy
The murine MG1 monoclonal antibody (MAb), an anti-CC531 IgG2a 
monoclonal antibody that recognizes a 80 kDa cell surface antigen and 
localizes preferentially in tumours when injected in rats bearing CC531 
tumours13, was purchased from Antibodies for Research Applications BV 
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(Gouda, The Netherlands). Labelling of the antibody with 177Lu was carried 
out as previously described.8 The purified 177Lu-MG1 preparation was diluted 
in PBS with 0.5% BSA to 0.4 MBq/μg (185 μg MG1/ rat, radiolabeled with 
74 MBq 177Lu in 3.0 ml) prior to injection. RIT  was applied intraperitoneally 
immediately after surgery.
Measurement of anastomotic and abdominal wall strength
Rats were killed by CO/CO2 asphyxiation at either the third or the fifth 
postoperative day. The abdomen was opened and, if necessary, adhesions 
were dissected carefully without manipulation of the anastomosis. Presence 
of adhesions, abscesses or anastomotic dehiscence was recorded. The 
segments containing the anastomoses were then resected. Anastomotic 
bursting pressure was measured in succession as described previously.14 
The abdominal wall breaking strength was measured in two isolated strips 
(2-5 mm x 10 mm) from the sutured midline incision using a tensiometer.
Biochemical analysis and histology
After measuring wound strength, tissue samples were cleaned from adhering 
tissue and debris, and 5-mm samples containing the anastomosis or the 
abdominal suture line in the middle were frozen in liquid nitrogen and 
stored at -80 °C until further processing. After lyophilization, samples were 
weighed, pulverized, and lyophilized again. The hydroxyproline content, as a 
measure of the collagen content, was measured by high-performance liquid 
chromatography after hydrolysis with 6 M HCl and derivatization with dabsyl-
chloride. Preparation of tissue extracts and procedures for quantitative 
gelatin zymography to measure the activity of matrix metalloproteinases 
(MMP) 2 and 9 have been described previously.15 
Sections of anastomoses and abdominal wall, originating from animals 
that had not been  subjected to strength measurements were stained using 
haematoxylin & eosin (H&E) and/or used for immunohistochemistry using 
the murine MG1 antibody in combination with a HRP conjugated horse-
anti-mouse IgG antibody, (Vector Laboratories Inc., Burlingame, CA, USA). 
For analysis of collagen fibres, sections were stained with picrosirius red.
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Autoradiography
Tissue sections containing the anastomosis and part of the abdominal wall 
containing the suture line were exposed to a storage phosphor imager screen 
for 20 min immediately after strength measurement at day 3. The screen was 
scanned in a phosphor imager system (Molecular Imager GS363, BioRad 
Laboratories, Hercules, CA) at a pixel size of 100x100 µm. Images were 
processed with Quantity One software (version 4.5.2, BioRad Laboratories, 
Hercules, CA). 
Results
Surgical procedures
No animals died and no complications occurred during the various treatment 
procedures. At dissection three animals, one in the control and two in the 
RIT group, showed abscess formation at the site of the anastomosis, without 
statistical differences between groups (P=0.4).
At the time of surgery, tumour nodules were present in the omentum, liver 
hilum, the mesentery and gonadal fat pads (1-3 mm diameter). Median 
PCI score at time of surgery was 5 (range 1-9) and was the same in all 
experimental groups (Table 1). Intra-abdominal temperature during the 
HIPEC procedure ranged between 39.0 0C and 43.2 0C, with a median of 
42.3 0C. The rectal temperature ranged between 34.1 0C and 34.8 0C, with 
a median of 34.6 0C.  
Pre-operative weight was similar in all groups. All animals lost weight and 
after five days  weight loss after CS, CS+HIPEC or CS+RIT was 10.1 ± 4.2%, 
14 ± 6.6% and 12.2 ± 5.2%, respectively (P<0.01 for CS vs. CS+HIPEC). Also, 
animals treated with CS+HIPEC were lethargic and showed signs of physical 
discomfort during the first days. In addition, these animals suffered from 
diarrhoea. 
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Table 1.
Disease 
characteristics
Median 
(range)
 CS + PBS CS +HIPEC CS + RIT
Day 3 Day 5 Day 3 Day 5 Day 3 Day 5
Body weight
Mean (range)
252 
(232-274)
254
(242-266)
258     
(246-270)
259
(244-270)
257
(248-277)
258
(243-269)
Tumor score 
per site
Greater 
omentum 2 (1-3) 2 (2) 2 (1-2) 2 (2) 2 (1-2) 2 (2-3)
Liver hilum 1 (1) 1 (0-1) 1 (1) 1 (1) 1 (0-1) 1 (1)
Perisplenic 0 (0) 0 (0-1) 1 (0-2) 0 (0) 0 (0) 0 (0)
Mesentery 1 (0-2) 1 (0-1) 1 (1) 1 (0-2) 0 (0-1) 1 (1-2)
Gonadal 
fatpads 1 (0-2) 0 (0-2) 1 (0-1) 1 (0-2) 0 (0-2) 1 (0-2)
Diaphragm 0 (0) 0 (0) 0 (0) 0 (0-1) 0 (0-1) 0 (0-1)
Parietal 
peritoneum 1 (1) 1 (1) 1 (0-1) 1 (0-1) 1 (0-1) 1 (1)
Total 5 (1-7) 6 (2-8) 5 (2-8) 6 (2-9) 5 (4-9) 5 (2-8)
Table 1. Treatment group characteristics (peritoneal cancer index; PCI) found during
laparotomy before the administration of the adjuvant therapy.
Wound strength
The bursting pressure at day 3 showed no differences between the three 
groups with respect to both absolute value or bursting site (always within the 
anastomotic area). The average bursting pressure of the ileal anastomoses 
increased significantly between day 3 and day 5 in all groups (P<0.0001, 
P<0.04 and P<0.03 for CS, CS+RIT and CS+HIPEC, respectively), although 
the relative increase was lowest in the CS+HIPEC group (Figure 1). In the 
colon anastomoses, bursting pressures significantly increased in the CS 
and CS+RIT groups (P<0.0001 and P<0.02, respectively) but not in the 
CS+HIPEC group. As a result, marked differences between groups were seen 
at day 5 (Figure 2). The lowest median bursting pressure in both ileal and 
colonic anastomoses was found in the CS+HIPEC group and the highest 
in the CS group (P<0.01). Although median values in the CS+RIT group 
were lower than in the CS group, these differences were non-significant. 
Loss of strength in the CS+HIPEC group was further illustrated by a shift 
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in bursting site, particularly in the colon. Here, rupture occurred within 
the suture line in 4 out of 12 cases in the CS group and in 11 out of 12 
(P<0.05) cases in the CS+HIPEC group, while the CS+RIT group showed an 
intermediate value (7/12). 
Figure 1. Gain of wound strength in intestinal anastomoses. Mean  
(± SEM) of the bursting pressure in ileal (A) and colonic (B) anastomoses 
at 3 and 5 days after operation, for the CS (■), CS+HIPEC (■) and CS=RIT 
(■) groups.
For the abdominal wall strength, significant differences were seen in 
breaking strength at both postoperative days (Figure 3). From day 3 to 
day 5 the abdominal breaking strength increased approximately 6-fold in 
all groups. Again, strength was highest in the CS group and lowest in the 
CS+HIPEC group: P<0.01 at both day 3 and day 5. Also, abdominal wound 
strength was significantly (P<0.01) lower in the CS+HIPEC group than in 
the CS+RIT group. The average wound strength was similar in the CS and 
CS+RIT groups.
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Figure 2. Anastomotic bursting 
pressure 5 days after operation. Data 
represent individual measurements in 
ileum (A) and colon (B). Closed symbols 
denote anastomoses rupturing within 
the suture line and open symbols those 
rupturing outside the wound area. 
Horizontal lines give the median values.
Figure 3. Fascial wound strength. 
The breaking strength is given for day 
3 (A) and day 5 (B) postoperatively. 
Horizontal bars represent medians and 
vertical bars range while boxes give 25-
75 percentiles. ***: P<0.001 vs CS; **: 
P<0.01 vs CS; ##: P<0.01 vs CS+HIPEC.
Hydroxyproline content and gelatinase activity 
The wound hydroxyproline content showed no differences between groups at 
day 3 after surgery. At day 5, the average hydroxyproline content at all three 
sites was lowest in the CS+HIPEC group and highest in the CS+RIT group 
(Figure 4). However, these differences remained non-significant in the colonic 
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anastomoses. In the ileum, values in the CS+RIT group were significantly 
higher than in both the CS (P<0.01) and the CS+HIPEC (P<0.001) group, 
while in the abdominal wound this was only the case if compared to the 
CS+HIPEC group (P<0.05). 
Figure 4. Wound hydro-
xyproline content 5 days after 
operation. Bars represent 
mean values (+SD) for ileal (A) 
and colonic (B) anastomoses 
and fascial wounds (C). ***, ** 
and *: P<0.001, 0.01 and 0.05, 
respectively, vs CS+RIT group.
There were no differences in proMMP-9 activity between groups. Active 
MMP-9 remained absent. On average, pro-MMP-2 activities were highest 
in the CS+RIT groups, most clearly in the intestinal wounds. More explicit 
differences were observed for active MMP-2 (Figure 5). With the exception 
of colonic anastomoses at day 3, median values were significantly higher in 
the CS+RIT group than in the other groups, in some cases by far more than 
100%. As a consequence, the ratio between active and inactive MMP-2 was 
also highest in the CS+RIT group. For instance, median values for this ratio 
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at day 3 in ileal anastomoses were 0.19 in both CS and CS+HIPEC groups 
and 0.37 (p<0.001 vs both other groups) in the CS+RIT group.
Figure 5. Active MMP-2 in wounds. Specific activity is given at both 3 (A,C,E) 
and 5 (B,D,F) days after operation in ileum (A,b), colon (C,D) and fascia (E,F). 
Horizontal bars represent medians and vertical bars range while boxes give 
25-75 percentiles. ***, ** and *: P<0.001, 0.01 and 0.05, respectively, vs 
CS+RIT group.# P<0.05 vs CS+HIPEC group.
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Histology 
H&E staining of sections of the ileum and colon showed an increased number 
of polymorphonuclear neutrophils at the anastomoses as compared to the 
adjacent bowel wall, indicating an inflammatory response in all groups, but 
no architectural differences as a result of adjuvant treatment (Figure 6).  
Picrosirius red staining of the ileum sections revealed few collagen fibres 
in the true wound area in all treatment groups. In contrast, in the colon 
anastomoses there was significant collagen formation in the CS and CS+RIT 
groups, whereas this appeared less pronounced in the CS+HIPEC group. 
Sections of the abdominal wall showed collagen formation in all treatment 
groups.
Figure 6. Representative H&E stained slices of colon anastomoses (CA) 5 days after surgery for 
the respective treatment groups. Arrows indicating the anastomoses.
Autoradiography 
Autoradiographic analysis of the bowel anastomosis and abdominal wall 
sections are shown in figure 7. Clearly, non-specific binding of the radiolabeled 
antibody to the surgical sites occurred, both at the anastomosis and the 
laparotomy wound.
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CA CTRL CA RIT CA HIPEC
Figure 7. Autoradiography of surgical 
wounds. A longitudinal cross section of an 
ileal anastomosis (A) showing uptake of the 
radiolabeled antibody at the surgical site (arrow). 
Autoradiographic images of an abdominal wall 
(b) containing the laparotomy wound, showing 
uptake of the radiolabeled antibody at the 
surgical site (arrow). CR indicating the cranial 
part, CA indicating the caudal part of the 
wound, R indicates the right side, L indicates 
the left side of the animal. 
Discussion
This study demonstrates that the use of adjuvant RIT after CS did not 
significantly affect anastomotic strength. In contrast, the adjuvant application 
of HIPEC was associated with a significantly decreased anastomotic strength. 
In addition, HIPEC as an adjuvant after CS resulted in significantly lower 
abdominal wall strength than adjuvant RIT. 
Morbidity after cytoreductive surgery followed by heated intraperitoneal 
chemotherapy is related to surgical / anastomotic related complications in 
35%-54% of the cases. 2,16,17 Moreover, the number of suture lines constructed 
is an independent variable linked to morbidity, suggesting that an increased 
number of anastomoses is associated with a growing chance for anastomotic 
leakage.18 A substantial part of anastomotic related complications stems 
from small bowel perforation or anastomotic leakage.2,3,17 Also, not only 
morbidity, but also mortality is linked to anastomotic related complications. 
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Patients may succumb to peritoneal sepsis due to intra-abdominal abscess 
formation related to anastomotic leakage and, as a consequence, succumb 
to sepsis.19 Therefore, the focus of new adjuvant treatment modalities should 
not be aimed at improving disease-free survival alone but also at reducing 
per-operative morbidity and mortality.
Few preclinical studies on the application of HIPEC or the intraperitoneal 
administration of MMC have been reported. In these reports, HIPEC 
and MMC were associated with marked toxicity in the form of lethargy, 
marked weight loss and bacterial translocation20. It is been well known 
that intraperitoneal cytostatics can severely affect anastomotic strength.21 
This has also been suggested to be the case for MMC, although in the most 
recent report anastomoses were analysed at the 10th postoperative day, 
when the bursting pressure does no longer reflect actual wound strength.22 
Makrin and colleagues performed a HIPEC procedure in rats,  using MMC 
in a concentration of 0.02 mg/mL in 200 ml of perfusate (total dose 4 mg), 
circulating for 20 minutes at a temperature of 40 0C. 23 The anastomosis 
consisted of a subtotal dissection (70%-80% of the circumference) of the 
cecum. Thus, the experimental setup deviated significantly from the clinical 
situation (incomplete anastomoses, short perfusion time), the investigators 
found a decreased bursting pressure in the MMC group as compared to 
controls. The most recent study on anastomotic strength and HIPEC was 
performed by Pelz and colleagues.11 Here, HIPEC was also performed 
with MMC (20 mg/m2, intraperitoneal temperature 40.5 0C-41 0C) either 
before or after anastomotic construction in the colon. In both cases, HIPEC 
significantly reduced the anastomotic bursting pressure as measured both 4 
and 10 days after surgery. However, so far all studies on the effects of HIPEC 
on wound repair in a preclinical setting have been performed in healthy rats 
lacking the preceding tumor growth and cytoreductive surgery applied in 
the present study. Moreover, in our study anastomoses were constructed in 
those parts of the bowel that in the clinical setting are prone to be resected 
during surgical debulking procedures (ileum and sigmoid colon). Thus, the 
present experiment more closely resembles the clinical situation than any of 
the experiments reported so far.
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In our previous report on the comparison of the adjuvant use of RIT versus 
the adjuvant application of HIPEC, we showed that adjuvant RIT was capable 
of achieving a significant improvement in survival as compared to CS alone 
in a model of peritoneal carcinomatosis of colonic origin in rats. In contrast, 
the increased survival after adjuvant HIPEC remained not significant.10 
In addition, the treatment related toxicity was highest in the CS+HIPEC 
group. So far, there have been no reports about complications in healing 
of wounds in the intestine or abdominal wall after intraperitoneal RIT. The 
reason for this might be the fact that in the clinical trials adjuvant RIT is 
administered weeks after any surgical procedure. At that time, anastomoses 
(and laparotomy wounds) are already strong and less prone to disruption. 
However, we also demonstrated that the optimal moment, in terms of 
maximal effect on survival, for administration of adjuvant RIT is immediately 
after cytoreductive surgery.9 The only preclinical data available on wound 
healing and irradiation regard the results of intra-operative external beam 
radiation therapy. In this setting, even moderate radiation doses delayed 
the healing of colonic anastomoses.24 There have been, as yet, no reported 
data on the potential effects of low dose radioimmunotherapy on (intestinal) 
wound healing. 
Although the bursting pressure of both anastomoses at day five after 
surgery was lowest in the HIPEC group, there was no significant difference 
in hydroxyproline content with the CS group. The same was true for the 
abdominal wall at both days after surgery. Thus, the hydroxyproline content 
in the segments containg the wound does not correlate with wound strength. 
This might be due to the fact that those segments contain an excess of 
uninjured tissue and thus are not very specific for the true wound area. On 
the other hand, it may also mean that a defect in collagen quality rather 
than quantity leads to the loss of wound strength in the CS+HIPEC group. 
Active MMP-2 levels were highest in the CS+RIT group but this did not lead 
to reduced wound strength. Apparently, the presence of enhanced MMP-
2 activity does not lead to a degree of matrix degradation which would be 
sufficient to affect wound strength. A rise in active MMP-2 and MMP-9 after 
radiation was also reported by Strup-Perrot after external beam radiation of 
the colon in rats.25
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A possible explanation for the presence of antibody at the site of the 
anastomosis, as observed by autoradiographic imaging, could be non-
specific binding. Non-specific antibodies such as IgG have been used in 
infection imaging. The nonspecific localization of antibodies in inflamed 
tissues is due to the enhanced vascular permeability in these tisssues.26 
This would then result in antibody accumulation at sites of vasodilation 
(surgical injury) as can be seen by autoradiography. However, the suggested 
non-specific binding was not associated with decreased wound strength in 
the present study. 
From the present data we conclude that the use of RIT as an adjuvant 
to cytoreductive surgery is a treatment with low toxicity which does not 
significantly impair wound healing. In contrast, today’s first choice of adjuvant 
treatment, HIPEC, is associated with a marked reduction in anastomotic and 
abdominal wall strength. These data therefore provide further justification 
for clinical studies utilizing intraperitoneal RIT postoperatively in case of 
peritoneal carcinomatosis of colorectal cancer.
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Abstract
In radioimmunotherapy (RIT), hematological toxicity is the dose limiting toxicity due to 
the long circulatory half-life of the antibody. Carbohydrate modification of antibodies 
could induce accelerated clearance of the antibody via the hepatic asialoglycoprotein 
receptor, thereby reducing exposure to normal tissues. In this study, we investigated 
whether galactosylation of an antibody in a model of peritoneal carcinomatosis (PC) 
of colonic origin could be used to improve targeting of i.p. growing tumors. Therefore, 
the biodistribution of the galactosylated and non-galactosylated anti-CC531 
antibody MG1 after intraperitoneal injection was determined in a model of peritoneal 
carcinomatosis of CC-531 colon tumors in Wag/Rij rats. Uptake of the radiolabeled 
antibodies in the tumor and relevant organs was determined at 2, 4, 24 and 48 hours 
after injection. Galactosylation of the antibody did not affect the binding affinity of 
MG1. The uptake of Gal-MG1 in tumors was higher than that of MG1 at 2 and 4hr 
after injection. After 24h and 48h, uptake of Gal-MG1 in tumor tissue was lower than 
that of MG1. Gal-MG1 cleared from the blood within hours after administration. At 
2hr-24 hr after administration, tumor-to-blood ratios obtained with Gal-MG1 were 
significantly higher than those obtained with unmodified MG1, resulting in improved 
tumor-non-tumor ratios. 
This could improve the efficiency of RIT, especially in combination with short-lived 
non-residualizing radionuclides.
Chapter 7
Antibody galactosylation to improve radioimmunotherapy
This chapter is based on:
Antibody galactosylation to improve radioimmunotherapy of induced peritoneal 
carcinomatosis of colonic origin in the rat. F. Aarts, T. Hendriks, A Eek, W.J.G. 
Oyen, R.P Bleichrodt and O.C. Boerman. Cancer Biother Radiopharm. Accepted

Introduction
Radioimmunotherapy (RIT) comprises selective irradiation of tumor cells 
with radiolabeled anti-tumor antibodies (Abs). RIT has been shown to be an 
effective treatment in hematological malignancies.1 However, in solid cancers, 
RIT is less effective, which is partly due to their intrinsic radioresistance 
and a limited uptake and penetration of antibodies in solid tumors.2 An 
inverse relation has been shown to exist between the size of the lesion and 
the uptake of the radiolabeled antibody.3 Therefore, RIT seems to be an 
attractive adjuvant therapy after surgical debulking procedures leaving only 
microscopic residual tumor. 
We have shown previously that adjuvant intraperitoneal administration of 
RIT after cytoreductive surgery (CS) is an effective treatment for experimental 
peritoneal carcinomatosis (PC) of colonic origin4,5 Survival in Wag/Rij rats 
with intraperitoneal CC531 (colon carcinoma) tumors improved significantly 
when CS was followed by the intraperitoneal administration of RIT with 2 
mCi of the 177Lu-labeled anti-CC531 antibody MG1. The effect was most 
explicit when RIT was administered immediately after surgery. In addition, 
RIT was found to be at least as effective as hyperthermic intraperitoneal 
chemotherapy (HIPEC), which is the current standard of care, while it 
resulted in significantly less treatment related toxicity.6 
In order to enhance the therapeutic efficacy of radiolabeled antibodies 
(Ab) different strategies have been pursued, ranging from locoregional 
administration of these Abs, as described above, to the application of Ab 
fragments and pretargeting systems.7 Here we studied galactosylation 
of the anti-tumor antibody as a new method to enhance the efficacy of 
intraperitoneally applied RIT for the treatment of intraperitoneal tumors. 
After direct tumor targeting following intraperitoneal administration, 
this modification induces very rapid blood clearance via the hepatic 
asialoglycoprotein receptor (AGPR). This could result in high tumor-to-blood 
and tumor-to-non-tumor ratios.8,9 As a consequence of rapid clearance, 
the radiation dose that is delivered to the bone marrow will be reduced, 
thus lowering hematological toxicity. Ultimately, this effect would allow 
administration of higher doses of radioactivity and potentially increase the 
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efficacy of RIT. To test this hypothesis, the tumor targeting and uptake in 
non-target tissues of intraperitoneally injected Gal-MG1 was compared with 
that of non-galactosylated MG1 in Wag/Rij rats with small volume peritoneal 
CC-531 carcinomatosis.
Materials and Methods
Reagents
Antibody
The murine MG1 monoclonal antibody (MAb), an anti-CC531 IgG2a 
monoclonal antibody (Antibodies for Research Applications BV, Gouda, The 
Netherlands) specifically directed against an 80 kDa cell surface antigen 
expressed on CC531 cells, was used in these studies. The MG1 MAb localizes 
preferentially in tumors when injected in rats bearing CC531 tumors 10. 
Galactosylation
To galactosylate MG1, cyanomethyl-2,3,4,6-tetra-O-acetyl-1-thio-beta- 
D-galactopyranoside (CAGP, C-4141 Sigma) was dissolved in methanol at 
a concentration of 34 mg/mL and mixed with 0.1 volume of 0.1 M sodium 
methoxide, also in methanol. After 48 hours at room temperature, the 
methanol was evaporated (Argon flow, 35 °C) to dryness and the residue was 
dissolved in 1 ml 0.025 M sodium borate buffer, pH 8.5, containing 5 mg 
MG1. After 2 hours at room temperature, the reaction mixture was dialyzed 
against  phosphate buffered saline (PBS). 
To determine the number of galactosyl groups that were conjugated per 
MG1 molecule, the method described by Dubois et al. was used with minor 
modifications.11 To 0.1 mL of galactose solution (0,8-20 µg), 0.1 mL of 5% 
phenol solution was added and mixed. Then 0.5 mL concentrated H2SO4, 
was added to the solution. The mixture was vortexed, and allowed to stand 
for 30 min at room temperature. The galactosylated antibody solution (0.1 
mL) was similarly treated. Absorbance at 490 nm was measured with a 
Pharmacia BioTech Ultrospec 2000 spectrophotometer. It was determined 
that 25 molecules of galactose were conjugated per MG1 molecule. 
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Radioiodination
Galactosylated MG1 was radioiodinated with 125I (Amersham, Den Bosch, The 
Netherlands) while the ungalactosylated MG1 was radioiodinated with 131I 
using the IODOGEN-method as described previously.12 Briefly, the antibody 
(1 mg) and the radioiodide  (600 µCi) were incubated at room temperature in 
phosphate buffer (pH 7.4) in an eppendorf tube, coated with 50 µg iodogen. 
After ten minutes, the reaction was stopped by adding 100 µl of a saturated 
tyrosine solution. The radioiodinated antibodies were purified on a PD-10 
column (Amersham Biosciences, Uppsala, Sweden), eluted with PBS, 0.5% 
bovine serum albumin (BSA). This resulted in a specific activity of 0.56 µCi/
µg for MG1 and 0.48 µCi/µg for galactosylated MG1.
Competitive binding assay
To determine the effect of galactosylation on the affinity of the  MG1 antibody, 
the IC50 value of Gal-MG1 and MG1 was determined in a competitive binding 
assay. Binding of the 125I-labeled MG1 was competed by unlabeled non-
galactosylated MG1 or Gal-MG1 and in a concentration dependent manner 
. 125I-labeled MG1 was used as the tracer in this assay. 6-well Costar culture 
plates (Corning Inc. USA) were seeded with CC531 cells and cultured  until 
confluency. The plates were washed twice with PBS. Then 3 mL binding 
buffer containing 50,000 cpm 125I-MG1 with a serial dilution (0 mg/ml - 
1.5x10-7 mg/ml) of non-labeled MG1 or galactosylated MG1 in binding buffer 
was incubated in the wells at 37 °C for 1 h. After incubation, the plates were 
washed three times with PBS. Radioactivity in each well was determined in 
a γ-counter (1480 Wizard, Wallac, Turku, Finland). IC50 values of MG1 and 
Gal-MG1 were calculated by non-linear regression using GraphPad Prism 
(GraphPad Prism 4.0 Software, San Diego, CA, USA).
Model of peritoneal carcinomatosis
The syngeneic rat colon carcinoma cell line CC531, originally induced in 
Wag/Rij rats by intravenous injection of 1,2- dimethylhydrazine13, was 
cultured and maintained as monolayer in RPMI-1640 medium (GIBCO, 
BRL Life Sciences Technologies, The Netherlands) supplemented with 10% 
fetal calf serum (GIBCO), 2 mM L-glutamine, penicillin (100 U/mL) and 
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streptomycin (100 μg/mL) at 37°C in a humidified atmosphere with 5% 
CO2. Tumor cells were harvested from culture flasks with 0.25% trypsin and 
resuspended in RPMI-1640 medium to a concentration of 1x106 cells/ ml. 
Two mL of this cell suspension was injected intraperitoneally, as previously 
described.14 Male WAG/Rij rats (10-12 weeks old, body weight 240-260 g, 
Harlan Horst, The Netherlands), were housed under non-sterile standard 
conditions (temperature, 20–24°C; relative humidity, 50-60%; 12 h light/ 
dark cycle) in filter-topped cages (2-3 rats per cage), with free access to food 
(Ssniff, Bio Services Uden, The Netherlands) and water. Rats were accustomed 
to laboratory conditions for at least one week before experimental use. All 
experiments were approved by the local Animal Welfare Committee of the 
Radboud University Nijmegen and were carried out in accordance with the 
Dutch Animal Welfare Act of 1997.
Biodistribution
The biodistribution of galactosylated MG1 labeled with 125I and non-
galactosylated MG1 labeled with 131I in Wag/Rij rats with intraperitoneally 
growing CC531 tumor nodules was determined at 2 h, 4 h , 24 h and 24 h (n=5 
/group) after intraperitoneal injection. Both radiolabeled Abs (1 ml/rat, 8 µCi 
131I-MG1/rat, 9 µCi 125I-Gal-MG1/rat) were administered simultaneously. At 
dissection, samples of the tumor, blood, liver, spleen, kidneys, intestine, 
lung, and muscle were removed and immediately weighed. Radioactivity was 
measured in a well-type γ-counter (Wizard; Pharmacia-LKB). To correct for 
physical decay and to calculate the uptake of the radiolabeled antibody in 
each sample as a fraction of the injected dose, aliquots of the injected dose 
were counted simultaneously. The uptake was expressed as the percentage 
of the injected dose per gram tissue (%ID/g).
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Results
Reagents
Affinity
The affinity of the galactosylated MG1 was determined in a competitive 
binding assay. The results are shown in Figure 1. Binding of 125I-MG1 to 
CC531 cells was competed by both Gal-MG1 and MG1 in a concentration 
dependent manner. Both IC50 values were in the nanomolar range with 1.6 
nM for MG1 and 1.2 nM for Gal-MG1. 
Figure 1. Competitive binding assay showing the affinity of both 
galactosylated and ungalactosylated MG1 for CC531 cells.
Biodistribution
The results of the biodistribution studies are summarized in Figure 2a-d. 
There was preferential uptake of both radiolabeled antibody preparations in 
the intraperitoneal tumors. At 2 and 4 hr post injection, the uptake of Gal-
MG1 in tumor tissue (14.0 ± 7.5 % ID/g and 9.9 ± 3.0 % ID/g, respectively) 
was significantly higher than that of the ungalactosylated MG1 (5.4 ± 1.9 % 
ID/g and 4.3 ± 1.0 % ID/g, P<0.04). Tumor-to-blood ratios at 2 and 4 hr 
after injection for Gal-MG1 were 10-fold higher than those obtained with 
ungalactosylated MG1 (32.4 ± 18.9 vs 3.2 ± 1.48 at 2 hr and 18.7 ± 5.51 
vs 1.9 ± 0.59 at 4 hr, P<0.0001). At 24 h and 48 h after administration, 
the uptake of Gal-MG1 in tumor tissue (0.7 ± 0.2 % ID/g at 24 hr and 0.2 
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± 0.1 % ID/g at 48 hr) tended to be lower than that of ungalactosylated 
MG1 (2.6 ± 1.0 % ID/g, P=0.06, and 1.5 ± 1.3 % ID/g, P=0.10, respectively). 
Although the tumor uptake of the galactosylated Ab was lower at 24 hr 
and 48 hr after administration, the tumor-to-blood ratios for Gal-MG1 
remained significantly higher at 24 hr (2.70 ± 0.81) than those obtained 
with ungalactosylated MG1 (1.04 ± 0.39, P<0.04. After 48 hr there was no 
significant difference in tumor to blood ratios. In addition, uptake of Gal-
MG1 in all normal tissues except the liver was lower than that of MG1 at 2 
and 4 hr after injection. One and two days after administration, liver uptake 
was lower for Gal-MG1 as compared to MG1. (Figure 2c/d) The uptake in 
non-target organs like muscle, lung, spleen and kidneys was low for both 
Abs, albeit lower for Gal-MG1 after 24 hr and 48 hr. 
The total area under the curve (AUC) for Gal-MG1 for the tumor was 502 
% ID/g·h as compared to 201 % ID/g·h for ungalactosylated MG1. For the 
blood, the total AUC for the galactosylated Ab was 7.9 % ID/g·h as compared 
to 24.5 % ID/g·h for MG1. The ratio of total AUC of Gal-MG1 in the tumor/
AUC for blood was 197 as compared to 8 for the ungalactosylated MG1.
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Figure 2a-d. Biodistribution results of Gal-MG1 and MG1 at 2, 4, 24 and 48 hr after 
intraperitoneal administration,expressed as mean % ID/g tissue. Bars indicate standard error 
of the mean (SEM)
Discussion
The aim of this study was to investigate whether galactosylation of anti-tumor 
antibody MG1 could improve the preferential targeting of intraperitoneal 
tumors in a rat model. The rationale for using a carbohydrated anti-tumor 
antibody is that galactosylated antibodies clear very rapidly from the blood 
via the hepatic asialoglycoprotein receptor (AGPR), resulting in low blood 
levels.8,9 In cases of intraperitoneal tumors, this could result in optimal 
tumor targeting after intraperitoneal administration with concomitant rapid 
clearance when the antibody enters the circulation. 
Indeed, at all the time points after intraperitoneal injection blood levels of 
Gal-MG1 were significantly lower than the blood levels of MG1. Ong and 
colleagues investigated the administration of galactosylated Abs in a model 
of an intraperitoneal ovarian cancer cell-line.15 The authors described 
a tuoruptake of 4.3% ID/g after 28 hr after injection with a peritoneal 
Antibody Galactosylation
143
C
h
a
pte
R 7
retention of the administered Ab of 10% after 24 hr after administration. 
In these experiments, however, peritoneal clearance was disturbed by the 
application by Freund’s adjuvant causing a major inflammatory respons, 
thus not resembling normal physiology. Sharma and colleagues used a 
model of subcutaneously growing human colon cancer xenografts in mice. 
16  The authors used blocking agents to obtain prolonged circulation of the 
galactosylated antibodies for the duration of 8 hrs. This resulted in tumor-
to-blood ratios of 45:1 
Galactosylation of MG1 did not affect the affinity of the Ab for the MG1 
antigen. Remarkably, within the first 24 hr after administration tumor 
uptake of the Gal-Ab was significantly higher, 2.6 fold at 2 hr and 2.3 fold 
at 4 hr after administration, than that of the non-galactosylated antibody. 
The higher tumor uptake could be due to a longer intraperitoneal retention 
time of the Gal-Ab. The more negative charge of the Gal-MG1 could result 
in a slower transit from the intraperitoneal cavity to the circulation. The 
lower tumor uptake of the galactosylated MG1 after 24 hr and 48 hr is due 
to the reduced blood levels of Gal-MG1. We assume that antibody uptake in 
intraperitoneal tumors after intraperitoneal injection is the result of delivery 
both directly from the peritoneal cavity as well as via the intravenous route. 
After 24 hr most of the galactosylated antibodies have cleared from the 
peritoneal cavity. As a consequence of galactosylation, the antibody will 
have cleared from the circulation, whereas the ungalactoslated antibody 
still circulates at relatively high levels in the blood. 17-19
Despite the significantly lower tumor uptake of Gal-MG1 after 24 hr and 48 
hr, the total AUC of the tumor was higher for the galactosylated antibody. 
Moreover, the ratio of AUC(tumor)/AUC(blood) for Gal-MG1 was 24 times higher 
than the ratio for ungalactosylated MG1. Thus, when normalized for the AUC 
of the blood, the AUCtumor of the galactosylated Ab is 24 times higher. Bone 
marrow toxicity is related to the AUCblood. The AUCtumor can be normalized for 
AUCblood and thus the comparison for both AUC for tumor at an equitoxic 
bone marrow dose can be determined. This would indicate that the radiation 
dose of 131I-Gal-MG1 to the tumor is approximately 24-times higher than that 
of 131I-MG1 at an equitoxic dose. Considering the high initial tumor uptake, 
the high tumor-to-non-tumor ratios after intraperitoneal injection of Gal-Ab 
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and the favourable normalized AUCtumor, RIT using these modified Abs seems 
feasible. In this model, tumor uptake peaks within 24 hr after intraperitoneal 
administration. As a result, the favourable effect of the galactosylated Ab 
could be more pronounced when other radionuclides with relatively short 
half-lives and non-radiometals were used. In addition, since clearance of 
galactosylated antibodies is via the hepatic AGPR, the use of residualizing 
radiometals like 177Lu and 90Ycould result in increased radiation dose to 
the liver. Almqvist et al. showed excellent tumor targeting of subcutaneous 
colon tumors in a mouse model with a low liver uptake of the 211At-labeled 
antibody A33. 20 211At is a non-residualizing radionuclide with a relatively 
short half-life (7.2 hr) and has exquisite characters for RIT of ip. tumors 
with galactosylated antibodies. Therefore, the intraperitoneal application 
of RIT for the treatment of peritoneal carcinomatosis using galactosylated 
antibodies need further exploration.
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Abstract
Pre-targeting, unlike directly radiolabeled antibodies, separate the radionuclide from 
the antibody, thus allowing time for tumour accumulation before the radionuclide-
carrier is given, thereby enhancing imaging contrast due to lower background 
ratios.
An open-label, non-randomized, single-arm trial to assess a pretargeting procedure 
that utilizes a bispecific antibody (bsAb) and an 111In-labeled peptide for diagnostic 
imaging of carcino-embryonic antigen (CEA)-producing cancers focusing on 
colorectal cancer was performed. The study focused on the assessment of safety, 
pharmacokinetics (Pk), and targeting ability of the 111In-peptide alone (3 patients) 
and in a pretargeting procedure with the bsAb (11 patients). Patients received 5 
mCi 111In-peptide in combination with the pretargeting procedure to assess the 
appropriate interval to be used with 5.0 mg of bsAb for the selection of the optimal 
time (3-, 4-, and 5-days) to allow the bsAb to clear from the blood and tissues before 
the administration of the radiolabeled peptide. The image quality at these 3 intervals 
were studied. 
Peptide pharmacokinetics showed increased circulating levels of 111In-labeled peptide 
in patients in the 3-day interval cohort as compared to the other cohorts. Tumor to 
background ratios were 4.5:1-6.5-1 in the 3-day interval group, 6.0:1-16.6:1 in the 
4-day interval group and 3.9:1-8.3:1 in the 5-day interval group. The best images were 
acquired with a 4-day interval, at 24 h after injection of the radiolabeled peptide. 
Chapter 8
Radioimmunoscintigraphy of colorectal cancer using a 
two-step pre-targeting method
This chapter is based on:
Radioimmunoscintigraphy of colorectal cancer using a two-step pre-targeting 
method. F. Aarts, R.P Bleichrodt, E. Visser, T. Hendriks, W.J.G Oyen,  
D.M Goldenberg, R. Shakey, O.C Boerman. In preparation

Introduction
The concept of targeting radionuclides to tumors using radiolabeled antibodies 
against tumor-associated antigens was proposed more than a century ago. 
Targeting antibodies to tumors is a slow and inefficient process. Upon 
intravenous injection, antibodies accumulate in tumors relatively slowly, 
and several days after injection maximally a few percent of the injected dose 
accumulates in the tumor. 
Clinically, radiolabeled anti-CEA antibodies have been used for the detection 
and therapy of colorectal, pancreatic, breast, lung, medullary thyroid and 
ovarian cancers.1-5 The anti-CEA mAb MN-14 is a high affinity anti-CEA 
antibody (Ka = 109 M-1).4 To reduce the immunogenicity, a humanized 
version of MN-14 antibody was produced (hMN-14). Radiolabeled hMN-14 
has been studied primarily for radioimmunotherapy (RIT) in patients with 
colorectal cancer.5-7 
RIS with radiolabeled (intact) antibodies resulted in moderate contrast 
several days after injection.3 Thus, there is a need for a more effective 
targeting strategy allowing to guide higher activity doses to the tumor. The 
driving force of accumulation of radiolabeled antibodies in tumor tissue is 
their sustained high level in the circulation. On the other hand, the long 
residence time of these radiolabeled mAbs in the blood enhances background 
activity, resulting in low contrast images and leads to long bone marrow 
exposure, the dose-limiting organ in RIT. Therefore, antibody fragments 
(Fab, F(ab)2, scFv) have been developed that clear faster from the blood. 
This, however, at the cost of reduced accumulation in the tumor. In fact, 
this is the central dilemma in antibody targeting: on one hand one aims to 
optimize the accumulation of the antibody in the tumor; on the other hand, 
the uptake in normal tissues, thus, the residence time in the circulation 
should be minimized. 
In pretargeting, the tumor is pretargeted with an unlabeled antibody 
construct. When this antibody construct has accumulated in the tumor and 
has cleared from the blood, the radioactivity is injected. The radionuclide is 
administered linked to a relatively small molecule in general, a peptide with 
affinity for the antibody construct, which is cleared rapidly from the blood. 
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This small molecule should distribute rapidly throughout the body and 
should bind to the pre-localized antibody construct in the tumor, whereas 
the unbound radiolabeled molecule should clear rapidly from the body. 
Two antibody-based pretargeting approaches can be distinguished: 1. 
procedures exploiting the avid interaction between (strept)avidin and biotin, 
and 2. procedures using bispecific antibodies (bsAb) with affinity for the 
tumor and for the radiolabeled small molecule. 
The group of Chatal and Barbet and colleagues have developed a pre-targeting 
system based on an anti-CEA × anti-DTPA bispecific F(ab’)2 antibody 
construct. In combination with high activity doses of a 131I-labeled di-DTPA 
peptide, this system was tested for pre-targeted radioimmunotherapy of 
CEA-expressing tumors. In patients with medullary tyroid carcinoma (MTC), 
this approach was shown to be very efficacious.8
These studies aimed to develop pretargeted RIT in patients with CEA 
expressing tumors. Therefore, relatively high peptide doses (labeled with 
high activity doses) are guided to the tumor. For RIS purposes, lower doses 
of the radiolabeled peptide need to be administered. Consequently, much 
lower doses of the bsAb are required. 
In the present study, the imaging ability of a bsAb (anti-CEA × anti-DTPA) 
pre-targeting method using an 111In-labeled peptide for the use of RIS in 
patients with CEA expressing primary colorectal cancer was investigated. 
The optimal time interval between injection of a low bsAb dose and the 
radiolabeled peptide was determined. 
Patients and Methods
Study design
This study is an open-label, non-randomized, single-arm trial intended to 
assess the feasibility of a pretargeting procedure that utilizes an anti-CEA 
× anti-DTPA-In bsMAb and an 111In-labeled peptide for diagnostic imaging 
of carcinoembryonic antigen (CEA)-expressing colorectal cancer. The first 
three patients enrolled in this study underwent an imaging study using 
the 111In-labeled di-DTPA peptide alone, thus providing information on the 
organ distribution, tumor uptake and clearance of the radiolabeled peptide 
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alone. Thereafter, the remaining patients received the bsAb in combination 
with the 111In-di-DTPA peptide. Three consecutive cohorts were studied after 
the administration of 5.0 mg of bsAb to assess the optimal interval (3-, 4-, 
and 5-days) for optimal imaging. The dose of the di-DTPA peptide was kept 
constant at 40 nanomoles. This peptide dose was labeled with 185 MBq 
111In.
Patient eligibility
The entry study protocol was approved by the institutional ethics committee. 
The inclusion criteria were: age over 18 years, a diagnosis of primary 
CRC, plasma CEA ≥10 ng/mL or immunohistology positive CRC. Patients 
should not have been treated with chemotherapy within four weeks prior 
to the start of the study or at least 2 weeks in cases of external radiation. 
In addition, patients should not have been injected for prior diagnostic or 
therapeutical procedures with murine or other antibodies. Women had to 
practice contraception during the procedure and for 3 months after imaging. 
A minimal life expectancy of more than 3 months; a Karnofsky performance 
score of more than 70; normal serum chemistries, normal peripheral CBC 
counts were required prior to inclusion in the protocol. Written informed 
consent was obtained from all patients.
Study agents and Administration
The anti-CEA × anti-DTPA-In bsAb hMN-14 × m734 F(ab’)2 (vial of 6 mg/ 
5ml) was provided by Immunomedics Inc. (Morris Plains NJ). This antibody 
was obtained by coupling an equimolar amount of the Fab’ fragment of the 
humanized anti-CEA monoclonal antibody (hMN-14) to the Fab’ fragment 
of the murine anti-DTPA-indium monoclonal antibody (m734) activated by 
o-phenylenebismaleimide. The infusion of the bsAb was divided into two 
parts; first, 10% of the injected volume (6 mg bsAb dissolved in 30 ml NaCl 
0.9%) was infused over 10 min, followed by the remaining volume in 10 min. 
Vital signs were monitored before, during and at the end of the infusion.
IMP-205 is a tyrosine-lysine dipeptide in which both primary amino groups 
are substituted with DTPA. Vials containing 0.5 ml, 0.25 M ammoniumacetate 
buffer, pH 5.5 (5 µg/ vial) were stored at -20 °C until use. The peptide was 
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labeled with 185 MBq 111In (Covidien, Petten, The Netherlands). Subsequently, 
the DTPA moieties were saturated with stable indium by adding a three-fold 
molar excess (15 nmol) of InCl3. Thereafter, the volume of the preparation 
was adjusted to 30 ml with 0.9% NaCl and the 111In-labeled IMP-205 peptide 
was infused intravenously. Radiochemical purity of the peptide was checked 
by RP-HPLC and always exceeded 95%. The 111In-labeled peptide was injected 
3-, 4-, and 5-days after the bsAb infusion at a rate of 3 ml/min.
Pharmacokinetic data
Serum was collected from all patients to assess the pharmacokinetics of 
the 111In-peptide. The peptide clearance was determined by radioactivity 
measurements of collected blood samples. For measurement of peptide 
clearance, samples were taken at 5, 15 and 30 minutes after the peptide 
infusion, as well as after 1, 2, 4 and 24 hours. Blood samples were taken 
during the infusion, at the end of the infusion 1 hr and 2 hr after the infusion 
of the antibody in order to determine bsAb pharmacokinetics. 
Imaging protocol, Follow-Up and Toxicity
Scintigraphic images were acquired at 30 min after injection of the 
111In-peptide and 4 and 24 hr later. Whole-body scans were acquired using 
a Siemens dual-head gamma camera (Ecam, Hoffmann Estates, IL) with 
medium-energy collimators. Both anterior and posterior whole-body scans 
were performed 30 min., three hours and 24 hrs after the 111In-labeled 
peptide administration. Symmetric 15% windows were used over both the 
172 KeV and 246 KeV energy peaks. The data were stored digitally in a 256 
× 1024 matrix. Tumor-to-non-tumor ratios were determined using planar 
whole body images using the para-iliacal region as standard background.
According to the study protocol, routine blood chemistry and blood cell 
counts with differential counts were obtained before, on the day of bsAb 
injection, 24 hr, 1 and 2 weeks and 1 month after antibody administration. 
All adverse effects were documented according to the National Cancer 
Institute Common Toxicity Criteria. 
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Dosimetry
To estimate the radiation-absorbed dose to the relevant organs, the 
scintigraphic images acquired at 0, 4 and 24 h after injection were analyzed 
quantitatively using the conjugated views counting technique with partial 
background subtraction and correction for attenuation and physical decay 
as described previously.9 The time activity curves for each organ were 
calculated using the SPRIND software package in combination with the 
OLINDA software (Vanderbilt University, Nashville Tennessee USA).10 This 
software calculates residence times based on whole-body planar scintigraphic 
images using first-order exponential decay. 
 
Results
Patient characteristics
In the 14 patients enrolled in the study, the primary disease site was the colon 
in nine patients, and the rectum in five patients (Table 1). The classification 
of rectal or colon cancer was based on the TNM/UICC classification. At time 
of surgery, one patient with rectal cancer had lymph node involvement. 
During the thirty three months follow-up, three patients (nr. 3, 5 and 9) 
died, of whom two due to advanced colorectal cancer. 
Antibody, Radiolabeling, and Administration
The infusion of both the bsAb and the radiolabeled peptide were well tolerated. 
During and immediately after the administration of both the bsAb and the 
radiolabeled peptide no adverse events occurred. However, in two patients, 
adverse events were seen at seven and nine days after the administration of 
the bsAb. This consisted of erythema confined to the hand and of erythema 
confined to the inguinal area. In both patients the erythema declined without 
the need for medical intervention and was graded as intensity grade 1. Serum 
chemistry and peripheral CBC counts remained normal during follow up.
Pharmacokinetics
Peptide pharmacokinetics showed highest blood levels (mean % ID 0.007 
± 0.002 % ID) 20 minutes after infusion of the peptide in the peptide alone 
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group. In contrast, in the patients that received the bsAb, peak % ID was 
observed 30 min after infusion. The highest blood levels were observed in 
the 3-day interval group (mean % ID 0.024 ± 0.007 at 30 min after injection), 
as compared to the 4-day interval and 5-day interval group. Figure 1.
Table 1.
Demographic
data
 Sex Age 
(Y)
Disease
 site
Stage
(AJCC)
CEA
(μgl/L)
Operative 
procedure
Cohort 1 
Peptide alone
1     M 59 Rectum IV 31.7 APR
2 M 75 Transverse colon III <1 HC
3 F 57 Cecum II 7.3 HC
Cohort 2
3-day interval
4 F 63 Cecum II 2.4 HC
5 M 86 Descending colon II 5.4 HC
6 F 59 Transverse colon III 1.1 SC
13 F 65 Rectum I 2.3 TEM
Cohort 3
4-day interval
7 M 46 Transverse colon II 1.2 SC
8 F 58 Cecum I <1 SC
9 F 60 Sigmoid colon III 3.4 TE
14 F 75 Rectum III 4.7 TME
Cohort 4
5-day interval
10 M 61 Rectum II 16.2 APR
11 M 67 Rectum III 3.1 APR
12 F 73 Ascending colon IV 1.3 HC
Table 1. APR: abdominoperineal resection; HC:hemicolectomy; SC: subtotal colectomy; TE: 
total excenteration, TME: total mesocolon excision.
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Figure 1. Peptide pharmacokinetics during 24 hr after intravenous administration in 
the 4 patient groups, expressed as mean percentage injected dose (% ID). Vertical bars 
indicate standard error of the mean (SEM).
Imaging
Wholebody scintigraphy of the patients in cohort 1 revealed tumor 
visualization in one patient 24 hrs after injection with only low uptake. The 
other two patients in this cohort showed no tumor uptake. In the pretargeting 
cohorts, adequate tumor visualization was observed in 9 out of 11 patients 
(sensitivity 82%). In cohort 2, mean tumor-to-background ratio (determined 
from the images acquired 24 h after peptide infusion) was 5.7 ± 1.5, whereas 
this was 14.1 ± 5.4 and 6.1 ± 3.1 in cohort 3 and 4 respectively. Thus, best 
image quality was acquired in the 4-day interval group. In one patient (nr.11) 
inguinal- and para-aortic lymph node involvement was clearly visualized. 
These lymph nodes were confirmed by FDG- PET imaging. Figure 2.
Pre-targeted Radioimmunoscintigraphy
157
C
h
a
pte
R 8
Figure 2. Wholebody scintigraphic image of patient 
nr.11. Image acquired 24 hr. after administration of 
peptide. Shown are the primary rectum tumor (closed 
bold arrow) inguinal lymphnodes (dotted arrows) and 
para-aortic lymph nodes (double-lined arrow).
Dosimetry
Whole body residence time of the radiolabeled peptide was 5.5 h ± 2.3 h in 
the peptide alone group, 18.6 h ± 9.4 h in the 3-day interval group, 7.6 h 
± 0.6 h in the 4-day interval group and 9.3 h ± 4.6 h in the 5-day interval 
group. Mean effective dose was 0.029 ± 0.017 mSv/MBq for the peptide 
alone group, 0.047 ±0.022 mSv/MBq for the 3-day interval group, 0.039 
± 0.001 mSv/MBq for the 4-day interval group and 0.035 ± 0.01 mSv/MBq 
for the 5-day interval group. The bladder wall was the tissue that received 
the highest radiation dose with a mean bladder wall dose of 0.29 ± 0.09 
mSv/MBq in cohort 1 (peptide alone) and 0.27 ± 0.06 mSv/MBq, 0.32 ± 0.06 
mSv/MBq and 0.27 ± 0.05 mSv/MBq for the other respective cohorts. Mean 
renal dose, was 0.12 ± 0.03 mSv/MBq, whereas mean renal dose was 0.21 
± 0.03 mSv/MBq, 0.25 ± 0.09 mSv/MBq and 0.13 ± 0.04 mSv/MBq for the 
other cohorts, respectively. Radiation doses for other relevant organs were 
substantially lower. Table 2.
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Table 2. Mean ± SD
 Cohort 1
(Peptide alone)
Cohort 2
(3-day) 
Cohort 3
(4-day)
Cohort 4
(5-day)
Kidney
0.12 ± 0.03
0.21 ± 0.02 0.25 ± 0.09 0.13 ± 0.04
Liver 0.01 ± 0.003 0.1 ± 0.1 0.08 ± 0.04 0.05 ± 0.02
Spleen 0.02 ± 0.002 0.04 ± 0.01 0.03 ± 0.004 0.02 ± 0.01
Brain 0.006 ± 0.003 0.02 ± 0.008 0.007 ± 0.003 0.01 ± 0.008
Heart 0.009 ±0.004 0.04 ± 0.02 0.02 ± 0.002 0.02 ± 0.01
Lungs 0.008 ± 0.003 0.04 ± 0.02 0.01 ± 0.002 0.02 ± 0.01
Red 
Marrow 0.01 ± 0.003 0.03 ± 0.01 0.02 ± 0.002 0.02 ± 0.008
Bladder 
wall
0.29 ± 0.09 0.27 ± 0.06  0.32 ± 0.06 0.27 ± 0.05
Table 2. Organ dose (mSv/MBq)
Discussion
In the present study we showed that pretargeted radioimmunoscintigraphy 
of CRC is feasible. In twelve patients with primary CRC, this method resulted 
in excellent tumor imaging with only minor, grade 1, adverse events. Best 
images were acquired at 24 h after injection of the 111In-labeled peptide 
using an interval of 4 days between the administration of the bsAb and the 
radiolabeled peptide.
The application of the murine version of the anti-CEA × anti-DTPA bsAb for 
pretargeted RIS of primary colorectal cancer was first described by le Doussal 
and colleagues in 11 patients.3 In this study, the mean interval between the 
administration of the bsAb (0.9 - 9 mg/patient) and the radiolabeled peptide 
(111In-di-DTPA-TL, 5-8 mCi) was 3.3 days (range 2-8 days). Imaging allowed 
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detection of 11 out of 13 lesions and best images were acquired at the 
longer time intervals between the administration of the agents. In addition, 
imaging quality of the planar scintigraphic images was low, requiring SPECT 
imaging in almost all patients for adequate delineation of the tumor. Seven 
out of the 11 patients developed human anti mouse antibodies (HAMA). 
Chetanneau and colleagues also described imaging of known locations of 
recurrent colorectal cancer using a bispecific antibody and an 111In-labelled 
bivalent hapten conjugate.6 First, the unlabelled bispecific antibody (0.1 
mg/kg) was administered followed 4 to 5 days later by the administration 
of the divalent DTPA peptide labelled with 5 to 8 mCi 111In. Images were 
obtained after 4.5 and 24 h after injection of the radiolabeled peptide. Mean 
tumor-to-background ratios were 6.4. Imaging sensitivity was 91%, which is 
comparable to the imaging sensitivity found in the present study. 
Barbet and colleagues administered 5 mg/patient of a murine anti-CEA 
× anti DTPA bsAb in 44 patients with relapsed medullary thyroid cancer, 
followed four to five days later by the 111In-labeled hapten (100-200 MBq).11 
In this study, images were recorded 2, 4 and 24 hr after injection of the 
hapten, resulting in a true-positive rate of 74%. Images recorded two h after 
administration of the radiolabeled peptide showed blood-pool distribution. 
Images recorded after five and 24 h showed tumor uptake. Due to the use 
of a murine Ab, HAMA developed in 61% of the patients. In the present 
study, 111In was used to radiolabel the peptide for imaging purposes. 111In 
is more suited for imaging than 131I and will result in a lower radiation dose 
than 131I due to the shorter physical half life (2.8 days vs. 8 days), the lower 
energy of the γ-emission (245 keV and 171 keV) and the fact that 131I also 
emits ß-radiation (192 KeV). In addition, labelling procedures are less time 
consuming and technically less challenging. Also, peptides that can be used 
in combination with 99Tc have been developed, making the pretargeting 
approach more flexible.12 
The present study showed that pretargeting RIS in patients with primary 
CRC is feasible using a low dose bsAb (5 mg, 50 nmol) in combination with a 
low peptide dose (5 nmol) with an optimal time interval of four days between 
the administration of the two agents, 24 h after injection of the radiolabeled 
peptide.
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Chapter 9
Summary & Future Directions

Summary 
The investigations presented in this thesis were conceived based on the 
hypothesis that the combined treatment of cytoreductive surgery and 
radioimmunotherapy could be improved and its therapeutic efficacy would 
compare favorable to the gold standard for the treatment of peritoneal 
carcinomatosis. 
The clinical treatment of first choice for peritoneal carcinomatosis remains to 
be HIPEC. Numerous retrospective studies and a randomized trial confirmed 
that the adjuvant use of heated intraperitoneal perfusion with chemotherapy 
after cytoreductive surgery resulted in improved survival. Efforts to improve 
outcome and reduce morbidity resulted in the application of relatively new 
chemotherapeutical agents as oxaliplatin during the procedure. 
In an effort to improve outcome and reduce morbidity, new treatment 
strategies haven been developed, one of which is antibody guided radiotherapy 
or radioimmunotherapy. 
The results of clinical trials investigating the potential of radioimmunotherapy 
in the setting of regional administration or intracavitary use have been 
described in Chapter 2. Intracavitary RIT in patients with ovarian cancer 
and glioma showed improved targeting after local administration as 
compared to the intravenous administration. In addition, various studies 
showed not only the feasibility of locally applied RIT in these patients but 
also showed adjuvant RIT to be at least as effective as the standard therapy. 
Clinical results about RIT for the treatment of peritoneal carcinomatosis of 
colorectal origin is scarce while results from pre-clinical data are promising. 
Studies on the application of radiolabeled antibodies in early urothelial cell 
cancer showed that intracavitary RIT may hold a promise. In patients with 
malignant pleural mesothelioma or malignant pleural effusion, RIT may play 
a role in the palliative treatment.
In Chapter 3, it was investigated whether survival after intraperitoneally 
administered RIT can be enhanced by altering the time interval between the 
surgical procedure and the intraperitoneal administration of RIT, and if so, 
what the optimal time interval between these two treatment modalities would 
be. In this experiment, PC was induced by intraperitoneal inoculation of CC-
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531 colon carcinoma cells in Wag/Rij rats. Fourteen days later, animals 
were subjected to exploratory laparotomy (Sham), cytoreductive surgery 
(CS) only or CS + RIT at different time points after surgery. RIT consisted of 
55 MBq 177lutetium labeled anti-CC531 antibody MG1 (183 μg). The primary 
endpoint was survival. The results showed that CS with or without RIT 
was well-tolerated. Median survival of animals in the Sham and CS group 
was 29 days and 39 days, respectively (P<0.04). Compared to CS alone, 
median survival of rats after adjuvant RIT was 77 days (P<0.0001), 52 days 
(P<0.0001) and 45 days (P<0.0001) when given directly, 4 days and 14 days 
after surgery, respectively. From this study we concluded that the efficacy 
of adjuvant RIT after CS for the treatment of PC of colonic origin decreases 
when the administration of the radiolabeled MAbs is postponed. 
The background for the found differences in survival in chapter 3 was 
thought to be due to tumor cell entrapment within fibrin clots or adhesions 
that are formed during and immediately after the surgical procedures. The 
tumor cells within these clots would thus be unsusceptible for the adjuvant 
therapy, RIT, and consequently would not be killed. Due to the success 
of immediately administered RIT, we hypothesized that the administration 
of fibrinolytic therapy, consisting of two daily doses of recombinant tissue 
plasminogen activator (rtPA) for three consecutive days, would enhance the 
therapeutic efficacy of RIT after extensive surgery. 
It is known that the application of hyperthermia can improve survival in the 
treatment of cancer when applied locally for the treatment of cervical cancer 
in women. In animal studies this has also been investigated in combination 
with RIT. We therefore investigated In Chapter 4, using the same model of 
induced PC in rats, the former two treatments in combination with adjuvant RIT 
after surgery in an effort to improve treatment outcome. Animals underwent 
CS, CS+whole body hyperthermia (WBH) at a temperature of 400C for the 
duration of 3 hours), CS+RIT (74 MBq 177Lu-labelled MG1) or CS+WBH+RIT. 
Median survival after CS and CS+WBH was 34 and 37 days. The adjuvant 
administration of RIT significantly improved survival. Median survival after 
CS+RIT or CS+RIT+WBH was 63 and 86 days (P<0.0003, P<0.0006 compared 
to CS+WBH). However, the concomitant application of WBH did not have a 
significant additive effect on survival, both after CS alone or after CS+RIT.
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In the second experiment, rats underwent CS, CS+RIT, CS plus recombinant 
tissue plasminogen activator (rtPA, twice daily, 3 days) or CS+RIT+rtPA. 
Median survival after CS and CS+rtPA was 50 and 42 days (P=0.1). Median 
survival was 106 days after CS+RIT and 103 days after CS+RIT+rtPA 
(P<0.0001 compared to CS+rtPA). No difference was found between CS+RIT 
and CS+RIT+rtPA (P= 0.83). 
We thus concluded that the application of WBH or rtPA in combination with 
adjuvant RIT after CS for the treatment of PC of colonic was feasible, but did 
not significantly potentiate the efficacy of RIT.
The survival of the standard of care treatment in our studies, CS immediately 
followed by intraperitoneal RIT, was than compared to the standard of care 
in clinical practice, HIPEC, in Chapter 5. 
Treatment, after using the same model of induced PC described in the 
former studies, comprised CS only, CS+RIT or CS+HIPEC, immediately after 
surgery. RIT consisted of intraperitoneal administration of 74 MBq Lutetium-
177 labelled MG1. HIPEC was performed by a closed abdomen perfusion 
technique using mitomycin C (16 mg/l during 60 minutes). Results showed 
that rats receiving CS+HIPEC were lethargic, suffered from diarrhea and lost 
significantly more weight in the first postoperative week. Median survival of 
rats treated with CS+RIT was significantly longer than after CS alone (97 
and 57 days, respectively, P<0.004), whereas survival after CS+HIPEC or CS 
alone were not significantly different (76 and 57 days, respectively, P=0.17). 
Thus, survival after CS was significantly improved by RIT whereas adjuvant 
HIPEC did not improve survival and was more toxic than adjuvant RIT.
The treatment related toxicity and –morbidity found in Chapter 5 are also 
present in clinical use of HIPEC. The main complications and morbidity seen 
in patient studies are derived from intestinal and anastomotic dehiscence 
related factors. 
In Chapter 6 we therefore aimed to investigate the effects of adjuvant RIT 
or HIPEC after cytoreductive surgery on the healing of small and large bowel 
anastomoses and the abdominal wall.
After the induction of PC, animals were subjected to CS and anastomotic 
construction only or followed by RIT or HIPEC. RIT consisted of 74 MBq 
177lutetium-labelled anti-CC531 antibody MG1. HIPEC was performed as 
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described above. Anastomotic and abdominal wall strength measurements 
were performed 3 and 5 days after surgery. At day 5, bursting pressure in 
ileum and colon anastomoses was lowest in the HIPEC group, CS vs. HIPEC 
P<0.05 and P<0.001, respectively. In the CS group, the bursting site was 
more common outside the true anastomotic area (6/12 animals) than in the 
HIPEC (1/12) and RIT (4/12) groups. Abdominal wall strength was highest in 
the CS group at both days after surgery (CS vs. HIPEC P<0.05 at day 3 and 
CS vs. HIPEC P<0.001 at day 5). In addition, there was a significantly lower 
abdominal wall strength after HIPEC than after RIT (P<0.05 at day 5).
We concluded that RIT, when administered as adjuvant treatment to CS, 
is superior to HIPEC regarding anastomotic and abdominal wall wound 
strength in a model of PC of CRC. 
Unlike HIPEC, most of the toxicity of clinically applied RIT is derived from 
its effect on the hematological system due to the long circulatory half-
life of the antibody. Although intraperitoneal RIT results in high uptake 
of intraperitoneally growing tumors, the radiolabeled antibody enters the 
circulation, resulting in bone marrow toxicity. Carbohydrate modification 
of antibodies could induce accelerated clearance of the antibody via the 
hepatic asialoglycoprotein receptor, thereby reducing exposure to normal 
tissues. In Chapter 7 we therefore investigated whether carbohydrate 
modifications of the antibody could achieve the effects described above. 
The biodistribution of the galactosylated and non-galactosylated anti-
CC531 antibody MG1 after intraperitoneal injection was determined in a 
model of peritoneal carcinomatosis of CC-531 colon tumors in Wag/Rij rats. 
Uptake of the radiolabeled antibodies in the tumor and relevant organs 
was determined at 2, 4, 24 and 48 hours after injection. Galactosylation 
of the antibody did not affect the binding affinity of MG1. Remarkably, 
the uptake of Gal-MG1 in tumors was higher than that of MG1 at 2 and 
4hr after injection. After 24h and 48h, uptake of Gal-MG1 in tumor tissue 
was lower than that of MG1. Gal-MG1 cleared from the blood within hours 
after administration. At 2hr-24 hr after administration, tumor-to-blood 
ratios obtained with Gal-MG1 were significantly higher than those obtained 
with unmodified MG1. Antibody galactosylation resulted in improved 
tumor-non-tumor ratios after intraperitoneal injection in a model of PC. 
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This could improve the efficiency of RIT, especially in combination with 
short-lived non-residualizing radionuclides as alpha-emitters.
The preliminary data of a patient study where a two-step pretargeting 
radioimmunoscintigraphy technique was used, are presented in the final 
chapter, Chapter 8. In this study the optimal time interval between the 
administration of the antibody and the administration of the radiolabeled 
peptide was investigated in patients with colorectal cancer. These data show 
excellent tumor targeting where the best time interval was shown to be three 
or four days after Ab injection.
Summary & Future Directions
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Future Directions
In the majority of patients with peritoneal carcinomatosis (PC) that are 
eligible for cytoreductive surgery (CS), a R0 resection can be performed. 
With the use of pre-operative diagnostic imaging it is difficult to adequately 
predict the extent of PC.1 Final staging is therefore performed per-operatively. 
During these extensive surgical procedures however, small tumor nodules 
may be missed and left in situ. New molecular imaging techniques that 
can sensitively detect small lesions may preclude this problem. Alencar and 
colleagues investigated the use of near-infrared (NIR) fluorescent probes in 
mice with orthotopically implanted colon cancer.2 They were able to detect 
lesions of 0.3 mm-1.4 mm). (Pre-) Clinical application of NIR during CS might 
further improve the results of surgery. 
The recent incorporation of bevacizumab (anti-VEGF antibody) to the 
standard systemic chemotherapy for the treatment of metastatic colon 
carcinoma, resulted in an increase in overall survival of only three months.3 
The adoption of relatively new chemotherapy agents in HIPEC procedures 
resulted in the application of platinum-based compounds. This, however 
resulted in increased morbidity as compared to the use of Mitomycin-
C whereas the effects on survival are not yet reported.4 Thus, the scope 
for the development of new treatment strategies for the treatment of PC of 
colorectal origin might not be based on treatment with either intravenously 
or intraperitoneally administered chemotherapy.
Excellent response rates have been obtained with radioimmunotherapy 
(RIT) in patients with B-cell lymphomas (response rates of 60-70%) with 
radiolabeled anti-CD20 antibodies (90Y, Zevalin® and 131I, Bexxar®).5,6 
The results of RIT for the treatment of solid tumor are less encouraging. 
Studies on the therapeutic efficacy and toxicity of intracavitary application 
of RIT in patients with ovarian cancer (90Y-HMFG-1, 177Lu-B72.3) and 
malignant glioma (131I-81C6), indicated that the adjuvant application of RIT 
within a confined area limits toxicity and may improve tumor targeting.7 
In smaller lesions (e.g. in patients with minimal residual disease or in 
microscopic disease), improved/enhanced tumor uptake of the radiolabeled 
antibody was observed.8 The studies described in this thesis investigated the 
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tumor targeting and efficacy after administration of 177Lu-labeled antibodies 
in animals with microscopic disease after cytoreductive surgery. In this 
described setting of minimal residual disease (lesion size 0.5 mm.- 3mm.), 
the application of 177Lu-labeled Abs resulted in an increased suvivival as 
compared to other radionuclides as 90Y- or 188Re-labeled Abs.9 In patients 
who undergo R0 resections, 177Lu may be an inappropriate radionuclide due 
to its physical properties (range of ß–particles in tissue: 3 mm). In these 
cases, alpha emitting radionuclides  may be more suitable. The results of a 
phase I trial on the regional administration of 211At-labeled 81C6 (an anti-
tenascin antibody) after a total or near total resection in 18 patients with 
recurrent glioma showed the clinical feasibility of  radioimmunotherapy with 
alpha-emitters.10 In this study  median survival (57 weeks for glioblastoma 
multiforme) was similar to the median survival obtained with administration 
of the 131I-labeled Ab, while  no dose-limiting toxicity occurred. Thus patients 
were treated at a suboptimal dose level, whereas the latter Ab construct 
was administered at the maximum tolerable dose. The use of 211At-labeled 
antibodies seems particularly suitable for intraperitoneal administration 
in view of direct tumor targeting and the physical half-life of 7.2 hrs in 
combination with the peritoneal clearence time of antibodies that is within 
24 hrs (≈ 10% is still present after 24 hrs, Thus, systemic toxicity would 
be limited when the short-lived radiolabeled antibodies enter systemic 
circulation. 
One of the limitations of RIT in solid tumors is slow tumor uptake and 
low tumor-to-non-tumor ratios. It has been shown that solid tumors can be 
targeted more effectively using a pretargeting system. Pre-targeting techniques 
that utilize bispecific antibodies  have been shown to achieve increased 
tumor-to-non-tumor ratios which could results in enhanced therapeutic 
efficacy when used in a therapeutic setting. Until now, the production of 
sufficient amounts of bispecific antibodies has been a major limitation to 
test this approach clinically. The recently developed DNL method allows the 
production of fully humanized trivalent bispecific monoclonal antibodies in 
high yields. Studies performed with these new pre-targeting constructs 
resulted in excellent tumor targeting and high tumor-to-non-tumor ratios 
with additional rapid blood clearance in mice bearing human colonic tumor 
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xenografts.11 In general, higher radiation doses will be delivered to the 
tumor by means of pre-targeting as compared to the use of directly labeled 
antibodies.12
These recent advances in new imaging modalities and molecular science 
may preclude the clinical application of local or regionally applied RIT to 
treat microscopic tumor residue after CS for PC of colorectal origin.
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Samenvatting
Dikkedarmkanker (coloncarcinoom) is na longkanker bij mannen en 
borstkanker bij vrouwen de meest voorkomende oorzaak van aan kanker 
gerelateerde sterfte in Europa en de Verenigde Staten. In ongeveer 1/5 van 
de patiënten bij wie deze diagnose gesteld wordt is de ziekte reeds uitgezaaid. 
Een specifiek patroon van deze uitzaaiingen, buiten de lever en de longen, is 
regionale uitbreiding in de buikholte, ofwel carcinosis peritonei (CP). Dit kan 
optreden in 1/3 van de patiënten na verwijdering van de darmkanker terwijl 
bij 25% van hen die na verwijdering van de tumor hernieuwde tumorgroei 
hebben, dit de enige plaats is waar de uitzaaiing voorkomen. Bij CP worden 
de tumoren meestal gevonden langs de rechter dikkedarm, het vetschort, 
rondom de lever en onder het middenrif. Indien onbehandeld, zullen deze 
tumoren aanleiding geven tot klachten van darmafsluiting en uiteindelijk tot 
overlijden. De overleving van deze categorie patiënten was slecht, gemiddeld 
bedroeg deze zes maanden, waarbij de behandeling bestond uit het opheffen 
van de afsluiting of slechts chemotherapie. 
In de hoop deze mensen een beter uitzicht op overleving te bieden is in 
de loop der jaren uitgebreid onderzoek gedaan t.b.v. de verbetering van de 
behandeling. Dit heeft uiteindelijk geresulteerd in uitgebreide chirurgische 
verwijdering van alle zichtbare tumor, gevolgd door het spoelen van de 
buikholte met verwarmde chemotherapie (HIPEC). Dit zijn echter zeer 
langdurige en uitgebreide procedures waarbij het complicatierisico hoog 
is, nl 65%. Dit leidt echter wel tot een verbetering van overleving naar 
gemiddeld drie jaar. Vanwege de ernstige complicaties is het nodig dat er 
nieuwe strategieën ontwikkeld worden om deze naar de buikholte uitgezaaide 
dikkedarmkanker te behandelen. Een van deze nieuwe methoden is het 
gebruik van selectieve bestraling van tumorcellen door middel van het 
koppelen van radioactieve stoffen aan tumorspecifieke antilichamen, ofwel 
radio-immuuntherapie (RIT). 
De resultaten van klinisch onderzoek, waarbij gebruik wordt gemaakt van 
RIT worden besproken in Hoofdstuk 2. In dit hoofdstuk ligt de nadruk op 
de regionale toepassing ervan in een afgesloten holte (intracavitair). Uit de 
resultaten van dit onderzoek is geconcludeerd dat de toepassing van RIT 
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effectief is indien er een minimale hoeveelheid tumor aanwezig is (minimaal 
residuale of microscopische ziekte). Tevens blijkt dat er een groter anti-
tumor effect verwacht kan worden indien men deze therapie ter plaatse van 
de tumor (lokaal of regionaal) aanbiedt in vergelijking met toediening via de 
bloedbaan.
In Hoofdstuk 3 is in een proefdiermodel van geinduceerde CP het optimale 
tijdsinterval tussen de chirurgische ingreep en het toedienen van het 
radioactieve antilichaam onderzocht. De achterliggende hypothese is dat 
tumorcellen die tijdens de operatie achterblijven wellicht in bloedstolsels 
achterblijven. Hierdoor zouden deze tumorcellen onbereikbaar zijn voor het 
antilichaam en uit kunnen groeien tot nieuwe tumoren. Uit de resultaten van 
dit experiment bleek dat RIT, wanneer toegediend direct aansluitend aan de 
operatie, het beste overlevingsresultaat geeft wanneer dit wordt vergeleken 
met toediening na 4 of 14 dagen na operatie.
Vervolgens werd in Hoofdstuk 4 , in hetzelfde proefdiermodel onderzocht of 
het toedienen van fibrinolytische therapie met behulp van rtPA, een stof die 
bloedstolsels oplost, zou kunnen zorgen voor een verbeterde beschikbaarheid 
van RIT ter plaatse van tumorcellen. Het uiteindelijke doel in dit experiment 
was verbetering van overleving. In dit hoofdstuk werd eveneens onderzocht of 
een gecombineerde behandeling met RIT en verhoging van de lichaamswarmte 
(hyperthermie) zou leiden tot een verbeterde overleving. Deze combinatie 
van bestraling met hyperthermie wordt reeds toegepast bij vrouwen met 
baarmoederhalskanker. Uit de resultaten van deze experimenten bleek dat 
zowel de gecombineerde behandeling van RIT met rtPA als de combinatie van 
RIT met hyperthermie niet zorgde voor een significant betere overleving in 
vergelijking met de behandeling met RIT alleen. Hieruit werd geconcludeerd 
dat beide combinaties niet zinvol werden geacht als aanvullende therapie en 
dat enkel het gebruik van RIT de optimale aanvullende therapie is na CS in 
het gebruikte model.
Nadat uit de voorgaande experimenten herhaaldelijk was gebleken dat de 
toediening van RIT na chirurgie zorgde voor een langere overleving dan de 
toepassing van chirurgie alleen, werd deze behandeling vergeleken met de 
huidige standaardbehandeling die toegepast wordt bij mensen, HIPEC. De 
resultaten hiervan zijn beschreven in Hoofdstuk 5. Wederom bleek dat 
het toedienen van RIT na chirurgie zorgde voor een langere overleving dan 
het gebruik van chirurgie alleen. HIPEC echter bleek in dit model niet in 
staat te zorgen voor een langere overleving. Bovendien traden er na HIPEC 
meer bijwerkingen op en waren de proefdieren gedurende de eerste week na 
toediening zieker dan wanneer RIT werd toegediend.
Deze bevindingen leidden tot het experiment uitgevoerd zoals beschreven 
in Hoofdstuk 6. In dit hoofdstuk werd onderzocht of de toepassing van RIT 
na chirurgie leidde tot een verminderde darm- en buikwandgenezing. In de 
huidige klinische toepassing van HIPEC geeft deze verminderde genezing 
aanleiding tot het ontstaan van abcessen en verbindingen tussen de darm 
en de buikwand. Uit de resultaten van dit experiment bleek dat zowel de 
genezing van darmanastomosen als ook die van de buikwand significant 
slechter was na toedienen van verwarmde chemotherapie dan wanneer 
alleen chirurgie werd uitgevoerd. Het toedienen van RIT na chirurgie zorgde 
niet voor een significante verslechtering van deze genezing.
De dosisbeperkende factor van RIT is de toxiciteit die optreedt door 
beenmergdepressie. Dit is het gevolg van het langer in het bloed circulerende 
radioactieve antilichaam. In Hoofdstuk 7 worden de resultaten van 
een experiment beschreven waarin met behulp van modificaties aan het 
antilichaam getracht is de hoeveelheid in het bloed circulerende antilichaam 
te verminderen. Deze aanpassing betreft het koppelen van suikergroepen 
(galactose) aan het antilichaam. Deze suikergroepen worden vervolgens 
herkend door receptoren in de lever (asialoglycoprotein receptor of ASGP) en 
binnen een aantal uren uit het lichaam geklaard. Uit dit experiment bleek 
dat in de eerste 24 uur na injectie van het gemodificeerde  antilichaam in de 
buikholte er een hogere opname van dit antilichaam in de tumor bestond dan 
het niet gemodificeerde antilichaam. Tevens was er een significante lagere 
bloedspiegel van dit antilichaam gedurende de eerste 48 uur na injectie. Uit 
deze studie werd geconcludeerd dat het theoretisch mogelijk zou moeten 
zijn een hogere dosis radioactief antilichaam toe te dienen met daarbij een 
gelijkblijvende toxiciteit.
In Hoofdstuk 8 worden de resultaten beschreven van een pre-targetingstudie 
in patiënten met een colorectaal carcinoom. In pre-targeting wordt gebruik 
gemaakt van een anti-tumor antilichaam die los wordt toegediend van de 
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radioactiviteit. Dit heeft als voordeel dat het antilichaam zich kan ophopen 
in de tumor, hetgeen enkele dagen kan duren, alvorens radioactiviteit 
toegediend wordt. In de hier beschreven studie werd eerst het niet-
radioactieve antilichaam toegediend, na drie tot vijf dagen gevolgd door het 
toedienen van 111Indium. In deze studie is onderzocht welk tijdsinterval, van 
drie tot vijf dagen, het beste resultaat geeft met betrekking tot het afbeelden 
van de tumor. Uit deze studie bleek dat een interval van vier dagen tussen 
het toedienen van het antilichaam en radioactief gelabelde peptide de beste 
afbeelding van de tumoren en uitzaaiingen toonde.
Op basis van de dierexperimentele studies beschreven in dit proefschrift 
concluderen wij dat het gerechtvaardigd is de toepassing van RIT na 
chirurgische debulking in de klinische praktijk te gaan vergelijken met 
HIPEC. Eveneens zou de toepassing van RIT kunnen liggen bij patiënten in 
de palliatieve setting indien er geen curatie meer mogelijk is.
De toekomst van RIT voor de behandeling van carcinosis peritonei van 
colorectale tumoren in de klinische praktijk zou dan ook een onderdeel van 
de huidige multidisciplinaire behandeling kunnen zijn alsmede een minimaal 
invasieve palliatieve therapie.


Dankwoord
Op het ene moment zit je op de stoel bij de professor aan wie je vertelt 
dat jij chirurg wilt worden en onderzoek wilt doen, het andere moment ligt 
er een proefschrift. Dit alles binnen een periode van drie jaar. Met andere 
woorden: het is allemaal erg snel gegaan en ik voel mij dan ook bevoorrecht. 
Bij een strakke planning zijn vaak anderen betrokken om alles goed te laten 
verlopen; zo ook bij de tot stand koming van mijn proefschrift. 
Professor Bleichrodt: dank u voor het aanbieden van dit onderzoek, uw 
kritische blik en het enthousiasme voor het internationaal uitdragen van 
research uit Nijmegen.
Dr. Thijs Hendriks: beste Thijs, het moet niet eenvoudig zijn geweest om zo 
vaak te zijn gestoord door zo’n ongeleid projectiel met al zijn ideeën. Uiteindelijk 
wist jij deze dan weer zo te relativeren dat er een goede wetenschappelijke 
publicatie uit voort kwam. Bedankt voor je steun en de leuke tijd.
Professor Boerman: beste Otto, ook jij moet spijt hebben van het feit dat de 
deur van jouw kantoor de gehele dag openstaat en er dan ook regelmatig 
opmerkingen het aquarium in geroepen werden ter discussie. Bedankt voor 
jouw snelle doch zeer kritische inbreng m.b.t. mijn ideeën, experimenten en 
artikelen. Volgens mij waren mijn laatste loodjes jouw zwaarste.
Professor Oyen: ik dank u voor het mogelijk maken van dit onderzoek in 
samenwerking met de afdeling Nucleaire Geneeskunde.
Dr. Manuel Koppe: Manuel, ook al was het jouw model, ik ben er verder mee 
gegaan. Met jouw inbreng en kennis van zaken is dit binnen zeer korte tijd 
een mooi proefschrift geworden. Mijn dank is groot.
Beste bewoners van het aquarium (Martin, Peter, Huub, Ingrid, Annemieke, 
Cathelijne en Alexander), misschien wel dankzij de steeds wisselende 
samenstelling van deze kweekvijver van ideeën heb ik met veel plezier mijn 
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onderzoekstijd bij jullie doorgebracht. Bedankt voor jullie inbreng en uitleg 
van zaken waar een toekomstig chirurg geen kennis van heeft.
Mijn bijzondere dank gaat uit naar Annemarie: jij hebt veel laboratoriumwerk 
voor mij verricht, met name op het gebied van het galactoseexperiment. 
Bedankt voor jouw steun, geduld en uitleg over de chemie.
In de “acknowlegdements” zijn zij vaak genoemd maar dit doet hun rol zeker 
te kort, Ben en Roger, die uren met mij op het CDL en op het Research 
lab. doorbrachten, bedankt voor jullie praktische inbreng en ondersteuning. 
Succes in de komende periode met de vele veranderingen binnen het 
Research lab.
De ondersteuning, vakkennis en praktische tips van de mensen op het 
centraal dieren laboratorium mogen zeker niet onvermeld blijven: Gerry, 
Hennie, Bianca en Maarten, bedankt voor jullie inzet. Jullie weten nu dat het 
doen van proefdieronderzoek ook voor wetenschappers bijna onoverkomelijk 
kan zijn.
Pa en Ma, bedankt voor jullie steun in al die jaren die ik nu al bezig ben en 
die het mogelijk heeft gemaakt te komen waar ik nu ben.
En als laatsten, maar zeker de belangrijksten:
Mijn proefschrift draag ik op aan hen die mij het meest dierbaar zijn; 
Diaan, dank je voor jouw ongelooflijke steun, ook in die perioden waar het 
niet allemaal zo ging als wij gehoopt hadden. Jij bent het beste wat mij 
ooit is overkomen. Jouw steun zal nooit meer overtroffen kunnen worden, 
ongeacht wat de toekomst ons brengt....
Mael, dank je voor jouw zijn en de glimlach waarmee jij mijn dag maakt. 
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177Lu  Lutetium 177, radionuclide 
111In  Indium-111, radionuclide
Bio  Biotinylated
BSA  bovine serum albumine
bsAb  bispecific antibody
CRC  colorectal cancer
CS  cytoreductive surgery
CP  Carcinosis peritonei
DTPA  diethylenetriaminepentaacetic acid
Gal  Galactose
HAMA  Human Anti Murine Antibody
HACA  Human Anti Chimeric Antibody
HIPEC  heated intraperitoneal chemotherapy
ID  injected dose
ITLC  instant thin layer chromatography
i.p  intraperitoneal
i.v  intravenous
MAb  monoclonal antibody
MBq  megabequerel
mCi  millicurie (1 mCi = 37 Mbq)
MG1  cell surface antibody raised against CC531 cells
PBS  phosphate buffered saline
PC  peritoneal carcinomatosis
RIT  radioimmunotherapy
r-tPA  recombinant tissue plasminogen activator
SA  Streptavidin
TAA  tumour associated antigen
WBH  Whole Body Hyperthermia


